WorldWideScience

Sample records for chickenpox vaccine

  1. Who Needs Chickenpox Vaccine

    Science.gov (United States)

    ... Vaccines and Immunizations Share Compartir Who Needs Chickenpox Vaccine For Public Children under age 13 years should ... who have never had chickenpox or received chickenpox vaccine should get two doses, at least 28 days ...

  2. Varicella (Chickenpox) Vaccine

    Science.gov (United States)

    ProQuad® (as a combination product containing Measles Vaccine, Mumps Vaccine, Rubella Vaccine, Varicella Vaccine) ... up to about 1 person in 5) and measles-like rash (about 1 person in 20) than MMR and varicella vaccines given separately. Moderate Problems:Seizure (jerking or staring) ...

  3. Chickenpox

    Science.gov (United States)

    Varicella; Chicken pox ... from a chickenpox blister If someone with the disease coughs or sneezes near you Most cases of ... occur in children younger than age 10. The disease is most often mild, although serious complications may ...

  4. Chickenpox

    Science.gov (United States)

    ... and breast milk. Those at risk for severe disease or serious complications — such as newborns whose mothers had chickenpox ... aspirin has been associated with a rare but serious disease, Reye syndrome , which can lead to liver failure ...

  5. Possible Side Effects of Chickenpox Vaccine

    Science.gov (United States)

    ... or not. Possible reactions after ProQuad® (or MMRV) vaccination Children who get the first dose of ProQuad® ... MMRV) Vaccine Aspirin use and possible reactions after vaccination You should not take aspirin products for 6 ...

  6. Neurological complications of chickenpox

    OpenAIRE

    Girija A.; Rafeeque M; Abdurehman K

    2007-01-01

    Aim: To assess the neurological complications of chickenpox with prognosis. Background: The neurological complications occur in 0.03% of persons who get chickenpox. There is no universal vaccination against chicken pox in India. Most patients prefer alternate modalities of treatment. Hence these complications of chickenpox are likely to continue to occur. Study Design: A prospective study was conducted for 2 years (from March 2002) on the admitted cases with neurological complicat...

  7. Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England ☆

    OpenAIRE

    Field, N.; Amirthalingam, G.; Waight, P; Ladhani, S. N.; van Hoek, A. J.; Miller, E.; Andrews, N.; Maple, P. A. C.; Brown, K E

    2014-01-01

    Introduction: In the UK, primary varicella is usually a mild infection in children, but can cause serious illness in susceptible pregnant women and adults. The UK Joint Committee on Vaccination and Immunisation is considering an adolescent varicella vaccination programme. Cost-effectiveness depends upon identifying susceptibles and minimising vaccine wastage, and chickenpox history is one method to screen for eligibility. To inform this approach, we estimated the proportion of adolescents wit...

  8. Hemorrhagic Chickenpox

    Directory of Open Access Journals (Sweden)

    sengupta B

    1995-01-01

    Full Text Available A case of chickenpox in a boy of 16 years is described for its uncommon presentation with hemorrhagic vesicles, gum-bleeding without being preceded by any prodromal symptom and unassociated with any immunosuppressive disorder.

  9. Eruptive keloids after chickenpox

    Directory of Open Access Journals (Sweden)

    Nicolas Kluger

    2011-07-01

    Full Text Available Hypertrophic scars and keloids result from abnormal wound healing in predisposed individuals. They occur within months of cutaneous trauma (surgical wounds, piercing, lacerations or inflammation (acne, folliculitis, vaccination site. They have rarely been reported after chickenpox. Herein we report a dramatic case in a 4-year-old black girl and discuss the issues related to the management of hypertrophic scars and keloids in this peculiar situation.

  10. Neurological complications of chickenpox

    Directory of Open Access Journals (Sweden)

    Girija A

    2007-01-01

    Full Text Available Aim: To assess the neurological complications of chickenpox with prognosis. Background: The neurological complications occur in 0.03% of persons who get chickenpox. There is no universal vaccination against chicken pox in India. Most patients prefer alternate modalities of treatment. Hence these complications of chickenpox are likely to continue to occur. Study Design: A prospective study was conducted for 2 years (from March 2002 on the admitted cases with neurological complications after chickenpox (with rash or scar. Patients were investigated with CT/MRI, CSF study, EEG and nerve conduction studies and hematological workup. They were followed-up for 1 year and outcome assessed using modified Rankin scale. Results: The latency for the neurological complications was 4-32 days (mean: 16.32 days. There were 18 cases: 10 adults (64% and 8 children (36%. Cerebellar ataxia (normal CT/MRI was observed in 7 cases (32% (mean age: 6.85 years. One patient (6 years had acute right hemiparesis in the fifth week due to left capsular infarct. All these cases spontaneously recovered by 4 weeks. The age range of the adult patients was 13-47 years (mean: 27 years. The manifestations included cerebellar and pyramidal signs (n-4 with features of demyelination in MRI who recovered spontaneously or with methylprednisolone by 8 weeks. Patient with encephalitis recovered in 2 weeks with acyclovir. Guillain Barre syndrome of the demyelinating type (n-2 was treated with Intravenous immunoglobulin (IVIG and they had a slow recovery by a modified Rankin scale (mRs score of 3 and 2 at 6 months and 1 year, respectively. One case died after hemorrhage into the occipital infarct. There were two cases of asymmetrical neuropathy, one each of the seventh cranial and brachial neuritis. Conclusion: Spontaneous recovery occurs in post-chickenpox cerebellar ataxia. Rarely, serious complications can occur in adults. The demyelinating disorders, either of the central or peripheral

  11. Chickenpox ARDS in a health care worker following occupational exposure.

    LENUS (Irish Health Repository)

    Knaggs, A

    2012-02-03

    A case is described of chickenpox acute respiratory distress syndrome in an ambulance driver after the inter-hospital transfer of a patient known to have chickenpox pneumonia. Following this exposure, he neither avoided patient contact nor received varicella zoster immune globulin. He subsequently required 13 days of ventilatory support before making a full recovery. The case described supports the contention that health care workers should be screened by serology for immunity to chickenpox before patient contact occurs, with subsequent vaccination of those who are non-immune, when the vaccine becomes available.

  12. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available Immunizations Chickenpox (Varicella) One family's struggles with chickenpox We provide this video in a variety of formats ... not possible without a visit to your doctor. Immunizations stop disease from spreading. Check with your family ...

  13. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available Immunizations Chickenpox (Varicella) One family's struggles with chickenpox We provide this video in a variety of formats and lengths for use by your organization free-of-charge. Branded videos contain the " ...

  14. Investigation of epidemic factors and protective efficacy of vaccine in an outbreak of chickenpox in school%一起学校水痘暴发的流行因素及其疫苗保护效率调查

    Institute of Scientific and Technical Information of China (English)

    罗念慈; 李刚; 李苑

    2013-01-01

    目的 调查一起学校水痘暴发的流行因素,探讨水痘疫苗的保护效率.方法 采用1:1频数匹配病例对照研究方法,即以病例作为病例组,随机选择同班级、同性别,且无水痘患病史的相同数量未发病的健康学生作为对照组.使用自行设计的水痘危险因素调查表,对病例和对照进行问卷调查.结果 此次疫情共报告32例水痘病例,总罹患率为0.80%.波及深圳市龙岗区某学校4个班级,其中二年级23例,五年级9例,各班罹患率差异有统计学意义(P<0.05);接种过水痘疫苗的病程时间(中位时间5d)比未接种过水痘疫苗的病程时间(中位时间10 d)短;经常与其他年级或班级学生玩耍感染水痘的危险性是未与其他年级或班级学生玩耍的10.71倍,接触班里水痘病例的危险性是未接触的41.89倍;水痘疫苗的保护效率为6.76%,95%CI:10.00%~83.51%.接种进口水痘疫苗的罹患率远低于接种国产疫苗的罹患率(P<0.05).结论 这是一起发生在某小学的水痘暴发疫情,经常与其他班级或年级的学生玩耍以及水痘疫苗保护效率欠佳,是此次疫情暴发的危险因素.%Objective To investigate the epidemic factors and protective efficacy of vaccine in an outbreak of chickenpox in school.Methods The 1:1 frequency matching case-control study was performed.Thirty-two students with chickenpox were served as case group,while 32 healthy students without history of chickenpox as control group.The students in two groups were inquired by self-designed questionnaires of chickenpox risk factors.Results A total of 32 cases were found in the outbreak,with an overall attack rate of 0.80%.The cases were found in four classes,including 23 in grade two and 9 in grade five.The attack rates were significantly different in various classes (P < 0.05).The disease course of cases vaccinated (at a median of 5 d) was shorter than those unvaccinated (at a median of 10 d

  15. Chickenpox Prevention and Treatment

    Science.gov (United States)

    ... Multimedia Related Links Medline Plus Healthfinder.gov Shingles Prevention & Treatment Language: English Español (Spanish) Recommend on Facebook ... by Your Doctor Español: Prevención y tratamiento Prevention The best way to prevent chickenpox is to ...

  16. Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

    Directory of Open Access Journals (Sweden)

    Benson Ogunjimi

    Full Text Available Varicella-zoster virus (VZV causes chickenpox and may subsequently reactivate to cause herpes zoster later in life. The exogenous boosting hypothesis states that re-exposure to circulating VZV can inhibit VZV reactivation and consequently also herpes zoster in VZV-immune individuals. Using this hypothesis, mathematical models predicted widespread chickenpox vaccination to increase herpes zoster incidence over more than 30 years. Some countries have postponed universal chickenpox vaccination, at least partially based on this prediction. After a systematic search and selection procedure, we analyzed different types of exogenous boosting studies. We graded 13 observational studies on herpes zoster incidence after widespread chickenpox vaccination, 4 longitudinal studies on VZV immunity after re-exposure, 9 epidemiological risk factor studies, 7 mathematical modeling studies as well as 7 other studies. We conclude that exogenous boosting exists, although not for all persons, nor in all situations. Its magnitude is yet to be determined adequately in any study field.

  17. Clinical Epidemiology of Chickenpox in Iraq from 2007-2011

    OpenAIRE

    Khaleel, Hanan Abdulghafoor; Abdelhussien, Hassan Muslem

    2012-01-01

    Varicella zoster (chickenpox) infection is an acute common disease caused by the varicella zoster virus (VZV). Children are most susceptible to infection. In non-vaccinated populations, primary infection tends to occur at a younger age. In 1998, the World Health Organization (WHO) recommended that routine childhood varicella vaccination be considered in countries where the disease is a relatively important public health and socioeconomic problem, and where high (85 to 90%) and sustained vacci...

  18. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... One family's struggles with chickenpox We provide this video in a variety of formats and lengths for use by your organization free-of-charge. Branded videos contain the "PKIDs.ORG" end slate; unbranded videos ...

  19. Chickenpox Can Be Serious. Protect Yourself and Your Child.

    Science.gov (United States)

    ... Button Past Emails CDC Features Chickenpox Can Be Serious Language: English Español (Spanish) Recommend on Facebook Tweet ... about getting a second dose. Chickenpox Can Be Serious Chickenpox can be serious especially for babies, pregnant ...

  20. Human Vaccines & Immunotherapeutics: News

    OpenAIRE

    Riedmann, Eva M.

    2013-01-01

    Long-term effectiveness shown for Merck’s chickenpox vaccine Again—no link between vaccines and autism Experimental ovarian cancer vaccine successful in phase 1 Sinovac’s HFMD vaccine meets phase 3 study goal A vaccine for long-suffering cat allergy patients Vaccines are key to breaking infectious disease-malnutrition cycle Cancer vaccine failures due to the adjuvant IFA? Novartis’ typhoid vaccine make good progress

  1. Outbreak of chickenpox in a refugee camp of northern Thailand

    Directory of Open Access Journals (Sweden)

    Camélique Olivier

    2010-02-01

    Full Text Available Abstract Although chickenpox is a generally mild, self-limited illness of children, it can cause fatal disease in adults. Accumulating reports from tropical countries showed a high prevalence of seronegativity among the adults, implying that varicella diseases could become a heavy burden in tropical countries. However, in the situation of humanitarian emergencies in tropical areas, chickenpox has largely been ignored as a serious communicable disease, due to lack of data regarding varicella mortality and hospital admissions in such a context. This is the first report describing an outbreak of chickenpox in a refugee camp of tropical region. In 2008, we experienced a varicella outbreak in ethnic Lao Hmong refugee camp in Phetchabun Province, northern Thailand. The attack rate was 4.0% (309/7,815 and this caused 3 hospitalizations including one who developed severe varicella pneumonia with respiratory failure. All hospitalizations were exclusively seen in adults, and the proportion of patients ≥15 years old was 13.6% (42/309. Because less exposure to varicella-zoster virus due to low population density has previously been suggested to be one of the reasons behind higher prevalence of susceptible adults in tropics, the influx of displaced people from rural areas to a densely populated asylum might result in many severe adult cases once a varicella outbreak occurs. Control interventions such as vaccination should be considered even in refugee camp, if the confluence of the risk factors present in this situation.

  2. Chickenpox infection after renal transplantation

    OpenAIRE

    Kaul, Anupma; Sharma, Raj K.; Bhadhuria, Dharmendra; Gupta, Amit; Prasad, Narayan

    2012-01-01

    Background. Chicken pox, although a common infection among children, is rare in immunocompromised patients, particularly renal transplant recipients, and carries a very high incidence of morbidity and mortality There is little data on chickenpox in adult renal transplant recipients, although reports have suggested that it may follow a virulent course requiring frequent hospitalization, and in severe cases can cause death. Aims. To evaluate the incidence, severity and complications of a varice...

  3. A Case Report of Chickenpox in Conjunctiva

    OpenAIRE

    Deniz Turgut Coban

    2011-01-01

    Chickenpox is a primarily infection of Varicella-zoster virus and is childhood disease. Although varicella virus infections are usually benign skin disease, they can have serious systemic manifestations and complications. In this study, it is aim the presentations of a case report of chickenpox in conjunctiva.

  4. Chickenpox

    Science.gov (United States)

    ... the heart muscle Pneumonia Joint pain or swelling Cerebellar ataxia may appear during the recovery phase or later. ... M.D., © Greene Ink, Inc. Read More Acute cerebellar ataxia Arthritis Encephalitis Myocarditis Pneumonia - adults (community acquired) Reye ...

  5. 上海市闵行区4~17岁儿童水痘减毒活疫苗接种情况及其保护效果%Analysis of protective effect of using chickenpox live attenuated vaccine among 4-17 years old children in Minhang district, Shanghai

    Institute of Scientific and Technical Information of China (English)

    杜艳; 余峰; 张莉萍; 汪曦; 金宝芳; 王烨; 梅克雯; 陆佳; 蒋露芳

    2014-01-01

    Objectives To survey on the vaccination of varicella live attenuated vaccine among 4-17 children in Minhang District, and analyze the protective effect against varicella.Methods We collected outbreak chickenpox cases reported from infectious disease report system and surveillance units in Minhang district from 1st May in 2012 to 30th Apr in 2013.The 1∶3 matched case-control study was conducted to questionnaire the legal guardian of the cases and control group, and calculate the protective effect and effective term of protection.The survey included vaccination, chickenpox exposure history, previous history of varicella illness, suffering from the symptoms of chickenpox, the vaccinations brand, etc.The criteria of accepted case were those healthy students who were in the same class with those chickenpox cases.The accepted matched controlling data were those children who were from the same class with outbreak chickenpox cases without varicelliform eruption, similar live condition, the closest house, the same gender, the closest age.This study investigated 390 cases of patients and the control group included 1 170 cases. Chi-square test was used to compare the vaccination of cases and controls, as well as the incidence of chickenpox vaccination different brands VarV, Mantel-Haenzel chi-square test was applied to compare the protective effect of the two groups.Results VarV overall vaccination rate was 68.3%( 1 065/1 560 ) , among them, the case group coverage was 45.1% ( 176/390 ) , significantly lower than the control group (76.0%(889/1 170)) (χ2 =128.55,P<0.01) .The coverage in children of 4-10 years old group was 88.4%(375/424), significantly higher than the 11-17 years old group (60.7%(690/1 136)) (χ2 =109.40,P <0.01 ) .The overall protective effect of VarV was 78.10%( 71.82%-82.98%) .Vaccinated group incidence ratio was 16.5% ( 176/1 065 ) , significantly lower than the unvaccinated group ( 43.2%(214/495))(χ2 =128.55,P<0.01).The chickenpox risk of the children

  6. Hemorrhagic Pericarditis in a child with primary varicella infection (chickenpox

    Directory of Open Access Journals (Sweden)

    Nandeesh B

    2009-04-01

    Full Text Available Chickenpox (Varicella representing the primary infection by Varicella zoster virus is a common benign and self-limited infectious disease of childhood. Although the disease can be associated with complications, they are generally mild and tend to occur in adults and immunocompromised children. Severe and life-threatening complications are extremely rare, particularly those involving the cardiovascular system. We report a malnourished 5-year-old girl with chicken pox complicated by hemorrhagic pericarditis and deep vein thrombosis leading to fatal pulmonary thromboembolism. Though varicella infection runs a benign self-limiting course, it continues to cause significant morbidity and mortality when associated with complications, particularly in malnourished children. Hence, the importance of vaccination and early recognition of complications is emphasized.

  7. Hemorrhagic Pericarditis in a child with primary varicella infection (chickenpox).

    Science.gov (United States)

    Nandeesh, B N; Mahadevan, Anita; Yasha, T C; Shankar, S K

    2009-01-01

    Chickenpox (Varicella) representing the primary infection by Varicella zoster virus is a common benign and self-limited infectious disease of childhood. Although the disease can be associated with complications, they are generally mild and tend to occur in adults and immunocompromised children. Severe and life-threatening complications are extremely rare, particularly those involving the cardiovascular system. We report a malnourished 5-year-old girl with chicken pox complicated by hemorrhagic pericarditis and deep vein thrombosis leading to fatal pulmonary thromboembolism. Though varicella infection runs a benign self-limiting course, it continues to cause significant morbidity and mortality when associated with complications, particularly in malnourished children. Hence, the importance of vaccination and early recognition of complications is emphasized. PMID:19332925

  8. Chickenpox Chorioretinitis with Retinal Exudates and Periphlebitis

    Directory of Open Access Journals (Sweden)

    Hirokuni Kitamei

    2012-05-01

    Full Text Available Background: Chickenpox is rarely associated with posterior segment inflammation. We report on a case of unilateral chickenpox chorioretinitis with retinal exudates and periphlebitis. Case Presentation: A 21-year-old healthy man, who suffered from chickenpox 2 weeks prior to symptom development, exhibited mild anterior chamber cells, vitreous opacity, sheathing of retinal veins, and yellow-white exudates in his right eye. Varicella zoster virus DNA was detected by polymerase chain reaction in the aqueous humor. He was treated with intravenous acyclovir followed by oral prednisolone and valaciclovir. Aqueous cells quickly disappeared and retinal exudates diminished within 1 month, leaving faint retinal scarring. Retinal arteritis had never been observed in this patient. Conclusions: Although the ocular findings in this case were similar to acute retinal necrosis (ARN, the clinical features differed from ARN in the following points: (1 mild anterior chamber inflammation, (2 absence of retinal arteritis, and (3 prompt resolution of inflammatory findings. The distinctive clinical features indicated that chorioretinitis associated with chickenpox may not have the same pathological conditions as ARN.

  9. An observational study of complications in chickenpox with special reference to unusual complications in an apex infectious disease hospital, Kolkata, India

    Directory of Open Access Journals (Sweden)

    A K Kole

    2013-01-01

    Full Text Available Background: Chickenpox can cause serious complications and even death in persons without any risk factors. Aims: To observe the different complications with special reference to unusual complications of chickenpox and their outcomes. Materials and Methods: The present study was a prospective observational study where 300 patients suffering from chickenpox were evaluated with special reference to unusual complications and outcomes. Results: The usual complications of chickenpox commonly observed were acute hepatitis in 30 (10% and cerebellar ataxia in 22 patients (7.3%, whereas common unusual complications were acute pancreatitis in 45 (15%, hemorrhagic rash in 10 (3.3%, Guillain-Barrι syndrome in 4 (1.3%, disseminated intravascular coagulation in 4 (1.3%, necrotizing fasciitis in 4 (1.3%, and acute renal failure in 3 patients (1%. It had been observed that most of these unusual complications occurred in patients without any risk factor. A total of 18 patients (6% died in this study and of them 12 patients (4% died due to unusual complications. Conclusions: Compulsory childhood varicella vaccination including vaccination of risk groups and susceptible individuals are all essential to reduce the incidence of chickenpox, associated complications, and subsequent death.

  10. Simultaneous Onset of Chickenpox and Scarlet Fever: a Case Report

    Directory of Open Access Journals (Sweden)

    M Karimi

    2012-05-01

    Full Text Available Introduction: Chickenpox is a contagious febrile illness with rash that is caused by varicella zoster virus. Most children up to age 15 are infected with the virus. Scarlet fever is caused by erythrogenic toxin of streptococcus group A and usually causes skin reactions such as fine red and often itchy papules on the trunk and extremities as well as skin redness, especially on the groin and forearm. Case: Patient is a 3-year-old girl that two days after chickenpox while she had active lesions of the chickenpox, was infected with scarlet fever. Skin lesions at different stages along with the clinical symptoms confirmed the diagnosis of chickenpox. Chickenpox is a febrile illness, more contagious and associated with the rash, which rarely has been reported with scarlet fever. Macular lesions spreading all over the body especially the trunk, with strawberry red tongue and exudative lesions of tonsils with good response to penicillin confirmed the complication of scarlet fever following chickenpox. Rarely scarlet fever is a complication of chickenpox and symptoms of both conditions may be seen simultaneously. Considering that diagnosis of both diseases are based on clinical findings, so physicians should start the appropriate treatment if they have clinical suspicion.

  11. [Measles and chickenpox susceptibility among immigrants].

    Science.gov (United States)

    Gétaz, Laurent; Casillas, Alejandra; Wolff, Hans

    2016-05-01

    Exposure of immigrants to infectious diseases in their country of origin influences their susceptibility to infections later in life. Susceptibility to certain infections may significantly differs between immigrants depending on their regions of origin. Both measles and chickenpox (varicella) are conditions for which the level of exposure in the country of origin influences the preventive measures that immigrant health providers should propose. Through these two illustrative examples, this article summarizes the practical implications for clinicians who care for immigrants originating from southern countries. PMID:27323481

  12. Outbreak of chickenpox in a Union Territory of North India

    Directory of Open Access Journals (Sweden)

    M P Singh

    2015-01-01

    Full Text Available Purpose: Primary infection with a varicella-zoster virus (VZV leads to chickenpox. Though the incidence of the disease has decreased in many developed countries due to the introduction of the varicella vaccine, outbreaks continue to occur in developing countries. Materials and Methods: The present study reports an outbreak of varicella in an urbanised village in the vicinity of Chandigarh City in North India in November 2013. The outbreak was confirmed by the detection of VZV IgM antibodies in serum samples of clinically suspected patients. Vesicular fluid samples were collected from 8 patients with active lesions and tested for VZV DNA by polymerase chain reaction. Blood samples were also collected from 17 healthy controls residing in the same locality and tested for the presence of VZV IgM and IgG antibodies. Results: A total of 18 cases occurred, and the majority of them (67% were <15 years of age. Of 17 samples collected from patients with the clinically suspected disease, 13 (76.5% showed the presence of VZV IgM antibodies. Of the healthy controls, 6 were VZV IgM positive and 4 of them developed symptomatic disease on follow-up. VZV DNA was positive in 5/8 (62.5% of the patients. In one patient, VZV DNA was detected in the absence of an IgM antibody response. Conclusion: The introduction of varicella vaccine in the universal immunisation programme of India may help to prevent these outbreaks; however, the cost-benefit analysis needs to be carried out before making such policies.

  13. Acute Peripheral Facial Palsy after Chickenpox: A Rare Association

    Directory of Open Access Journals (Sweden)

    Helena Ferreira

    2014-01-01

    Full Text Available Chickenpox, resulting from primary infection by the varicella-zoster virus, is an exanthematous disease very common during childhood and with good prognosis. However, serious complications, namely, neurological syndromes, may develop during its course, especially in risk groups, including adolescents. Peripheral facial palsy is a rare neurologic complication that has been previously described. Conclusion. We report the case of a teenager with peripheral facial palsy as a complication of chickenpox, aiming to increase the awareness of this rare association.

  14. Epidemiologic lessons: Chickenpox outbreak investigation in a rural community around Chandigarh, North India

    Directory of Open Access Journals (Sweden)

    Mini Pritam Singh

    2011-01-01

    Full Text Available Purpose: Primary infection with Varicella Zoster virus (VZV leads to Varicella or chickenpox. The epidemiology of Varicella has changed dramatically since the introduction of the Varicella vaccine in 1995. The routine childhood immunization in a few countries in the western world like Germany and the United States has reduced the incidence of the disease, associated complications, hospital admissions and deaths related to its complications. However, chickenpox outbreaks are common in naive unvaccinated communities in India. Materials and Methods: We report an outbreak of chickenpox that occurred in a village situated on the outskirts of Chandigarh city in North India in the winter of 2007. The outbreak was confirmed by the detection of VZV IgM by enzyme-linked immunosorbent assay (ELISA on serum samples from the patients. In patients showing active lesions, Giemsa and indirect immunofluorescence was carried out on scrapings from vesicular lesions. Results: A total of 162 cases occurred in the present outbreak. The serum samples were collected from 20 patients, and all of them showed positive serology for VZV IgM antibodies while 19 showed a positive VZV IgG result by ELISA. The scrapings were collected from two patients showing active lesions, and both were positive by the Tzanck smear examination, and VZV antigen could be demonstrated by immunofluorescence. Conclusions: There is an urgent need to identify naive communities and unvaccinated individuals at risk. Also, there is a need for regular training programmes of health workers posted in peripheral centers so that highly contagious communicable diseases can be picked up in time and such outbreaks can be prevented.

  15. Vaccinations

    Science.gov (United States)

    ... vaccinated? For many years, a set of annual vaccinations was considered normal and necessary for dogs and ... to protect for a full year. Consequently, one vaccination schedule will not work well for all pets. ...

  16. Chickenpox – What You Need to Know

    Centers for Disease Control (CDC) Podcasts

    2011-09-29

    This podcast discusses chickenpox, its symptoms, how it spreads, and how to protect you and your family from getting it.  Created: 9/29/2011 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.   Date Released: 9/29/2011.

  17. [Vaccination for international travelers].

    Science.gov (United States)

    Arrazola, M Pilar; Serrano, Almudena; López-Vélez, Rogelio

    2016-05-01

    Traveler's vaccination is one of the key strategies for the prevention of infectious diseases during international travel. The risk of acquiring an infectious disease is determined in each case by the characteristics of the traveler and the travel, so the pre-departure medical advice of the traveler must be individualized. The World Health Organization classifies travelerś vaccines into three groups. - Vaccines for routine use in national immunization programs: Haemophilus influenzae type b, hepatitis B, polio, measles-mumps-rubella, tetanus-diphtheria-whooping a cough, and chickenpox. - Vaccinations required by law in certain countries before to enter them: yellow fever, meningococcal disease and poliomyelitis. - Vaccines recommended depending on the circumstances: cholera, japanese encephalitis, tick-borne encephalitis, meningococcal disease, typhoid fever, influenza, hepatitis A, hepatitis B, rabies and BCG. This review is intended to introduce the reader to the field of international vaccination. PMID:26920587

  18. 43例大学生水痘患者防治及护理%Prevention treatment and nursing on 43 cases of college students with chickenpox

    Institute of Scientific and Technical Information of China (English)

    苏春华

    2014-01-01

    目的:总结大学生水痘的临床表现、防治原则及护理要点,减少疾病传播,促进患者康复。方法回顾性分析2012年1月至2014年6月在本校医院就诊的43例大学生水痘病例。结果43例水痘患者均顺利出院,住院时间9~21 d,平均(13.1±5.2)d。结论水痘有较强的传染性,减毒疫苗尚未普及,而高校学生学习生活集中,故高校医务人员应加强大学生水痘患者的防治及护理,避免水痘大范围内爆发流行。%Objective To summarize the clinical manifestations ,control principles and care points of college students with chickenpox, reducing the spread of disease, and promoting the rehabilitation of patients. Methods A retrospective analysis on 43 college students with chickenpox, treated in the university hospital from January 2012 to June 2014. Results 43 cases with chickenpox were discharged, hospital stay were 9-21 d, the average( 13. 1± 5.2) d. conclusion Varicella was strongly infectious, attenuated vaccines is not yet universal, and college students’ living focus, so the medical staff in college should be strengthened prevention and care of college students with chickenpox to avoid the varicella large-scale outbreak.

  19. Hemorrhagic Pericarditis in a child with primary varicella infection (chickenpox)

    OpenAIRE

    Nandeesh B; Mahadevan Anita; Yasha T; Shankar S

    2009-01-01

    Chickenpox (Varicella) representing the primary infection by Varicella zoster virus is a common benign and self-limited infectious disease of childhood. Although the disease can be associated with complications, they are generally mild and tend to occur in adults and immunocompromised children. Severe and life-threatening complications are extremely rare, particularly those involving the cardiovascular system. We report a malnourished 5-year-old girl with chicken pox complicated by hemorrhagi...

  20. Cervical Transverse Myelitis After Chickenpox in An Immunocompetent Patient

    OpenAIRE

    Mehrnaz Rasoolinejad; Zahra Abdi Layali; Esfandiar Shojaei; Saeed Kalantari

    2010-01-01

    Varicella-zoster viruses complications involving the CNS are estimated to occur rarely, transverse myelitis after Varicella-zoster virus in most patients is characterized by an abrupt onset of progressive weakness and sensory disturbance in the lower extremities , like other viruses. We describe the case of 17 year-old boy who experienced cervical transverse myelitis after chickenpox with inability to walk and with urinary retention. He was not treated with any medication but complete revover...

  1. Varicella vaccination in HIV-1-infected children after immune reconstitution

    NARCIS (Netherlands)

    V. Bekker; G.H.A. Westerlaken; H. Scherpbier; S. Alders; H. Zaaijer; D. van Baarle; T. Kuijper

    2006-01-01

    Background: HIV-1-infected children have an increased risk of severe chickenpox. However, vaccination is not recommended in severely immunocompromised children. Objective: Can the live-attenuated varicella zoster virus (VZV) Oka strain be safely and effectively given to HIV-1-infected children despi

  2. 2007-2010年深圳市沙井街道水痘流行特征分析%Analysis on Epidemiological Characteristics of Chickenpox in Shajing Street Block of Shenzhen City from 2007 to 2010

    Institute of Scientific and Technical Information of China (English)

    刘德坚; 郑磊; 黎小炳; 陆剑勇; 袁坚

    2011-01-01

    [Objective]To grasp the epidemiological characteristics of chickenpox, provide a scientific basis for making prevention and control strategies. [Methods]The data of chickenpox in Shajing street block of Shenzhen city from 2007 to 2010 were analyzed by descriptive epidemiology method. [Results] 1 626 cases of chickenpox were reported in Shajing street block from 2007 to 2010, and the annual incidence rates ranged from 33. 95/lakh to 66. 09/lakh. There were 8 outbreaks of chickenpox, all occurred in schools and kindergartens, and 2 were public health emergencies. The autumn and winter was peak season, which was from November to next January, and the highest peak was in December. 69.99% of total cases were people under IS years old, and 28.48% were people aged 15-30 years old. Students, scattered children and preschool children accounted for 71.46% of the total patients. 18.33% of cases were workers. Outbreak investigation showed that most patients had no history of chickenpox immunization or unknown immunization history. [Conclusion]The epidemic situation of chickenpox in Shajing street block is serious, and the vaccination is the most effective means for chickenpox control. It is recommended that chickenpox vaccine should be regarded as the class I vaccine management in some areas, so as to reduce the incidence of chickenpox.%目的 及时掌握水痘的流行病学特征,为制定预防控制策略提供科学依据.方法 对深圳沙井街道2007-2010年的水痘发病资料采用描述性流行病学方法进行统计和分析.结果 2007-2010年沙井街道累计报告确诊水痘病例1626例,年发病率位于33.95/10万~66.09/10万之间;发生水痘暴发疫情8起,全部在学校和幼儿园,其中突发公共卫生事件2起;呈现秋冬季节高发特点,11月至次年1月是高峰期,最高峰在12月;15岁以下人群水痘发病数占总数的69.99%,15 ~30岁的人群发病数占报告病例总数的28.48%;学生、散居儿童和托

  3. Cervical Transverse Myelitis After Chickenpox in An Immunocompetent Patient

    Directory of Open Access Journals (Sweden)

    Mehrnaz Rasoolinejad

    2010-11-01

    Full Text Available "nVaricella-zoster viruses complications involving the CNS are estimated to occur rarely, transverse myelitis after Varicella-zoster virus in most patients is characterized by an abrupt onset of progressive weakness and sensory disturbance in the lower extremities , like other viruses. We describe the case of 17 year-old boy who experienced cervical transverse myelitis after chickenpox with inability to walk and with urinary retention. He was not treated with any medication but complete revovery has been occured.

  4. Brote de varicela en Herrera del Duque (Badajoz Chickenpox outbreak in Herrera del Duque, Badajoz, Spain

    Directory of Open Access Journals (Sweden)

    F.J. Valadés

    2003-06-01

    in Extremadura. Methods: Between November 2000 and March 2001, a descriptive study was performed. Cases of chickenpox were actively sought in a cohort of schoolchildren in Herrera del Duque (Badajoz. The protocols of the Monitoring Network of the Autonomous Community of Extremadura was used for case definition. Microbiological confirmation was performed by isolation of the virus and the presence of IgM and IgG markers in serum. We analyzed the direct and indirect tangible costs as well as the intangible costs of the outbreak. Results: Seventy-five cases were identified, of which 94.7% occurred in children aged between 1-9 years, mainly boys. The attack rate was 18.5 cases per 1,000 inhabitants and 68.2% occurred in children aged less than 10 years charing a home. The clinical course was benign, without hospital admissions or complications. A total of 71.6% of children aged between 3 and 8 years were susceptible. A possible temporary aggregation of cases in the school was analyzed and a relative risk of 5.01 (p < 0.0001 was obtained. The virus was isolated in the 4 vesicle samples studied and serology was positive (IgM in the 9 serum samples studied. The total cost of the outbreak was of 927,21 e, with a mean of 12,53 e per case and 205 school days lost. Conclusion: A chickenpox outbreack was confirmed in Herrera del Duque, with person-to-person transmission, affecting children aged between 1 and 9 years. The high susceptibility of the pupils, the characteristics of teaching, and the meetings prior to the carnivals played a determining role in the transmission of the epidemic. The estimated cost of this outbreak was 76% less than the cost that would have been generated by single-dose vaccination of the 75 individuals who contracted the disease.

  5. 一起水痘突发疫情流行病学分析%Epidemiological Analysis on An Outbreak of Chickenpox

    Institute of Scientific and Technical Information of China (English)

    彭玉琴; 王红卫

    2012-01-01

    目的:对北京市怀柔区某小学一起水痘突发疫情进行流行病学分析,为今后更好的处理水痘暴发疫情提供流行病学依据.方法:收集中国疾病控制信息系统中北京市怀柔区某小学的一起水痘突发疫情个案病例和突发疫情信息,采用描述流行病学方法分析流行病学特征.结果:水痘发病年龄(6~12) 岁,以一年级为主,共27 例,占总病例数的67.50%; 应急后免疫未超过1个月发病的2例,免疫史超过3年的发病3例,超过4年的发病3例,超过5年的发病25 例,分别占5.88% 、8.82% 、8.82% 、73.53%.结论:水痘易在学校等集体单位暴发流行,发病以低年级儿童为主,免疫史超过5年的突破病例较多.学校等集体单位在严格落实各项防控措施的同时,接种水痘减毒活疫苗(Varicella Attenuated Live Vaccine;VarV) 是预防和控制水痘最有效和最可靠的手段.%Objective:To analysis an outbreak of chickenpox in a primary school of Beijing Huairou district, to provide epidemiological basis for dealing with the epidemic of chickenpox. Methods: the information of chickenpox cases of a primary school in Beijing Huairou district was collected from Chinese Centers for Disease Control Information System, and descriptive epidemiology was used to analyze epidemiology characters of chickenpox .Results: The average age of cases was 7.08y(rangre 6y ~12y). The cases were diagnosed maily in grade 1, about 27 cases accounting for 67.50%. 2 cases within 1 month immune following stress, 3 cases withI more than 3 years immune history, 3 cases with more than 4 years immune history, 25 cases with more than 5 years immune history were diagnosed,accounting for 5.88%, 8.82%, 8.82% and 73.53% respectively. Conclusion:Chickenpox is outbreaked in collective units such as schools frequently, and the incidence cases are maily in low-grade children especially who with more than 5-year immune history. Schools and other collective units should implement

  6. Sequencing and characterization of Varicella-Zoster virus vaccine strain SuduVax

    OpenAIRE

    Kim Jong; Jung Gyoo; Kim Yu; Ji Ga; Kim Hyung; Wang Wen; Park Ho; Park Song; Kim Geun; Kwon Shi; Lee Keon; Ahn Jin; Yoon Yeup; Lee Chan

    2011-01-01

    Abstract Background Varicella-zoster virus (VZV) causes chickenpox in children and shingles in older people. Currently, live attenuated vaccines based on the Oka strain are available worldwide. In Korea, an attenuated VZV vaccine has been developed from a Korean isolate and has been commercially available since 1994. Despite this long history of use, the mechanism for the attenuation of the vaccine strain is still elusive. We attempted to understand the molecular basis of attenuation mechanis...

  7. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination.

    NARCIS (Netherlands)

    Melker, Hester E de; Berbers, Guy A M; Hahné, Susan J M; Rümke, Hans; Hof, Susan van den; Wit, G Ardine de; Boot, Hein J

    2006-01-01

    We studied the epidemiology of varicella (chickenpox) and herpes zoster (shingles) in The Netherlands to assess the desirability to implement routine varicella zoster virus vaccination in The Netherlands. Data on seroprevalence of varicella zoster virus in the general population (1995-1996), consult

  8. Simultaneous chickenpox and measles infection among migrant children who stayed in Italy during the second half of June 2011

    Directory of Open Access Journals (Sweden)

    Igor Ivi?-Hofman

    2011-11-01

    Full Text Available We are reporting on a household outbreak of measles, in which cases of simultaneous measles and chickenpox infection occured in children of a family who resided in Italy during the incubation period (June 2011. In three children, fever and generalized confluent macular rash were the dominant symptoms. Serology testing revealed simultaneous measles and chickenpox infection in four children.

  9. WAYS TO IMPROVE PREVENTION OF CHICKENPOX AT CHILDREN OF UKRAINE IN MODERN CONDITION

    Directory of Open Access Journals (Sweden)

    Kirsanova T.O.

    2015-05-01

    Full Text Available Introduction. Chickenpox (CP in recent years has tended to steady increase in the incidence of various regions of Ukraine, especially among children. The situation regarding the incidence of PA nowadays, especially among children, determines the relevance of infection and requires the solution of problems in finding the most effective ways to prevent the population of Ukraine against CP. Purpose: to theoretically justify the introduction of the National vaccination calendar of Ukraine vaccine against CP based on the study of modern epidemiological, clinical and paraclinical features of CP in children of Kharkiv region of Ukraine. Materials and methods. The analysis of statistical data on the incidence of PA in Kharkiv region and 2780 data from case histories of children aged one month PA-18, admitted to the Kharkiv Regional Hospital of Pediatric Infectious Diseases in the last five years. The diagnosis is established on the basis of characteristic clinical manifestations. Results and discussion. During the period 2010-2014 epidemiological curve morbidity in children with CP has tended to rise with maximum performance in 2011, prevailed among patients, children who lived in the city. The largest recorded incidence in children under 15 years old, had a tendency to increase the proportion of high school age children. Among dominated diseased children attending organized children's groups (kindergartens, schools, including more than a third part of patients lived in closed children's institutions (orphanages, boarding schools, etc.. Clear seasonal disease was traced to the rise of the autumn-winter period. Monitoring the number of children with CP, admitted to hospital, also showed growth in their numbers. The reason for hospitalization were: pronounced intoxication syndrome, abundant rash on skin and mucous membranes, complicated disease, epidemiological indications. The most affected age groups were children 1-10 years. The disease ran mostly in

  10. Investigation and analysis of an outbreak of chickenpox in a middle school in Shanghai%上海市某中学水痘暴发疫情调查分析

    Institute of Scientific and Technical Information of China (English)

    许闯; 李物华; 魏大伟

    2016-01-01

    目的:通过分析上海市某中学一起水痘爆发疫情的流行病学特征,为以后更好地处置水痘爆发疫情提供参考依据。方法:对2013年10月—12月40例水痘疫情开展现场流行病学调查,采用描述性流行病学方法分析流行病学特征。结果:在40例中,罹患率5.7%(40/707),患者年龄介于14~15岁。有水痘免疫接种史的27例,占67.5%,水痘疫苗接种组与未接种组间发病率有统计学差异(χ2=4.31,P<0.05)。结论:提高学校晨检质量,及时发现并隔离水痘病例,相对隔离发病班级,加强消毒及健康教育,提高水痘疫苗接种率,发病学生返校须有医院开具的证明,这些是预防和控制水痘疫情的有效措施。%Objective:To analyze the epidemiologic feature of an outbreak of chickenpox in a middle school of Shanghai to provide a reference for dealing with the outbreak of chickenpox well in the future. Methods:From Oct. to Dec. 2013, the ifeld epidemiological investigation of the chickenpox outbreak of 40 cases was carried out, and the descriptive epidemiological method was used to analyze the epidemiological characteristics. Results:In 40 cases, the attack rate was 5.7%(40/707), and the age of the cases ranged from 14 to 15 years old. There were 27 cases with the history of chickenpox immunization, accounting for 67.5%, and the incidence between the varicella vaccination group and non vaccinated group had the statistical difference(χ2=4.31, P<0.05). Conclusion:To improve the quality of school morning inspection, timely detect and isolate the cases of chickenpox, relatively isolate the class with the infected students, strengthen disinfection and health education, improve the vaccination rate of chickenpox vaccine, and allow the students to return to school with the proof issued by the hospital are these effective measures for prevention and control of varicella epidemic.

  11. Analysis of the epidemiological characteristics of chickenpox in Jiading District%嘉定区2005-2010年水痘流行病学特征分析

    Institute of Scientific and Technical Information of China (English)

    陈冬华; 钟培松; 钱杰; 李强; 汤伟琴; 杨帆; 陈斌; 季莹; 张一英; 周浩

    2013-01-01

    Objective:To know the epidemiological characteristics of chickenpox in Jiading District in order to provide some information for the control and prevention of chickenpox. Methods:Circular distribution was used to analyze the seasonal trend of chickenpox. Results:The total number of incidence was 6 091 cases from 2005-2010. Children under 14 years old accounted for 63.22%. The maximum annual incidence was 10.93/million. Circular distribution analysis showed that the seasonal trends were more obvious and their value was 0.60 and 0.63 (P<0.05). The ifrst peak time was April 3 and the second was Oct. 26. Conclusion:Chickenpox has the seasonal trend and the pre-school children and school students are in high risk. We should carry out the strategy of combined routine immunization with replanting vaccine to increase the level of immunity of chickenpox before the incidence peak.%目的:了解嘉定区水痘疫情的流行特征,为水痘防控提供依据。方法:运用圆形分布法对2005-2010年水痘疫情进行统计分析,计算角度离散度指标r值、平均角、推算高峰日,并进行雷氏检验。结果:嘉定区2005-2010年水痘总发病数为6091例,年发病率最高在2008年,为109.29/10万;14岁以下的儿童占63.22%。季节性趋势较为明显, r值分别为0.60和0.63(P<0.05),第1发病高峰时间为4月3日,第2发病高峰时间为10月26日。结论:水痘具有明显的季节性发病高峰,学龄前儿童和中小学生是水痘的高发人群,应该在高峰来临前采用学龄前儿童常规接种和在学生中补种相结合的策略开展水痘疫苗的群体水平免疫。

  12. Optic Neuritis in an Adult Patient with Chickenpox

    Directory of Open Access Journals (Sweden)

    Ana Rita Azevedo

    2012-01-01

    Full Text Available Central nervous system involvement in a patient with primary infection with Varicella zoster virus is rare, especially in the immunocompetent adult. In particular, isolated optic neuritis has been described in a small number of cases. The authors present a case of optic neuritis in an immunocompetent patient. A 28-year-old woman presented to the emergency room with a history of headaches during the previous week, without visual symptoms. The examination was unremarkable, except for a rash suggestive of chickenpox and hyperemic and edematous optic disc, bilaterally. Visual acuity and neurological examination were normal. Two days later, she complained of pain on eye movement and decreased visual acuity, which was 20/32 in her right eye and 20/60 in her left eye. Four days after admission, her visual acuity started to improve, and two months later, she had 20/20 visual acuity in both eyes. To our knowledge, this is the first reported case of an immunocompetent adult in which a Varicella zoster virus associated optic neuritis presented with fundoscopic changes before decreased visual acuity. This suggests that this condition may be underdiagnosed in asymptomatic patients.

  13. The incidence of chickenpox in the community: lessons for disease surveillance in sentinel practice networks.

    NARCIS (Netherlands)

    Fleming, D.M.; Schellevis, F.G.; Falcao, I.; Vega Alonso, T.; Padilla, M.L.

    2002-01-01

    Sentinel practice networks have been established in many European countries to monitor disease incidence in the community. To demonstrate the value of sentinel networks an international study on the incidence of chicken pox has been undertaken. Chickenpox was chosen as an acute condition for which i

  14. Occupationally Related Outbreak of Chickenpox in Hospital Staff: A Learning Experience

    OpenAIRE

    Sood, Smita

    2013-01-01

    Varicella (chicken pox) is a highly contagious disease which is caused by Varicella Zoster Virus (VZV), a ubiquitous human α herpes virus. Nosocomial varicella in hospital employees can be costly to the hospital and disruptive to patient care. This case report describes an occupationally related outbreak of chickenpox in hospital staff and the lessons which were learnt by the hospital during this experience.

  15. 北京市东城区一起学校水痘暴发疫情的调查分析%Investigation of a chickenpox outbreak in a primary school of Dongcheng district

    Institute of Scientific and Technical Information of China (English)

    王婷

    2013-01-01

    Objective To evaluate the epidemiologic features of chickenpox outbreak in a primary school of Beijing,investigate the source of the outbreak,and provide recommendations for the chickenpox control and prevention.Methods Descriptive epidemiological method was used to describe the epidemiological characters of this chickenpox outbreak.Results 57 students were infected with chickenpox virus from January 5,2012 to April 15,2012.There were 1320 students in the school.The attack rate of students in storied building was 6.5%.There were no statistics difference in the attack rate among the students of the second floor,the third floor and the fourth floor.Conclusions The main reasons of the outbreak were poor ventilation and low inoculation rate.It is important to improve the vaccination rate to reduce the risk of outbreak.%目的 分析2012年北京市东城区一所小学水痘暴发疫情的流行病学特征,初步探讨暴发疫情发生的原因,为学校水痘暴发疫情控制措施调整提供建议.方法 对本起疫情开展现场流行病学调查,采用描述流行病学的方法进行分析,总结疫情流行病学特征,分析暴发疫情发生原因.结果 2012年1月5日~4月15日该校累计57名学生发病,患者年龄8-9岁.该校在校学生1320人,平房无病例报告,楼房学生罹患率6.5%.二、三、四楼层学生罹患率无统计学差异(x2=3.634,P=0.163).结论教室通风差、疫苗接种率低为暴发疫情发生的主要原因.学校应提高学生水痘疫苗接种率,降低暴发疫情发生的风险.

  16. Precipitation of stroke-like event by chickenpox in a child with MELAS syndrome

    Directory of Open Access Journals (Sweden)

    Jian-Ren Liu

    2005-01-01

    Full Text Available The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes syndrome (MELAS is a rare congenital disorder of mitochondrial DNA (mtDNA. Herein we report a case of MELAS, whose second stroke-like episode was provoked by chickenpox. A point mutation at nucleotide (nt 3243 in mtDNA supported the diagnosis of MELAS in this case. History of myopathy, the presence of lesions that did not conform to accepted distributions of vascular territories on cranial magnetic resonance imaging (MRI, normal result of cranial magnetic resonance angiography, hyperintensity on diffusion weighted MRI and apparent diffusion coefficient mapping indicating the presence of vasogenic edema in the fresh stroke-like lesion, and mitochondrial DNA analysis helped to exclude the diagnosis of ischemic cerebral infarction which can also be induced by chickenpox.

  17. Ischemic retinal vasculitis in an 18-year-old man with chickenpox infection

    Directory of Open Access Journals (Sweden)

    Poonyathalang A,Sukavatcharin S

    2014-02-01

    Full Text Available Anuchit Poonyathalang, Somsiri Sukavatcharin, Tharikarn Sujirakul Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract: Ocular involvement after primary infection with varicella zoster virus is very rare. We report a case of a healthy 18-year-old man who presented with unilateral ischemic retinal vasculitis 10 days after the onset of chickenpox. He developed acute severe visual loss and a relative afferent pupillary defect in his right eye. Fundus imaging, optical coherence tomography, fundus fluorescence angiography, and electrophysiologic studies confirmed the diagnosis of retinal vasculitis, which led to generalized retinal ischemia. Although aggressive treatment with systemic steroids and antiviral drugs was administered, a poor visual outcome still resulted. Keywords: ischemic retinal vasculitis, chickenpox, varicella zoster virus

  18. Occupationally related outbreak of chickenpox in hospital staff: a learning experience.

    Science.gov (United States)

    Sood, Smita

    2013-10-01

    Varicella (chicken pox) is a highly contagious disease which is caused by Varicella Zoster Virus (VZV), a ubiquitous human α herpes virus. Nosocomial varicella in hospital employees can be costly to the hospital and disruptive to patient care. This case report describes an occupationally related outbreak of chickenpox in hospital staff and the lessons which were learnt by the hospital during this experience. PMID:24298507

  19. Characteristics of chickenpox in children and adults at a tertiary health center in Sarajevo, Bosnia-Herzegovina

    Directory of Open Access Journals (Sweden)

    Rusmir Baljic

    2012-06-01

    Full Text Available Introduction: Chickenpox is very contagious childhood disease, which occurs due to varicella-zoster virus (VZV primaryinfection. Disease in healthy children resolves usually without complications, but risk of complication is much higherin adults and immunocompromised hosts. The goal of this study was to determine different clinical and epidemiologicalcharacteristics, laboratory features, clinical course, and outcome of chickenpox in children and adults.Material and methods: The descriptive study was conducted at the Department of Infectious Diseases, Clinical Centerin Sarajevo, Bosnia-Herzegovina. The study included 120 patients chosen randomly. We compared their clinical andepidemiological characteristics, laboratory investigations, complications and the outcome of the disease.Results: Age of patients was in range from one to 48 years. Male patients prevailed in both groups (65% in adults,52% in children. Hospitalization rate was 10.7/100,000 inhabitants. Positive contact with chickenpox was confirmed in80% adults and 82% children. Dominating symptoms were fever, rash and muscle aches. Levels of C-reactive protein,erythrocyte sedimentation rates (ESR and fibrinogen levels were elevated in both groups, while thrombocytopenia waspresented in 33% of adults and 3% of children. Adults had complications in 83.3% and their hospitalization rate waslonger compared to children (11.5 days vs. 9.5 days, p<0.001.Conclusions: Chickenpox is a potentially severe illness in adult patients. Introduction of active immunization in Bosnia-Herzegovina should be considered to prevent severe forms of chickenpox. J Microbiol Infect Dis 2012; 2(2: 64-67Key words: Chickenpox, complications, pneumonia

  20. Poliovirus Vaccines

    OpenAIRE

    Isik Yalcin

    2008-01-01

    The two types of poliovirus vaccines are inactivated vaccine, given parenterally, and live virus vaccine, given orally. Oral poliovirus is the vaccine of choice for global eradication. Either inactivated vaccine or oral vaccine may be given concurrently with other routinely recommended childhood vaccines. No serious adverse events have been associated with the vaccine. Oral poliovirus vaccine can cause vaccine associated paralytic poliomyelitis.

  1. Chickenpox pneumonia. Case presentation. Dora Ngiza hospital, Port Elizabeth, South Africa.

    Directory of Open Access Journals (Sweden)

    Gilberto Serrano Ocaña

    2009-03-01

    Full Text Available Chickenpox is an exanthematic highly infectious disease produced by the Varicella zoster virus (VZV, commonly occurs in childhood, 90% of cases occurred in children under 12 years of age, 10% of the population over 15 years is susceptible to suffer it. It is an airborne illness, the inhale virus cause an infection in the initial respiratory epithelium, the virus spreads to distant cells of the reticuloendothelial system, finally, there is a state of viremia with skin lesions, although the spread can also be extended to the viscera. The deterioration of the cell-mediated immunity caused by coexisting diseases, HIV infection, cancer, hemato-oncology illnesses, steroid use, as well as advanced age, smoking, chronic obstructive pulmonary disease and hemorrhagic nature of the Skin lesions, are risk factors for developing Varicella-Zoster pneumonia. In this article we describe a case of chickenpox in a young HIV positive patient complicated with Varicella-Zoster pneumonia. Despite of the treatment with acyclovir, prednisone and supportive measures had a fatal outcome.

  2. Vaccine Safety

    Science.gov (United States)

    ... the safety of Tdap, Meningococcal, and HPV vaccines Human Papillomavirus (HPV) Vaccine is Very Safe Read about the safety of ... Hepatitis A Vaccine Safety Hepatitis B Vaccine Safety Human Papillomavirus (HPV) Vaccine Safety FAQs about HPV Safety Influenza (Flu) Vaccine ...

  3. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs.

    Science.gov (United States)

    Gabutti, Giovanni; Franchi, Michele; Maniscalco, Licia; Stefanati, Armando

    2016-06-01

    Varicella or chickenpox is a common and highly contagious exanthematic disease caused by the varicella-zoster virus (VZV) that during primary infection has the ability to establish latency. VZV reactivation, even decades after primary infection, causes herpes zoster. In healthy immunocompetent subjects, children in particular, varicella results in mild to moderate illness and for this reason, regardless its high morbidity, it is not considered a public health priority. Varicella still represents the most widespread vaccine preventable childhood infectious disease in industrialized countries; due to its relevant burden on healthcare resources several countries has introduced varicella vaccination into the recommended routine childhood national immunization schedule. Nowadays, live attenuated monovalent and combined MMRV vaccines are licensed worldwide. The use of several millions of doses has demonstrated the excellent safety and efficacy level of varicella vaccines as well as of combined MMRV vaccines. Universal vaccination adopted in many countries with a two-dose strategy has allowed to significantly reducing morbidity and mortality of this infectious disease. Anyway, an ample international debate is ongoing on the time range to be used between the two doses, and on the safety issues related to the use as first-dose of MMRV vaccine. Taking into account the availability of a zoster vaccine in subjects older than 50 years of age, it will be relevant to clarify if an impact on exogenous boosters and on the epidemiology of herpes zoster can occur after the adoption of extensive varicella immunization. PMID:27125440

  4. Perceived vaccination status in ecotourists and risks of anthropozoonoses.

    Science.gov (United States)

    Muehlenbein, Michael P; Martinez, Leigh Ann; Lemke, Andrea A; Ambu, Laurentius; Nathan, Senthilvel; Alsisto, Sylvia; Andau, Patrick; Sakong, Rosman

    2008-09-01

    Anthropozoonotic (human to nonhuman animal) transmission of infectious disease poses a significant threat to wildlife. A large proportion of travelers to tropical regions are not protected against vaccine-preventable illnesses, and a majority of these travelers demonstrate poor recall of actual vaccination status. Here we characterize self-perceived vaccination status among a large sample of ecotourists at the Sepilok Orangutan Rehabilitation Centre, Sabah, Malaysia. Despite their recognized travel itinerary to view endangered animals, tourists at wildlife sanctuaries are not adequately protected against vaccine-preventable illnesses. Of 633 surveys, over half reported being currently vaccinated against tuberculosis, hepatitis A, hepatitis B, polio, and measles. Fewer participants reported current vaccination status for influenza, rabies, and chickenpox. Despite the fact that the majority of visitors to Sepilok are from temperate regions where influenza is relatively more prevalent, 67.1% of those surveyed with medical-related occupations reported not being currently vaccinated for influenza. Ecotourists concerned about environmental protection are themselves largely unaware of their potential contribution to the spread of diseases to animals. The risks of negatively affecting animal populations must be communicated to all concerned parties, and this may begin by urging travelers to examine their actual vaccination status, particularly as the ecotourism industry continues its rapid expansion, and is seen increasingly as a possible tool to save great ape populations from extinction. PMID:18810550

  5. Management of Varicella Gangrenosa: A Life-Threatening Condition from Chickenpox

    Directory of Open Access Journals (Sweden)

    Judith P. M. Schots

    2014-01-01

    Full Text Available Varicella gangrenosa, in which gangrenous ulceration of the skin and/or deeper tissues is seen, is a rare but alarming complication of Varicella infection. An early surgical intervention is generally advised, especially in case of sepsis and/or the presence of large necrotic lesions. We describe a case of a previously healthy 12-month-old boy presenting with sepsis due to Varicella gangrenosa. He presented with moderate lesions of moist gangrene. We treated our patient initially with antibiotics (ceftriaxone and metronidazole and later on flucloxacillin and antiviral therapy (acyclovir whereupon his condition rapidly improved and all skin lesions healed entirely. This report highlights the possibility of conservative treatment and emphasizes the significance of acyclovir in the management of chickenpox complicated by moist gangrene due to bacterial superinfection.

  6. Epidemiological analysis of infection outbreaks of chickenpox in Fangshan District of Beijing from 2008 to 2010%北京市房山区2008-2010年水痘暴发疫情流行病学分析

    Institute of Scientific and Technical Information of China (English)

    孟毅; 于海柱; 张士清; 周伟; 高美丽

    2012-01-01

    Objective To collect more information on infection outbreaks of chickenpox in Fangshan District of Beijing from January 2008 to December 2010 so as to take more effective precautions against chickenpox in kindergartens and schools. Methods The methods of descriptive epidemiology were used to analyze the frequency of infection outbreaks of chickenpox in Fangshan District from January 2008 to December 2010. Results A total of twenty - one outbreaks occurred in Fangshan District from January 2008 to December 2010. 193 cases were reported during the period, and the incidence rate was 1.72% . Fifteen outbreaks occurred in 2008, two in 2009 , four in 2010. Five of these outbreaks occurred in kindergartens and sixteen in schools. Conclusions Chickenpox is highly infectious. Once the virus enters kindergartens or schools, it will spread rapidly. Strengthening surveillance,isolating the source of infection ,emergency vaccination of susceptible populations, and disinfection are important measures to prevent the outbreak of chicken-pox.%目的 了解北京市房山区2008-01至2010-12水痘暴发疫情情况,为制订托幼园所、学校水痘疫情防制措施提供科学依据.方法 对房山区2008-01至2010-12水痘暴发疫情进行流行病学分析研究.结果 共发生水痘暴发疫情21起,总病例数为193例,罹患率为1.72%.2008年发生15起,2009年发生2起,2010年发生4起.其中5起发生在托幼园所,16起发生在小学.结论 水痘传染性强,病毒一旦引入托幼园所、学校,传播迅速;加强监测,落实传染源隔离、对易感人群应急接种、消毒等措施是预防水痘暴发的重要措施.

  7. Observation and nursing experience of adverse reactions of children vaccinated with chicken pox vaccine%儿童接种水痘疫苗的不良反应观察及护理体会

    Institute of Scientific and Technical Information of China (English)

    李晓琴

    2015-01-01

    objective: to investigate the children chickenpox vaccine adverse reactions and the nursing countermeasures. Methods: retrospectiveanalysis of 226 cases of children had chickenpox vaccine in our adverse reactions and the nursing measures. Results: all children within a few hours after inoculation, there are different degree of mild fever, swelling pain, mild skin rashes, mild chicken pox adverse reaction, nursing measures, reduce the adverse reaction. Conclusion: the adverse reactions of vaccinated children appear in the corresponding nursing measures, can effectively reduce the occurrence of adverse reactions, and improve the success rate of the vaccination is chickenpox vaccine ascending children's health.%目的:探讨儿童接种水痘疫苗的不良反应及护理对策.方法:回顾分析我院已经接种水痘疫苗的儿童226例的不良反应及护理措施.结果:所有儿童在接种结束后的几小时内,出现有不同程度上的轻微发热、局部红肿疼痛、轻微皮疹、轻度水痘不良反应,采取护理措施后,不良反应减少.结论:针对接种后的儿童出现的不良反应进行相应的护理措施,能够有效的减少不良反应的发生,提高接种是水痘疫苗的成功率,提升儿童的身体健康.

  8. Chickenpox (Varicella)

    Science.gov (United States)

    ... Freedberg, Irwin M., ed. Fitzpatrick's Dermatology in General Medicine . 6 th ed. pp.2070, 2080-2081, 2434-2437. New York: ... German Measles (Rubella) Measles (Rubeola) Roseola (Sixth Disease) Viral ...

  9. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix).

    Science.gov (United States)

    Kreth, Hans W; Lee, Bee-Wah; Kosuwon, Pensri; Salazar, Jose; Gloriani-Barzaga, Nina; Bock, Hans L; Meurice, François

    2008-01-01

    Without vaccination, chickenpox (varicella) will affect almost every person in the world during their lifetime. The burden of disease due to varicella is often unrecognized. Varilrix is a varicella vaccine derived from the Oka strain of varicella virus. The vaccine, as a frozen formulation, was licensed for use in 1984 and was the first commercially available varicella vaccine. It subsequently became the first refrigerator-stable varicella vaccine; its development commenced in 1991 and it has been licensed for use since 1994. Varilrix is indicated for use in high-risk groups, potentially immunocompromised individuals, and healthy subjects in many countries. This article reviews data from extensive worldwide experience with the refrigerator-stable version of the vaccine, including information derived from its use in over 10,000 individuals participating in clinical trials investigating its immunogenicity, efficacy, effectiveness, and safety, as well as postmarketing data including its use in universal mass vaccination programs. Sixteen years of clinical and postmarketing experience with the same formulation represents the longest and most extensive experience with a refrigerator-stable varicella vaccine worldwide. Varilrix, in conjunction with the trivalent measles-mumps-rubella vaccine Priorix, has also been the basis for clinical development of the tetravalent measles-mumps-rubella-varicella vaccine (Priorix-Tetra). PMID:18998756

  10. Chickenpox pneumonia. Case presentation. Dora Ngiza hospital, Port Elizabeth, South Africa. Neumonia varicelosa. Presentacion de caso.

    Directory of Open Access Journals (Sweden)

    Ilen Ochoa Tamayo

    2009-03-01

    Full Text Available Chickenpox is an exanthematic highly infectious disease produced by the Varicella zoster virus (VZV, commonly occurs in childhood, 90% of cases occurred in children under 12 years of age, 10% of the population over 15 years is susceptible to suffer it. It is an airborne illness, the inhale virus cause an infection in the initial respiratory epithelium, the virus spreads to distant cells of the reticuloendothelial system, finally, there is a state of viremia with skin lesions, although the spread can also be extended to the viscera. The deterioration of the cell-mediated immunity caused by coexisting diseases, HIV infection, cancer, hemato-oncology illnesses, steroid use, as well as advanced age, smoking, chronic obstructive pulmonary disease and hemorrhagic nature of the Skin lesions, are risk factors for developing Varicella-Zoster pneumonia. In this article we describe a case of chickenpox in a young HIV positive patient complicated with Varicella-Zoster pneumonia. Despite of the treatment with acyclovir, prednisone and supportive measures had a fatal outcome.La varicela es una infección exantemática producida por el virus Varicela zoster (VZV que comúnmente ocurre en la infancia. Se reporta el 90 % de los casos en niños menores de 12 años, el 10 % de la población mayor de 15 años es susceptible a padecerla. La enfermedad se adquiere por inhalación de partículas que contienen el virus y que son expulsadas por la nasofaringe de individuos infectados. Esto causa una infección inicial en el epitelio respiratorio. El virus se disemina a células distantes del sistema retículo endotelial y, finalmente, se produce un estado de viremia con manifestaciones en la piel, aunque la diseminación también se puede extender a las vísceras. El deterioro de la inmunidad celular ocasionado por enfermedades coexistentes, infección por VIH, cáncer, enfermedad hemato-oncológica, uso de esteroides, así como, la edad avanzada, el hábito de fumar

  11. HPV vaccine

    Science.gov (United States)

    Vaccine - HPV; Immunization - HPV; Gardasil; Cervarix; HPV2; HPV4; Vaccine to prevent cervical cancer ... Girls ages 11 and 12 should receive the HPV vaccine series: The vaccine is given in three shots ...

  12. Sequencing and characterization of Varicella-Zoster virus vaccine strain SuduVax

    Directory of Open Access Journals (Sweden)

    Kim Jong

    2011-12-01

    Full Text Available Abstract Background Varicella-zoster virus (VZV causes chickenpox in children and shingles in older people. Currently, live attenuated vaccines based on the Oka strain are available worldwide. In Korea, an attenuated VZV vaccine has been developed from a Korean isolate and has been commercially available since 1994. Despite this long history of use, the mechanism for the attenuation of the vaccine strain is still elusive. We attempted to understand the molecular basis of attenuation mechanism by full genome sequencing and comparative genomic analyses of the Korean vaccine strain SuduVax. Results SuduVax was found to contain a genome that was 124,759 bp and possessed 74 open reading frames (ORFs. SuduVax was genetically most close to Oka strains and these Korean-Japanese strains formed a strong clade in phylogenetic trees. SuduVax, similar to the Oka vaccine strains, underwent T- > C substitution at the stop codon of ORF0, resulting in a read-through mutation to code for an extended form of ORF0 protein. SuduVax also shared certain deletion and insertion mutations in ORFs 17, 29, 56 and 60 with Oka vaccine strains and some clinical strains. Conclusions The Korean VZV vaccine strain SuduVax is genetically similar to the Oka vaccine strains. Further comparative genomic and bioinformatics analyses will help to elucidate the molecular basis of the attenuation of the VZV vaccine strains.

  13. Aplicación del teorema del umbral estocástico de Whittle a un brote de varicela Application of Whittle's stochastic threshold theorem to a chickenpox outbreak

    Directory of Open Access Journals (Sweden)

    Doracelly Hincapié Palacio

    2006-08-01

    model was applied. The basic reproductive rate (R0 was estimated using the maximum likelihood method based on probability distribution for the total size of the epidemic and making an approach of almost complete epidemic. Based on R0, the theorem was applied to establish some preventive measures for preventing a chickenpox outbreak. RESULTS: Each initially infected subject produced three new cases of infection requiring minimum vaccination coverage of 62% to prevent the outbreak or to reduce in 62% the contact among members of the group or to increase in 170% removal of infected subjects. CONCLUSIONS: The stochastic threshold theorem allows to identifying measures that could be implemented to prevent and control chickenpox outbreaks. Although the distribution of the epidemic size showed similar probability of occurrence of large and small outbreaks in a typical bimodal pattern, it illustrates the uncertainty of epidemic process in small groups, requiring close detection of outbreaks in such groups.

  14. Avaliação da suscetibilidade à varicela no paciente pediátrico portador de insuficiência renal crônica Evaluation of chickenpox susceptibility in children with chronic renal failure

    Directory of Open Access Journals (Sweden)

    Evandro Roberto Baldacci

    2008-03-01

    previously vaccinated by non-governmental agencies and were excluded. Varicella antibodies were evaluated by Enzyme-Linked Immuno Sorbent Assay and antibody titers above 100mUA/mL were considered protective. RESULTS: The median age was 11 years old, 66% were male, 60% lived in the city of São Paulo, with an average glomerular filtration rate of 33.6mL/min/1.73m². Clinical diagnosis of chickenpox was done by pediatricians in 39 patients and four of these 39 were seronegative for varicella. Susceptibility to chickenpox was found in 21/80 (26% patients and the relative prevalence of susceptibility to the disease was 7.93 (95%CI=3.29-19.12 higher in patients under six years of age. CONCLUSIONS: Susceptibility to varicella infection decreased with age. Patients younger than six years were eight times more susceptible than older patients and twice more susceptible compared to the Brazilian pediatric population of the same age group.

  15. Geographical epidemiology study on chickenpox features in China%我国水痘疫情的地理流行学研究

    Institute of Scientific and Technical Information of China (English)

    闫磊; 殷红梅; 黄国; 申锦玉; 牛建军; 王世文

    2011-01-01

    [Objective]To understand the epidemic features of chickenpox in China from 2007-2010 by using the geographical epidemiology methods.[Methods]Using the surveillance data from national internet-based information system of infectious diseases in China Disease Prevention and Control Center, the analysis of the status of chickenpox epidemic in China from 2007 to 2010 was conducted by GIS software(ArcGIS) and statistical software(Stata).[Results]the national average incidence of chickenpox was 20.6, 23.8, 24.1, and 24.3 per 100 000 populations in 2007-2010 respectively.Using the cases/incidence of chickenpox in 2010 as an example, there were 162 counties which incidence of chickenpox was higher than 100/100 000.Most of them were located in Tebit, Xinjiang, Sichuan, Liaoning, Guangdong, Gansu provinces and accounted for 52% of 162 counties.From 2007 to 2010, the incidence of chickenpox increased yearly.[Conclusions]The risk factors of chickenpox epidemic are different among the provinces.The prevention strategies should be developed based on the local situation.%[目的]从地理流行病学的角度了解我国2007~2010年水痘发病情况.[方法]使用中国疾病预防控制中心"疾病监测信息报告管理系统",ArcGIS地理信息系统软件,Stata统计分析软件对2007-2010年全国水痘疫情分布进行了分析.[结果]2007-2010年全国平均发病率分别为十万分之20.6、23.8、24.1、和24.3,以2010年为例,发病率大于100/10万共有162的县,多数集中在西藏、新疆、四川、辽宁、广东、甘肃六个省,占总数的52%.2007-2010年全国水痘病例报告的人数和平均发病率的有逐年增高的趋势.[结论] 水痘发病的地域区别较大,影响发病率的因素较多,各地应根据自身情况与实际特点有针对性的进行防控.

  16. Pneumococcal vaccine.

    OpenAIRE

    1999-01-01

    Streptococcus pneumoniae is a frequent cause of pneumonia and meningitis. This article looks at the pneumococcal vaccine, its uses, efficacy, and adverse effects and how vaccination may be improved. We also look at the role of the new conjugate vaccines.

  17. Polio Vaccination

    Science.gov (United States)

    ... to its advantages over IPV in providing intestinal immunity and providing secondary spread of the vaccine to unprotected contacts. Who needs this vaccine and when? Side Effects Excerpt from Vaccine Information Statement A Polio-Free ...

  18. Smallpox Vaccination

    Science.gov (United States)

    ... Newsletters Events Also Known As Smallpox = Vaccinia Smallpox Vaccination Recommend on Facebook Tweet Share Compartir The smallpox ... like many other vaccines. For that reason, the vaccination site must be cared for carefully to prevent ...

  19. Social epidemiology of a large outbreak of chickenpox in the Colombian sugar cane producer region: a set theory-based analysis Epidemiología social de una gran epidemia de varicela en la región colombiana productora de caña de azúcar: un análisis basado en teoría de conjuntos

    Directory of Open Access Journals (Sweden)

    Alvaro J. Idrovo

    2011-07-01

    Full Text Available There are few social epidemiologic studies on chickenpox outbreaks, although previous findings suggested the important role of social determinants. This study describes the context of a large outbreak of chickenpox in the Cauca Valley region, Colombia (2003 to 2007, with an emphasis on macro-determinants. We explored the temporal trends in chickenpox incidence in 42 municipalities to identify the places with higher occurrences. We analyzed municipal characteristics (education quality, vaccination coverage, performance of health care services, violence-related immigration, and area size of planted sugar cane through analyses based on set theory. Edwards-Venn diagrams were used to present the main findings. The results indicated that three municipalities had higher incidences and that poor quality education was the attribute most prone to a higher incidence. Potential use of set theory for exploratory outbreak analyses is discussed. It is a tool potentially useful to contrast units when only small sample sizes are available.Hay pocos estudios de epidemiología social sobre epidemias de varicela, aunque resultados previos sugieren un importante rol de los determinantes sociales. Este estudio describe el contexto de una gran epidemia de varicela en la región del Valle del Cauca, Colombia (2003 a 2007, con énfasis en algunos macro-determinantes. Exploramos las tendencias temporales de la incidencia de varicela en 42 municipios para identificar los lugares con mayor ocurrencia. Analizamos las características municipales (calidad de educación, cobertura de vacunación, desempeño de los servicios de salud, inmigración relacionada con violencia, y área cultivada con caña de azúcar mediante análisis basados en teoría de conjuntos. Diagramas de Venn de Edward fueron usados para presentar los principales hallazgos. Los resultados indicaron que tres municipios tuvieron las mayores incidencias y que la educación de pobre calidad fue el atributo m

  20. Vaccine Hesitancy.

    Science.gov (United States)

    Jacobson, Robert M; St Sauver, Jennifer L; Finney Rutten, Lila J

    2015-11-01

    Vaccine refusal received a lot of press with the 2015 Disneyland measles outbreak, but vaccine refusal is only a fraction of a much larger problem of vaccine delay and hesitancy. Opposition to vaccination dates back to the 1800 s, Edward Jenner, and the first vaccine ever. It has never gone away despite the public's growing scientific sophistication. A variety of factors contribute to modern vaccine hesitancy, including the layperson's heuristic thinking when it comes to balancing risks and benefits as well as a number of other features of vaccination, including falling victim to its own success. Vaccine hesitancy is pervasive, affecting a quarter to a third of US parents. Clinicians report that they routinely receive requests to delay vaccines and that they routinely acquiesce. Vaccine rates vary by state and locale and by specific vaccine, and vaccine hesitancy results in personal risk and in the failure to achieve or sustain herd immunity to protect others who have contraindications to the vaccine or fail to generate immunity to the vaccine. Clinicians should adopt a variety of practices to combat vaccine hesitancy, including a variety of population health management approaches that go beyond the usual call to educate patients, clinicians, and the public. Strategies include using every visit to vaccinate, the creation of standing orders or nursing protocols to provide vaccination without clinical encounters, and adopting the practice of stating clear recommendations. Up-to-date, trusted resources exist to support clinicians' efforts in adopting these approaches to reduce vaccine hesitancy and its impact. PMID:26541249

  1. Analysis of single nucleotide polymorphism among Varicella-Zoster Virus and identification of vaccine-specific sites.

    Science.gov (United States)

    Jeon, Jeong Seon; Won, Youn Hee; Kim, In Kyo; Ahn, Jin Hyun; Shin, Ok Sarah; Kim, Jung Hwan; Lee, Chan Hee

    2016-09-01

    Varicella-zoster virus (VZV) is a causative agent for chickenpox and zoster. Live attenuated vaccines have been developed based on Oka and MAV/06 strains. In order to understand the molecular mechanisms of attenuation, complete genome sequences of vaccine and wild-type strains were compared and single nucleotide polymorphism (SNP) was analyzed. ORF22 and ORF62 contained the highest number of SNPs. The detailed analysis of the SNPs suggested 24 potential vaccine-specific sites. All the mutational events found in vaccine-specific sites were transitional, and most of them were substitution of AT to GC pair. Interestingly, 18 of the vaccine-specific sites of the vaccine strains appeared to be genetically heterogeneous. The probability of a single genome of vaccine strain to contain all 24 vaccine-type sequences was calculated to be less than 4%. The average codon adaptation index (CAI) value of the vaccine strains was significantly lower than the CAI value of the clinical strains. PMID:27376245

  2. Adolescent Vaccination

    OpenAIRE

    Mustafa Hacımustafaoğlu

    2008-01-01

    Adolescent period usually are omitted regarding the vaccination and the other health evaluations, in our country. Adolescent period is usually considered as between the ages of 8-18 years. During this period, it is important to evaluate routine adolescent examination as well as vaccination status.Childhood (0-18 years) vaccination can be considered in three stages; infantil period vaccinations (

  3. Hepatitis Vaccines

    OpenAIRE

    Ogholikhan, Sina; Schwarz, Kathleen B

    2016-01-01

    Viral hepatitis is a serious health problem all over the world. However, the reduction of the morbidity and mortality due to vaccinations against hepatitis A and hepatitis B has been a major component in the overall reduction in vaccine preventable diseases. We will discuss the epidemiology, vaccine development, and post-vaccination effects of the hepatitis A and B virus. In addition, we discuss attempts to provide hepatitis D vaccine for the 350 million individuals infected with hepatitis B ...

  4. An Evaluation to assess the Knowledge regarding Prevention and Management of Chickenpox in Children among Mothers having Children below 10 years of age residing at selected community area of Allahabad (India

    Directory of Open Access Journals (Sweden)

    Jemy Elizabeth Joseph

    2013-01-01

    Full Text Available Chickenpox is a worldwide disease and is no respecter race or class. The incidence increases in spring & winter months in the temperate zones. In the tropics, the peak incidence is during winter and early spring. The disease in fact started spreading from February itself. Lack of knowledge among common people on preventing water contamination is helping the virus to spread rapidly. The descriptive study attempts to assess the knowledge regarding prevention and management of chickenpox among mothers of below 10 years of age children who are residing at Naini, Allahabad with a view to develop an information booklet. Method: The study involved single group test without a control, using non-experimental descriptive design, with non-probability convenient sampling. 60 women were involved in data collection by using structured questionnaire. The study came to an end by implementation of information booklet on chickenpox and its prevention and management, and the results were described using descriptive and inferential statistics. Results: The overall mean knowledge score was found to be 48.86 % and S.D 5.87. The highest mean knowledge score was found on general health (46.5%. The mean knowledge score varied from 46.5% to 55.6% on different aspects of chickenpox.  Chi-square test implies that there was a statistically significant association between selected demographic variables with knowledge of prevention and home care management of chickenpox at 5 percent level. Conclusion: The overall findings of the study clearly showed that there is lack of knowledge of prevention and home care management of chickenpox among mothers and the results revealed that distribution of information booklet on chickenpox and its prevention and management will be helpful for the women to gain knowledge.

  5. 衡阳市2005-2007年水痘流行情况分析%Epidemiological analysis of chickenpox in Hengyang from 2005 to 2007

    Institute of Scientific and Technical Information of China (English)

    朱玲; 谢建民; 曾亚雄; 伍运生

    2008-01-01

    目的 分析衡阳市水痘流行情况,为水痘防制工作提供科学依据.方法 对2005-2007年衡阳市水痘疫情进行描述性流行病学分析.结果 衡阳市2005-2007共发生水痘1048例,无死亡,发病率呈逐年上升趋势.5、11月份为发病高峰月份,病例主要为学生.期间共有水痘暴发疫情20起,全部发生在农村中小学校.结论 加强学校卫生防病工作是预防控制水痘暴发和流行的工作重点.%Objective To analyze the epidemic situation of chickenpox in Hengyang,Hunan province and provide a scientific basis for effective prevention and control of the disease.Methods Descriptive epidemiologieal method was used to analyze the data of chickenpox activity in Hengyang from 2005 to 2007.Results Between 2005 and 2007,1048 cases of chickenpox were confirmed and no one died.The morbidity showed an increasing trend year by year.Most of the cases were seen in students.A total of 20 outbreaks were reported during the period,and the peak incidence appeared in May and November.All the events took place in rural schools.Conclusion Emphases should be put on strengthening rural schools'health management to prevent and control chickenpox effectively.

  6. HPV vaccine

    Science.gov (United States)

    Vaccine - HPV; Immunization - HPV; Gardasil; Cervarix; HPV2; HPV4; Vaccine to prevent cervical cancer ... HPV is a common virus that is spread through sexual contact. There are several types of HPV. ...

  7. Diphtheria Vaccination

    Science.gov (United States)

    ... children and adults - Tetanus-diphtheria-acellular Pertussis vaccine Diphtheria Vaccination Pronounced (dif-THEER-ee-a) Recommend on Facebook Tweet Share Compartir Diphtheria causes a thick covering in the back of ...

  8. Pneumococcal Vaccines

    OpenAIRE

    Chen-Fang Ho; Tzou-Yien Lin

    2005-01-01

    Streptococcus pneumoniae is the leading bacterial pathogen of infectious diseases inchildren and adolescents. The 23-valent pneumococcal polysaccharide vaccine could preventinvasive pneumococcal infection with broader serotype coverage but still has some limitations.On the other hand, 7-valent pneumococcal conjugate vaccine has been shown todecrease cases of nasopharyngeal acquired S. pneumoniae vaccine serotypes and provedherd immunity. The safety and efficacy against vaccine serotype pneumo...

  9. DNA vaccines

    OpenAIRE

    Coban, Cevayir; Kobiyama, Kouji; Jounai, Nao; Tozuka, Miyuki; Ishii, Ken J.

    2013-01-01

    Since the introduction of DNA vaccines two decades ago, this attractive strategy has been hampered by its low immunogenicity in humans. Studies conducted to improve the immunogenicity of DNA vaccines have shown that understanding the mechanism of action of DNA vaccines might be the key to successfully improving their immunogenicity. Our current understanding is that DNA vaccines induce innate and adaptive immune responses in two ways: (1) encoded protein (or polypeptide) antigen(s) by the DNA...

  10. The evaluation of emergent vaccination against varicells%水痘疫苗应急接种效果评价

    Institute of Scientific and Technical Information of China (English)

    赵伟

    2012-01-01

    Objective To valuation the effect of varicella vaccine's emergent vaccination and to understand the sero prevalence of varicella-zoster virus (VZV).Methods Sevevteen schools which had Chickenpox outbreak in the years of 2004~2006 were chosen as the field of epidemiological study.The chickenpox patients and close contects in 5 schools of them were investigated in Questionnaire.And we collected 85 serum samples of students before and after immunity in 2 schools to test IgG antibody of VZV using ELISA.Results The attack rates of chickenpox in the schools before and after emergent vaccination are 6.22% and 1.65%.The difference was significant(x2=10.99,P<0.01).The attack rate of exposure group was significant lower than the control group(x2=20.70,P<0.01).Antibodies effective rate after immunity was 90.70%,Antibody positive rate was 87.80%,and Immune success rate was 70.70%.Condusion Emergent vaccination can effectively control the chickenpox outbreak.So the result of study suggests that emergent vaccination should be done immediately once a chickenpox case has occured in a school.%目的 评价水痘疫苗应急接种效果及暴发后人群抗体水平,指导水痘暴发疫情控制.方法 以2004-2006年发生水痘暴发的17所学校为研究对象,对其中5所学校的患者及密切接触者进行问卷调查,并采集2所学校水痘疫苗应急接种后应急接种者免疫前后血清标本各85份进行水痘疫苗血清抗体滴度测定.结果 应急接种前学校水痘罹患率为6.22%,应急接种后学校水痘罹患率为1.65%,两者的差别有统计学意义(x2=10.99,P<0.01);接种疫苗者与未接种水痘者的水痘罹患率分别为8.60%和19.89%,免疫人群的水痘罹患率明显低于未免人群(x2=20.70,P<0.01);接种水痘疫苗后血清抗体有效率为90.70%,抗体阳转率为87.80%,免疫成功率为70.70%.结论 应急接种对控制学校水痘疫情暴发有重要作用,建议在出现水痘

  11. FLU VACCINATION

    CERN Multimedia

    2007-01-01

    People working on the CERN site who wish to be vaccinated may go to the Infirmary (ground-floor, bldg. 57), with their vaccine, without a prior appointment. The vaccine can be reimbursed directly by Uniqa providing you attach the receipt and the prescription that you will receive from the Medical Service the day of your injection at the infirmary. Ideally, the vaccination should take place between 1st October and 30th November 2007 (preferably between 14:00 and 16:00). CERN staff aged 50 or over are recommended to have influenza vaccinations. Vaccination is particularly important for those suffering from chronic lung, cardio-vascular or kidney problems, for diabetics and those convalescing from serious medical problems or after serious surgical operations. The Medical Service will not administer vaccines for family members or retired staff members, who must contact their normal family doctor. Medical Service

  12. Children with chickenpox:a care of 42 cases%42例小儿水痘护理体会

    Institute of Scientific and Technical Information of China (English)

    陈玉婷

    2014-01-01

    Objective To investigate the methods of care chickenpox in children. Methods Isolation of children, and to give calamine lotion and topical acyclovir ointment, pruritus obvious oral antihistamines. Care items including general care, barrier nursing, nursing fever, skin and blister care, diet care, psychological care, and close observation the changes to prevent complications. Results Of the 42 patients were cured after treatment 7d 23 cases, the cure rate was 54.76%, the total effective 33 cases, the total effective rate was 78.75%, 14d after treatment cured 37 cases, the cure rate was 88.1%, the total effective 42 cases, the total efficiency was 100.00%. Rash face healed without scar formation. Conclusion Variety attentive care measures and calamine lotion and ointment acyclovir topical, has good efficacy, fewer side effects, is one of the better way to treat children with chickenpox.%目的:探讨小儿水痘的护理方法。方法隔离患儿,并给予炉甘石洗剂及阿昔洛韦软膏外用,皮肤瘙痒明显者可口服抗组胺药。包括:一般护理、隔离护理、发热护理、皮肤与水疱护理、饮食护理、心理护理,并密切观察病情变化,以防并发症的发生。结果42例患儿治疗7d后痊愈23例,痊愈率为54.76%,总有效33例,总有效率78.75%,治疗14d后痊愈37例,痊愈率为88.1%,总有效率42例,总有效率为100.00%。皮疹面愈合良好,无瘢痕形成。结论多种细心护理措施和炉甘石洗剂及阿昔洛韦软膏外用,疗效好,副作用较少,是治疗小儿水痘的较好方法之一。

  13. 水痘疫苗(1剂)在控制水痘流行病中的作用%Study on role of chickenpox vaccine in controling chickenpox epidemic

    Institute of Scientific and Technical Information of China (English)

    王传波; 赵海

    2013-01-01

    目的 研究水痘疫苗1剂在控制水痘流行病中的作用.方法 对我社区随机选取的120例符合入组标准儿童进行分组调查分析其发病情况,然后进行统计学分析,观察接种水痘疫苗对发病的影响.结果 其中100例接种水痘疫苗1剂的儿童在3个月内未发生水痘感染情况,1年内有2位感染水痘.未接种组20位儿童,3个月内水痘感染1人,6个月内感染2人,1年感染3人,其感染人数比例及发病率均高于接种组.结论 接种水痘疫苗对水痘发病率具有良好的控制.

  14. Hepatitis Vaccines.

    Science.gov (United States)

    Ogholikhan, Sina; Schwarz, Kathleen B

    2016-01-01

    Viral hepatitis is a serious health problem all over the world. However, the reduction of the morbidity and mortality due to vaccinations against hepatitis A and hepatitis B has been a major component in the overall reduction in vaccine preventable diseases. We will discuss the epidemiology, vaccine development, and post-vaccination effects of the hepatitis A and B virus. In addition, we discuss attempts to provide hepatitis D vaccine for the 350 million individuals infected with hepatitis B globally. Given the lack of a hepatitis C vaccine, the many challenges facing the production of a hepatitis C vaccine will be shown, along with current and former vaccination trials. As there is no current FDA-approved hepatitis E vaccine, we will present vaccination data that is available in the rest of the world. Finally, we will discuss the existing challenges and questions facing future endeavors for each of the hepatitis viruses, with efforts continuing to focus on dramatically reducing the morbidity and mortality associated with these serious infections of the liver. PMID:26978406

  15. Hepatitis Vaccines

    Directory of Open Access Journals (Sweden)

    Sina Ogholikhan

    2016-03-01

    Full Text Available Viral hepatitis is a serious health problem all over the world. However, the reduction of the morbidity and mortality due to vaccinations against hepatitis A and hepatitis B has been a major component in the overall reduction in vaccine preventable diseases. We will discuss the epidemiology, vaccine development, and post-vaccination effects of the hepatitis A and B virus. In addition, we discuss attempts to provide hepatitis D vaccine for the 350 million individuals infected with hepatitis B globally. Given the lack of a hepatitis C vaccine, the many challenges facing the production of a hepatitis C vaccine will be shown, along with current and former vaccination trials. As there is no current FDA-approved hepatitis E vaccine, we will present vaccination data that is available in the rest of the world. Finally, we will discuss the existing challenges and questions facing future endeavors for each of the hepatitis viruses, with efforts continuing to focus on dramatically reducing the morbidity and mortality associated with these serious infections of the liver.

  16. Flu Vaccination

    CERN Multimedia

    2006-01-01

    People working on the CERN site who wish to be vaccinated against influenza may go to the Medical Service (ground floor, Bldg. 57) without an appointment (preferably between 14:00 and 16:00), PROVIDED THAT THEY BRING THEIR OWN VACCINE WITH THEM. Ideally, vaccination should take place between 1st October and 30th November 2006. The influenza vaccine is recommended for CERN staff aged 50 and over. Vaccination is particularly important for those suffering from chronic lung, cardio-vascular or kidney problems, for diabetics and for those convalescing from serious medical problems or major surgery. The Medical Service will not administer vaccines to family members or retired staff members, who must contact their family doctor. CERN Medical Service

  17. FLU VACCINATION

    CERN Multimedia

    2006-01-01

    People working on the CERN site who wish to be vaccinated against influenza may go to the Medical Service (ground floor, Bldg. 57) without an appointment (preferably between 14:00 and 16:00), PROVIDED THAT THEY BRING THEIR OWN VACCINE WITH THEM. Ideally, vaccination should take place between 1st October and 30th November 2006. The influenza vaccine is recommended for CERN staff aged 50 and over. Vaccination is particularly important for those suffering from chronic lung, cardio-vascular or kidney problems, for diabetics and for those convalescing from serious medical problems or major surgery. The Medical Service will not administer vaccines to family members or retired staff members, who must contact their family doctor. CERN Medical Service

  18. Flu vaccination

    CERN Multimedia

    CERN Medical Service

    2006-01-01

    People working on the CERN site who wish to be vaccinated against influenza may go to the Medical Service (ground floor, Bldg. 57) without an appointment (preferably between 14:00 and 16:00), PROVIDED THAT THEY BRING THEIR OWN VACCINE WITH THEM. Ideally, vaccination should take place between 1st October and 30th November 2006. The influenza vaccine is recommended for CERN staff aged 50 and over. Vaccination is particularly important for those suffering from chronic lung, cardio-vascular or kidney problems, for diabetics and for those convalescing from serious medical problems or major surgery. The Medical Service will not administer vaccines to family members or retired staff members, who must contact their family doctor.CERN Medical Service

  19. Flu Vaccination

    CERN Multimedia

    2006-01-01

    People working on the CERN site who wish to be vaccinated against influenza may go to the Medical Service (ground floor, Bldg. 57) without an appointment (preferably between 14:00 and 16:00), PROVIDED THAT THEY BRING THEIR OWN VACCINE WITH THEM. Ideally, vaccination should take place between 1st October and 30th November 2006. The influenza vaccine is recommended for CERN staff aged 50 and over. Vaccination is particularly important for those suffering from chronic lung, cardio-vascular or kidney problems, for diabetics and for those convalescing from serious medical problems or major surgery. The Medical Service will not administer vaccines to family members or retired staff members, who must contact their family doctor. CERN Medical service

  20. Leptospirosis vaccines

    OpenAIRE

    Jin Li; Wang Zhijun; Węgrzyn Alicja

    2007-01-01

    Abstract Leptospirosis is a serious infection disease caused by pathogenic strains of the Leptospira spirochetes, which affects not only humans but also animals. It has long been expected to find an effective vaccine to prevent leptospirosis through immunization of high risk humans or animals. Although some leptospirosis vaccines have been obtained, the vaccination is relatively unsuccessful in clinical application despite decades of research and millions of dollars spent. In this review, the...

  1. LGBT health and vaccinations: Findings from a community health survey of Lexington-Fayette County, Kentucky, USA.

    Science.gov (United States)

    Jones, Jeff; Poole, Asheley; Lasley-Bibbs, Vivian; Johnson, Mark

    2016-04-01

    Data on adult immunization coverage at the state level and for LGBT Americans in particular are sparse. This study reports the results of a 2012 Lexington-Fayette County, Kentucky, community health assessment's results asking about eight adult vaccinations among 218 lesbian, gay, bisexual, and transgendered (LGBT) respondents. Researchers collected data using an online survey distributed through LGBT social media, posters, and LGBT print media. The LGBT sample largely matches the demographics of the county as a whole except this group reports higher level of education and fewer uninsured individuals. Among LGBT respondents, immunization prevalence reaches 68.0% (annual Influenza), 65.7% (Hepatitis B), 58.8% (Chickenpox/Varicella), 55.9% (Hepatitis A), 41.2% (Smallpox), and 25.8% (Pneumonia). Among respondents who are currently within the recommended 19-26 years age range for the Human Papillomavirus (HPV) vaccine, the LGBT females are less likely to report receiving the vaccine (15.4%) compared to the national coverage percentage of 34.5%. Males, however, are more likely to have received the vaccine (10.3%) than the national percentage of 2.3%. The small number of LGBT seniors in the study report a much higher prevalence of the Shingles (Herpes Zoster) vaccines than for U.S. seniors 60 and older (71.4% compared to 20.1% nationally). LGBT respondents report higher percentages of adult vaccination. PMID:26930365

  2. Epidemic Situation of Chickenpox in Jinjiang District of Chengdu, 2006 -2010%2006-2010年成都市锦江区水痘疫情分析

    Institute of Scientific and Technical Information of China (English)

    王忠民

    2012-01-01

    Objective By understanding the epidemic situation of chickenpox in Jinjiang district, to provide scientific evidence for developing measures of chickenpox prevention. Method Data of chickenpox epidemic situation in Jinjiang district from 2006 to 2010 was analyzed. Results Totally 1 372 chickenpox patients were reported during 2006 to 2010, the annual incidence rate was 62. 63/105 Dongguang (14. 58% ) , Shizishan (10. 71% ) , Liujiang (9. 32% ) , and Sansheng (8. 53% ) were the jurisdictions with the highest proportion of chickenpox. Among the cases, 747 were male, and 625 were female. The proportions of 0 - 3, 4 - 9, 10-15 years old group were 13. 56% , 50. 58% , and 19. 02% respectively. The proportions of students, child -care children, and scattered children were 41. 84% , 33. 89% , and 11. 08% respectively. The incidence concentrated in A-pril to June (43. 00% ) and November to the next January (27. 11% ). Both the incidence in 2007 (78. 84/ 105) and 2009 (76. 28/105) were high. Conclusion The highest incidences of chickenpox were in 2007 and 2009 in Jinjiang district from 2006 to 2010, and peaked every two years, while the proportion of cases was high in the agriculture - related street area. .%目的 了解2006 - 2010年成都市锦江区水痘疫情情况,为制定水痘防制措施提供科学依据.方法 对2006 - 2010年锦江区水痘疫情资料进行分析.结果 2006 -2010年共报告水痘1 372例,年均发生率为62.63/10万.水痘发病数较高的涉农街道辖区分别为东光(14.58%,200/1 372)、狮子山(10.71%,147/1 372)、柳江(9.32%,128/1 372)和三圣(8.53%,117/1 372).男性747例,女性625例;0~3岁占13.56%(186/1 372)、4~9岁占50.58% (694/1 372)、10~ 15岁占19.02%(261/1 372),学生占41.84%、托幼儿童占33.89%、散居儿童占11.08%;发病时间集中在4~6月和11月~次年1月,分别占43.00%和27.11%.2007和2009年发病率较高,分别为78.84/10万和76.28/10万.结论 2006 -2010

  3. Ultra-violet radiation is responsible for the differences in global epidemiology of chickenpox and the evolution of varicella-zoster virus as man migrated out of Africa

    Directory of Open Access Journals (Sweden)

    Rice Philip S

    2011-04-01

    Full Text Available Abstract Background Of the eight human herpes viruses, varicella-zoster virus, which causes chickenpox and zoster, has a unique epidemiology. Primary infection is much less common in children in the tropics compared with temperate areas. This results in increased adult susceptibility causing outbreaks, for example in health-care workers migrating from tropical to temperate countries. The recent demonstration that there are different genotypes of varicella-zoster virus and their geographic segregation into tropical and temperate areas suggests a distinct, yet previously unconsidered climatic factor may be responsible for both the clinical and molecular epidemiological features of this virus infection. Presentation of the hypothesis Unlike other human herpes viruses, varicella-zoster virus does not require intimate contact for infection to occur indicating that transmission may be interrupted by a geographically restricted climatic factor. The factor with the largest difference between tropical and temperate zones is ultra-violet radiation. This could reduce the infectiousness of chickenpox cases by inactivating virus in vesicles, before or after rupture. This would explain decreased transmissibility in the tropics and why the peak chickenpox incidence in temperate zones occurs during winter and spring, when ultra-violet radiation is at its lowest. The evolution of geographically restricted genotypes is also explained by ultra-violet radiation driving natural selection of different virus genotypes with varying degrees of resistance to inactivation, tropical genotypes being the most resistant. Consequently, temperate viruses should be more sensitive to its effects. This is supported by the observation that temperate genotypes are found in the tropics only in specific circumstances, namely where ultra-violet radiation has either been excluded or significantly reduced in intensity. Testing the Hypothesis The hypothesis is testable by exposing

  4. Typhoid vaccines.

    Science.gov (United States)

    Aggarwal, A; Dutta, A K

    2001-08-01

    Typhoid fever continues to be a major public health problem in developing countries with about 33 million cases per year. Protective efficacy of traditional acetone/phenol killed vaccines is similar to newer typhoid vaccines (Ty21A and Vi antigen vaccine) but side effects of these newer vaccines are considerably less. Though the mortality is low, typhoid fever causes considerable morbidity and loss of working days. Problems during treatment are increasing due to emergence and spread of multidrug resistant S. typhi. Hence to decrease the incidence of typhoid fever in addition to ensuring safe water supply and excreta disposal a typhoid vaccine needs to be introduced in the National Immunization Schedule. PMID:11563251

  5. Tumor vaccines

    International Nuclear Information System (INIS)

    Tumor vaccines have several potential advantages over standard anticancer regiments. They represent highly specific anticancer therapy. Inducing tumor-specific memory T-lymphocytes, they have potential for long-lived antitumor effects. However, clinical trials, in which cancer patients were vaccinated with tumor vaccines, have been so far mainly disappointing. There are many reasons for the inefficiency of tumor vaccines. Most cancer antigens are normal self-molecules to which immune tolerance exists. That is why the population of tumor-specific lymphocytes is represented by a small number of low-affinity T-lymphocytes that induce weak antitumor immune response. Simultaneously, tumors evolve many mechanisms to actively evade immune system, what makes them poorly immunogenic or even tolerogenic. Novel immunotherapeutic strategies are directed toward breaking immune tolerance to tumor antigens, enhancing immunogenicity of tumor vaccines and overcoming mechanisms of tumor escape. There are several approaches, unfortunately, all of them still far away from an ideal tumor vaccine that would reject a tumor. Difficulties in the activation of antitumor immune response by tumor vaccines have led to the development of alternative immunotherapeutic strategies that directly focus on effector mechanisms of immune system (adoptive tumor- specific T-lymphocyte transfer and tumor specific monoclonal antibodies). (author)

  6. Arthropod vaccines.

    Science.gov (United States)

    Lee, R; Opdebeeck, J P

    1999-03-01

    Antigens located in the midgut of the tick are hidden from the host's immune system. Egg production of ticks can be reduced when ticks are fed on animals vaccinated with midgut antigens of the tick, and a subunit vaccine formulated with the recombinant antigen Bm86 is now available that can reduce the number of ticks infesting cattle grazing on pasture. Midgut antigens used in vaccines against insects that transmit pathogenic organisms to humans have not been as effective in reducing insect fecundity and an alternative approach may be necessary. Transmission-blocking vaccines directed at interfering with the vector-pathogen interaction could result in loss of vector competence and block the spread of disease-causing organisms. PMID:10198800

  7. Influenza vaccination

    DEFF Research Database (Denmark)

    Østerhus, Sven Frederick

    2015-01-01

    The Cochrane Library was systematically searched for meta-analyses regarding influenza vaccination of various populations, both healthy and sick. An effect in reducing the number of cases of influenza, influenza-like illness or complications to influenza was found in some studies, but, generally......, the quality of the studies was low, and several studies lacked hard clinical endpoints. Data on adverse effects were scarce. More randomised controlled trials investigating the effects of influenza vaccination are warranted....

  8. Antipneumococcal vaccination

    Directory of Open Access Journals (Sweden)

    Gian Vincenzo Zuccotti

    2013-06-01

    Full Text Available Streptococcus pneumoniae (SP is a gram-positive bacterium with more than 90 known serotypes causing around 11% of all deaths worldwide in children aged 1-59 months. A new era in prevention of SP-related diseases started in at the beginning of 2000s when a 7-valent pneumococcal conjugate vaccine (PCV7 was recommended as the vaccine of choice in pediatric age. PCV7 dramatically reduced invasive pneumococcal diseases (IPD among children with indirect effects noted among other age groups as well. However, thanks to a strict surveillance network, an increase in non-vaccine serotypes (NVTs causing IPD was noted worldwide and in late 2000s a new second generation vaccine (13-valent pneumococcal conjugate vaccine-PCV13 with an expanded serotype coverage was licensed. Due to the lack of solid effectiveness data, up to know it is difficult to predict how the composition of NVTs will change after the large-scale introduction of PCV13 or whether the characteristics of the serotypes will change. Long-term surveillance of both IPD, pneumonia, acute otitis media and carriage will be crucial to ascertain whether these second generation vaccines are having the desired effect of reducing the incidence of diseases in the long term. Proceedings of the 9th International Workshop on Neonatology · Cagliari (Italy · October 23rd-26th, 2013 · Learned lessons, changing practice and cutting-edge research

  9. Vaccines Against Malaria

    OpenAIRE

    Ouattara, Amed; Laurens, Matthew B.

    2014-01-01

    No licensed malaria vaccine currently exists; however, final phase 3 testing results of a leading candidate vaccine are forthcoming. Continued challenges to malaria vaccine developers include genetically diverse strains found in nature and establishment of a vaccine correlate of protection.

  10. HPV Vaccine and Pregnancy

    Science.gov (United States)

    ... recurrent respiratory papillomatosis (JORRP). What is the HPV vaccine? The HPV vaccine provides protection against some types of HPV. ... I am pregnant. Should I get the HPV vaccine? The HPV vaccine is not recommended for pregnant women because ...

  11. Ear Infection and Vaccines

    Science.gov (United States)

    ... an ENT Doctor Near You Ear Infection and Vaccines Ear Infection and Vaccines Patient Health Information News ... or may need reinsertion over time. What about vaccines? A vaccine is a preparation administered to stimulate ...

  12. Vaccines and Thimerosal

    Science.gov (United States)

    ... Preparedness Vaccine Safety Partners About ISO Thimerosal in Vaccines Recommend on Facebook Tweet Share Compartir Thimerosal is ... harm. Thimerosal prevents the growth of bacteria in vaccines. Thimerosal is added to vials of vaccine that ...

  13. Live Virus Smallpox Vaccine

    Science.gov (United States)

    ... A - Z Index SMALLPOX FACT SHEET The Live Virus Smallpox Vaccine The vaccinia virus is the "live ... it cannot cause smallpox. What is a "live virus" vaccine? A "live virus" vaccine is a vaccine ...

  14. Varicela complicada en un hospital pediátrico de referencia, Perú 2001-2011 Complicated chickenpox in a national pediatric Peruvian hospital, 2001-2011

    Directory of Open Access Journals (Sweden)

    Edwin Miranda-Choque

    2013-03-01

    Full Text Available El objetivo de estudio fue describir las características clínicas y epidemiológicas de los casos de varicela complicada atendidos en el Instituto Nacional de Salud del Niño (INSN del Perú durante los años 2001 al 2011. Se realizó una serie de casos que incluyó un total de 1073 niños con varicela complicada. La mediana de la edad fue de 2,5 años (RIQ 1,1-4,8 años; 578 (54% fueron de sexo masculino. El tipo de complicación más frecuente fueron las infecciones secundarias de piel y partes blandas con 768 casos (72%, se registró 13 (1,4% fallecidos. En conclusión, en el INSN se hospitalizan con mayor frecuencia casos de varicela complicada en niños menores de cinco años, con un tiempo de hospitalización corto y con una baja proporción de fallecidos, la mayoría de complicaciones siendo relacionadas con las infecciones secundarias de piel y partes blandasThe objective of the study was to describe the clinical and epidemiological characteristics of complicated chickenpox cases seen at the National Institute of Children’s Health (INSN, Spanish acronym of Peru from 2001 to 2011. A case series was collected, including a total of 1,073 children with complicated chickenpox. The median age was 2.5 years (IQR 1.1-4.8 years, of which 578 (54% were male. The most frequent complications were secondary skin and soft tissue infections with 768 cases (72%. 13 deaths (1.4% were recorded. In conclusion, the hospitalizations due to complicated chickenpox in the INSN included mostly children under five, with a short stay and a low proportion of deaths most complications being related to secondary skin and soft tissue infections

  15. Vaccine Vexes

    Institute of Scientific and Technical Information of China (English)

    Maya; Reid

    2011-01-01

    IT’S always nice when expectations are exceeded by half a billion dollars.This was the case for the Global Alliance for Vaccines and Immunization(GAVI) at its fundraising conference in June.A public-private initiative,GAVI,which works to ensure children in developing countries receive crucial vaccinations,had gone into the meeting hoping to net $3.7 billion.They came away with $4.3 billion,"despite the fact that donors everywhere are coping with budget crises," as Bill Gates

  16. Human Vaccines & Immunotherapeutics: News

    OpenAIRE

    Riedmann, Eva M

    2013-01-01

    Vaccinating boys against HPV to reduce cancer rates across the sexes New melanoma vaccine contains natural product from marine sponges Impact of Hib conjugate vaccines in developing countries Electronic Health Records to keep track of immunization status Pregnant women urged to get whooping cough vaccination New nano-coating developed to preserve vaccines Alternative approach to creating a universal flu vaccine New modular vaccine design: MAPS technology

  17. 口服阿昔洛韦治疗水痘的疗效评价%The curative effect of oral acyclovir in treatment of chickenpox

    Institute of Scientific and Technical Information of China (English)

    邓建军; 黄国珍; 朱渝; 喻韬; 万朝敏

    2012-01-01

    OBJECTIVE To evaluate the efficacy of oral acyclovir in treatment of chickenpox. METHODS Updated evidences were identified by searching Cochrane library, MEDUNE and EMBASE. Only systematic reviews, randomized controlled trials (RCTs) and quasi- RCTs were included. The efficacy of oral acyclovir in treatment of chickenpox in healthy children was analyzed through evidence-based methods. RESULTS Oral acyclovir was associated with the reductions in the number of days with fever and in the number of rash. There were less supportive evidences in shortening the number of days to get new rash and relieving pruritus. CONCLUSION The clinical importance of oral acyclovir treatment in healthy children remains uncertain.%目的 对口服阿昔洛韦治疗水痘的疗效进行循证评价.方法 使用相关检索词对Cochrane图书馆、MEDLINE及EMBASE等数据库进行检索,获得关于口服阿昔洛韦治疗水痘的疗效的系统评价及随机对照实验,用循证医学的方法对口服阿昔洛韦治疗水痘的疗效进行评价.结果 口服阿昔洛韦能减少患者发热的天数及水痘皮疹的数量,但在缩短新生皮损出现时间及减轻皮肤瘙痒等方面尚不明确.结论 阿昔洛韦在治疗平素健康儿童水痘患者的重要性仍不明确.

  18. Vexing Vaccines

    Science.gov (United States)

    Bowman, Darcia Harris

    2004-01-01

    Schools play a key role in ensuring that children are being immunized against diseases, but conflicting research is making enforcement difficult. This article discusses a growing trend of vaccine avoidance and the endless supply of conflicting information and research about immunization safety. Despite the controversy, many people appear to accept…

  19. Malaria vaccine.

    Science.gov (United States)

    1994-05-01

    Some have argued that the vaccine against malaria developed by Manuel Pattaroyo, a Colombian scientist, is being tested prematurely in humans and that it is unlikely to be successful. While the Pattaroyo vaccine has been shown to confer protection against the relatively mild malaria found in Colombia, doubts exist over whether it will be effective in Africa. Encouraging first results, however, are emerging from field tests in Tanzania. The vaccine triggered a strong new immune response, even in individuals previously exposed to malaria. Additional steps must be taken to establish its impact upon mortality and morbidity. Five major trials are underway around the world. The creator estimates that the first ever effective malaria vaccine could be available for widespread use within five years and he has no intention of securing a patent for the discovery. In another development, malaria specialists from 35 African countries convened at an international workshop in Zimbabwe to compare notes. Participants disparaged financial outlays for the fight against malaria equivalent to 2% of total AIDS funding as insufficient; noted intercountry differences in prevention, diagnosis, and treatment; and found information exchange between anglophone and francophone doctors to be generally poor. PMID:12287671

  20. Replicating vaccines

    Science.gov (United States)

    Early work on fish immunology and disease resistance demonstrated fish (like animals and humans) that survived infection were typically resistant to re-infection with the same pathogen. The concepts of resistance upon reinfection lead to the research and development of replicating (live) vaccines in...

  1. Fish Vaccines in Aquaculture

    Science.gov (United States)

    Vaccination is a proven, cost-effective method to prevent infectious diseases in animals. Current fish vaccines can be categorized as killed fish vaccines or modified live vaccines. The major advantage of live vaccine is their ability to stimulate both cell-mediated and humoral immune responses for ...

  2. Human Vaccines & Immunotherapeutics

    OpenAIRE

    Riedmann, Eva M.

    2013-01-01

    DNA vaccine for T1D promising in the clinic HPV vaccines halved infections in US teenage girls Modified DC immunotherapy against melanoma New study looks at clinical severity of human H7N9 infections Prevnar vaccines are valuable for healthcare systems GAPVAC: New consortium in the fight of brain cancer Cytomegalovirus vaccine to enter phase 3 Malaria vaccination using chemically attenuated parasites

  3. US children to get a second dose of chickenpox vaccine%美国儿童接种二次水痘疫苗

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    自1995年起,美国儿童一直常规接种水痘疫苗,其最初方法是单次接种抗水痘一带状疱疹病毒的减毒活疫苗。但从去年中期开始,美国免疫实践咨询委员会(ACIP)推荐,在有迹象表明儿童免疫力开始减退时应二次接种水痘疫苗。一项研究发现,加利福尼亚儿童接种水痘疫苗后,暴发性水痘发生率逐渐升高,第8年超过第1年发生率的12倍,这种趋势很明显,说明在单次接种水痘疫苗后,其免疫力随时间延长会逐渐降低,儿童还是会发生严重的水痘,不过此项研究只局限于8~12岁的儿童。该研究还发现,中重度水痘(超过50个水痘)患儿出现并发症的风险增加,如:肺炎、共济失调、皮肤细菌感染等。

  4. Rapid differentiation of rocky mountain spotted fever from chickenpox, measles, and enterovirus infections and bacterial meningitis by frequency-pulsed electron capture gas-liquid chromatographic analysis of sera.

    OpenAIRE

    Brooks, J B; McDade, J E; Alley, C C

    1981-01-01

    Normal sera and sera from patients with Rocky Mountain spotted fever, chickenpox, enterovirus infections, measles, and Neisseria meningitidis infections were extracted with organic solvents under acidic and basic conditions and then derivatized with trichloroethanol or heptafluorobutyric anhydride-ethanol to form electron-capturing derivatives of organic acids, alcohols, and amines. The derivatives were analyzed by frequency-pulsed electron capture gas-liquid chromatography (FPEC-GLC). There ...

  5. Vaccination in Fish

    DEFF Research Database (Denmark)

    Chettri, Jiwan Kumar

    vaccines have reduced the need for usage of antibiotics with more than 99 % since the 1980s. Fish can be vaccinated by three different administration routes: injection, immersion and oral vaccination. Injection vaccination (intraperitoneal injection of vaccine) is the most time consuming and labor...... intensive method, which however, provides the best protection of the fish. Immersion vaccination is used for immunization of a high number of small fish is cost-efficient and fast (30 sec immersion into vaccine). Oral vaccination (vaccine in feed) is the least efficient. As in higher vertebrates fish...... respond to vaccination by increasing the specific antibody titer and by activating the cellular responses. My talk will cover vaccination methods in fish, immune responses and some adverse effect of oil-adjuvanted vaccines in fish with reference to our work in rainbow trout, Oncorhynchus mykiss....

  6. Vaccinations during Pregnancy

    Science.gov (United States)

    ... you do need any vaccinations, wait 1 month after you get them before you try to get pregnant. ... vaccine during pregnancy, you can get it right after you give birth. Getting the Tdap vaccine soon after ...

  7. Vaccines Stop Illness

    Science.gov (United States)

    Skip Navigation Bar Home Current Issue Past Issues Vaccines Stop Illness Past Issues / Spring 2008 Table of ... meningitis won't infect, cripple, or kill children. Vaccine Safety In light of recent questions about vaccine ...

  8. Childhood Vaccine Schedule

    Science.gov (United States)

    ... Navigation Bar Home Current Issue Past Issues Childhood Vaccine Schedule Past Issues / Spring 2008 Table of Contents ... please turn Javascript on. When to Vaccinate What Vaccine Why Birth (or any age if not previously ...

  9. Pneumococcal Polysaccharide Vaccine

    Science.gov (United States)

    Pneumococcal polysaccharide vaccine (PPSV)Treatment of pneumococcal infections with penicillin and other drugs used to be more effective. But ... the disease, through vaccination, even more important. Pneumococcal polysaccharide vaccine (PPSV) protects against 23 types of pneumococcal ...

  10. Vaccines Stop Illness

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Diseases and Vaccinations Vaccines Stop Illness Past Issues / Spring 2015 Table ... if we take away the protection given by vaccination, more and more people will be infected and ...

  11. Vaccinations and HIV

    Science.gov (United States)

    ... 23, 2014 Select a Language: Fact Sheet 207 Vaccinations and HIV WHAT ARE VACCINATIONS? WHAT’S DIFFERENT FOR ... your viral load within 4 weeks of any vaccination. Flu shots have been studied more than any ...

  12. Vaccines for Pregnant Women

    Science.gov (United States)

    ... GO" or visit Healthmap Vaccine Finder . Vaccines for Pregnant Women Recommend on Facebook Tweet Share Compartir On ... and your growing family healthy. If you are pregnant or planning a pregnancy, the specific vaccinations you ...

  13. Vaccine-Preventable Disease Photos

    Science.gov (United States)

    Home | About | A-Z | Contact | Follow Vaccine Information You Need VACCINE BASICS Evaluating Online Health Information FAQs How Vaccines Work Importance of Vaccines Paying for Vaccines State Immunization Programs ...

  14. Influenza Vaccines

    OpenAIRE

    Ellebedy, A. H.; Webby, R J

    2009-01-01

    Influenza A viruses pose a substantial threat to the human population whether by purposeful manipulation and release or by the natural process of interspecies transmissions from animal reservoirs. The challenge with preparing for these events with vaccination strategies is that the best forms of protective immunity target the most variably of the viral proteins, hemagglutinin. Add to this even just the natural extent of variation in this protein and the challenges to vaccinologists become gre...

  15. [Poliovirus vaccine].

    Science.gov (United States)

    Shimizu, Hiroyuki

    2012-06-01

    To avoid the risk of vaccine-associated paralytic poliomyelitis (VAPP) and polio outbreaks due to circulating vaccine-derived polioviruses, an inactivated poliovirus vaccine (IPV) was introduced for routine immunization in a number of countries with a low risk of polio outbreaks. Currently, production and marketing of a standalone conventional IPV and two diphtheria-pertussis-tetanus-IPV (Sabin-derived IPV; sIPV) products have been submitted, and it is expected that the IPV products will be introduced in Japan in the autumn of 2012. At the same time, a decline in the OPV immunization rate became apparent in Japan due to serious public concerns about a remaining risk of VAPP and introduction of IPV in the near future. Therefore, the recent development of polio immunity gaps should be carefully monitored, and surveillance of suspected polio cases and laboratory diagnosis of polioviruses have to be intensified for the transition period from OPV to IPV in Japan. The development of sIPV is one of the most realistic options to introduce affordable IPV to developing countries. In this regard, further clinical studies on its efficacy, safety, and interchangeability of sIPV will be needed after the introduction of the sIPV products, which will be licensed in Japan for the first time in the world. PMID:23189825

  16. Vaccines against malaria

    OpenAIRE

    Hill, Adrian V. S.

    2011-01-01

    There is no licenced vaccine against any human parasitic disease and Plasmodium falciparum malaria, a major cause of infectious mortality, presents a great challenge to vaccine developers. This has led to the assessment of a wide variety of approaches to malaria vaccine design and development, assisted by the availability of a safe challenge model for small-scale efficacy testing of vaccine candidates. Malaria vaccine development has been at the forefront of assessing many new vaccine technol...

  17. Human Vaccines & Immunotherapeutics: News

    Science.gov (United States)

    Riedmann, Eva M.

    2014-01-01

    Oncolytic immunotherapy reduces the size of melanoma tumors in phase 3 trial EV71 vaccine protects children against HFMD Influenza vaccination important for risk groups Bharat‘s rotavirus vaccine is safe and modestly efficacious Successfully avoiding the cold-chain for vaccines FDA approval for Stallergenes’ sublingual grass pollen allergy immunotherapy HPV vaccination campaign could change from three to two doses in the UK Valneva continues phase 2/3 trial of Pseudomonas aeruginosa vaccine PMID:25290656

  18. Meningococcal Vaccine (For Parents)

    Science.gov (United States)

    ... Palsy: Shannon's Story" 5 Things to Know About Zika & Pregnancy Your Child's Immunizations: Meningococcal Vaccines KidsHealth > For Parents > Your Child's Immunizations: Meningococcal Vaccines ...

  19. Tetanus (Lockjaw) Vaccination

    Science.gov (United States)

    ... children and adults - Tetanus-diphtheria-acellular Pertussis vaccine Tetanus (Lockjaw) Vaccination Recommend on Facebook Tweet Share Compartir Tetanus (lockjaw) is a serious disease that causes painful ...

  20. Travelers' Health: Varicella (Chickenpox)

    Science.gov (United States)

    ... Learn About Destination See a Doctor Pre-Travel Appointment Your Health Status How Diseases Spread Pack Smart ... is higher in most other parts of the world than it is in the United States. Varicella ...

  1. Investigation on an outbreak of chickenpox in a primary school in Donghai county%东海县某小学一起水痘暴发疫情的调查

    Institute of Scientific and Technical Information of China (English)

    孙波; 李忠典; 钱忠

    2012-01-01

    目的 报告一起小学水痘暴发疫情及调查处理情况.方法 由专业技术人员进行现场调查处理并记录,根据现场记录总结分析.结果 该校12名学生被诊断为水痘,罹患率25.5%.其中三年级11例、占91.7%,二年级l例、占8.3%,男生9例,罹患率32.1%;女生3例,罹患率15.8%,无并发症及死亡病例.经专家确认是由水痘-带状疱疹病毒(VZV)引起的水痘暴发疫情.结论 由于报告不及时导致此次疫情暴发,采取了有效防控措施,疫情得到控制.%OBJECTIVE To investigate an outbreak of chickenpox in a primary school for controlling the epidemic quickly. METHODS Opened field investigation on outbreak of chickenpox in a primary school by the professional health staffs, and analyzed the data with descriptive method. RESULTS There were 12 chickenpox cases occurred among 47 kids, the attack rate was 25.5%. There were 11 cases in a class in Grade three, 1 case in Grade two. 9 of all cases was male, the attack rate for 32.1%, 3 cases of female, the attack rate was 15.8%. All cases was healed by treatments. This outbreak of chickenpox was caused by the varicella-zoster virus (VZV). CONCLUSION The chickenpox outbreak occurs in a primary school and is not controlled well at early time due to not reporting timely. But the epidemic is controlled finally under effective measures.

  2. History of vaccination

    OpenAIRE

    Plotkin, Stanley

    2014-01-01

    Vaccines have a history that started late in the 18th century. From the late 19th century, vaccines could be developed in the laboratory. However, in the 20th century, it became possible to develop vaccines based on immunologic markers. In the 21st century, molecular biology permits vaccine development that was not possible before.

  3. Nucleic Acid Vaccines

    Institute of Scientific and Technical Information of China (English)

    LU Shan

    2004-01-01

    @@ Anew method of immunization was discovered in the early 1990s. Several research groups independently demonstrated that direct inoculation of DNA plasmids coding for a specific protein antigen could elicit immune responses against that antigen[1-4].Since in theory the mRNA molecules also have the potential to be translated into the protein antigen, this vaccination approach was officially named by WHO as the nucleic acid vaccination even though the term DNA vaccine has been used more commonly in the literature. This novel approach is considered the fourth generation of vaccines after live attenuated vaccines, killed or inactivated vaccines and recombinant protein based subunit vaccines.

  4. Vaccines against poverty

    OpenAIRE

    MacLennan, Calman A.; Saul, Allan

    2014-01-01

    With the 2010s declared the Decade of Vaccines, and Millennium Development Goals 4 and 5 focused on reducing diseases that are potentially vaccine preventable, now is an exciting time for vaccines against poverty, that is, vaccines against diseases that disproportionately affect low- and middle-income countries (LMICs). The Global Burden of Disease Study 2010 has helped better understand which vaccines are most needed. In 2012, US$1.3 billion was spent on research and development for new vacc...

  5. Towards universal influenza vaccines?

    OpenAIRE

    Osterhaus, Ab; Fouchier, Ron; Rimmelzwaan, Guus

    2011-01-01

    Vaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the development and production of pandemic influenza vaccines are response time and production capacity as well as vaccine efficacy and safety. Several improvements can be envisaged. Vaccine production technologi...

  6. Oral vaccination of fish

    OpenAIRE

    Embregts, Carmen W.E.; Forlenza, Maria

    2016-01-01

    The limited number of oral vaccines currently approved for use in humans and veterinary species clearly illustrates that development of efficacious and safe oral vaccines has been a challenge not only for fish immunologists. The insufficient efficacy of oral vaccines is partly due to antigen breakdown in the harsh gastric environment, but also to the high tolerogenic gut environment and to inadequate vaccine design. In this review we discuss current approaches used to develop oral vaccines fo...

  7. Typhoid fever vaccination strategies.

    Science.gov (United States)

    Date, Kashmira A; Bentsi-Enchill, Adwoa; Marks, Florian; Fox, Kimberley

    2015-06-19

    Typhoid vaccination is an important component of typhoid fever prevention and control, and is recommended for public health programmatic use in both endemic and outbreak settings. We reviewed experiences with various vaccination strategies using the currently available typhoid vaccines (injectable Vi polysaccharide vaccine [ViPS], oral Ty21a vaccine, and injectable typhoid conjugate vaccine [TCV]). We assessed the rationale, acceptability, effectiveness, impact and implementation lessons of these strategies to inform effective typhoid vaccination strategies for the future. Vaccination strategies were categorized by vaccine disease control strategy (preemptive use for endemic disease or to prevent an outbreak, and reactive use for outbreak control) and vaccine delivery strategy (community-based routine, community-based campaign and school-based). Almost all public health typhoid vaccination programs used ViPS vaccine and have been in countries of Asia, with one example in the Pacific and one experience using the Ty21a vaccine in South America. All vaccination strategies were found to be acceptable, feasible and effective in the settings evaluated; evidence of impact, where available, was strongest in endemic settings and in the short- to medium-term. Vaccination was cost-effective in high-incidence but not low-incidence settings. Experience in disaster and outbreak settings remains limited. TCVs have recently become available and none are WHO-prequalified yet; no program experience with TCVs was found in published literature. Despite the demonstrated success of several typhoid vaccination strategies, typhoid vaccines remain underused. Implementation lessons should be applied to design optimal vaccination strategies using TCVs which have several anticipated advantages, such as potential for use in infant immunization programs and longer duration of protection, over the ViPS and Ty21a vaccines for typhoid prevention and control. PMID:25902360

  8. Who Should Not Get Vaccinated with These Vaccines?

    Science.gov (United States)

    ... be updated.) Top of Page HPV-Cervarix (Human Papillomavirus) vaccine Some people should not get HPV vaccine or ... updated.) Top of Page HPV-Gardasil-9 (Human Papillomavirus) vaccine Some people should not get HPV vaccine. Anyone ...

  9. Rotavirus vaccine: a review.

    Science.gov (United States)

    Kumar, Goel Manish; Arun, Kumar; Bilas, Jain Ram; Ruchi, Jain; Pardeep, Khanna; Pradeep, Siwach

    2012-12-01

    Worldwide, large proportion i.e., 37% of deaths due to diarrhea in young children is attributed to rotavirus. A monovalent P1A[8] G1 vaccine and a pentavalent bovine-human reassortant vaccine human rotavirus vaccine had shown good clinical efficacy without any increase in intussusception among vaccine recipients. WHO recommends that the first dose of rotavirus vaccine should be administered to infants up to age of 6-15 weeks irrespective of the prior history of rotavirus infection and the maximum age for administering the last dose of the vaccine should be 32 weeks. Booster doses are not recommended. The current update reviews the issues related to rotavirus vaccines and their usages like milestones in the development of rotavirus vaccines, concerns regarding their efficacy and cost-effectiveness, immunity after natural infection, potential for changes in virus strains, current recommendations, post marketing surveillance, and future challenges and scope for further research regarding rotavirus vaccines. PMID:25145068

  10. Human Papillomavirus (HPV) Vaccine (Gardasil)

    Science.gov (United States)

    ... changes or ringing in the ears.Like all vaccines, HPV vaccines will continue to be monitored for unusual ... visit CDC's website at http://www.cdc.gov/vaccines. HPV Vaccine (Gardasil) Information Statement. U.S. Department of Health ...

  11. Human Papillomavirus (HPV) Vaccine (Cervarix)

    Science.gov (United States)

    ... changes or ringing in the ears. Like all vaccines, HPV vaccines will continue to be monitored for unusual ... gov/std/hpv and http://www.cdc.gov/vaccines HPV Vaccine (Cervarix) Information Statement. U.S. Department of Health ...

  12. Vaccine-Preventable Childhood Diseases

    Science.gov (United States)

    ... About CDC.gov . Vaccines and Immunizations Share Compartir Vaccine-Preventable Childhood Diseases On this Page Protect Your ... American Academy of Family Physicians (AAFP). Descriptions of Vaccine-preventable Child Diseases The following vaccine-preventable diseases, ...

  13. Current Vaccine Shortages and Delays

    Science.gov (United States)

    ... CDC.gov . Vaccines and Immunizations Share Compartir Current Vaccine Shortages & Delays Last Updated December 7, 2015 On ... schedule are included in this update. Chart of Vaccines* in Delay or Shortage Vaccines are listed in ...

  14. Diphtheria Vaccination: Who Needs It?

    Science.gov (United States)

    ... and adults - Tetanus-diphtheria-acellular Pertussis vaccine Diphtheria Vaccination: Who Needs It? Recommend on Facebook Tweet Share ... Vaccine Information Statement (VIS) See also: Healthcare Personnel Vaccination Recommendations [1 page] July 2008 Top of Page ...

  15. Chikungunya vaccines in development.

    Science.gov (United States)

    Schwameis, Michael; Buchtele, Nina; Wadowski, Patricia Pia; Schoergenhofer, Christian; Jilma, Bernd

    2016-03-01

    Chikungunya virus has become a global health threat, spreading to the industrial world of Europe and the Americas; no treatment or prophylactic vaccine is available. Since the late 1960s much effort has been put into the development of a vaccine, and several heterogeneous strategies have already been explored. Only two candidates have recently qualified to enter clinical phase II trials, a chikungunya virus-like particle-based vaccine and a recombinant live attenuated measles virus-vectored vaccine. This review focuses on the current status of vaccine development against chikungunya virus in humans and discusses the diversity of immunization strategies, results of recent human trials and promising vaccine candidates. PMID:26554522

  16. Vaccines today, vaccines tomorrow: a perspective

    OpenAIRE

    Loucq, Christian

    2013-01-01

    Vaccines are considered as one of the major contributions of the 20th century and one of the most cost effective public health interventions. The International Vaccine Institute has as a mission to discover, develop and deliver new and improved vaccines against infectious diseases that affects developing nations. If Louis Pasteur is known across the globe, vaccinologists like Maurice Hilleman, Jonas Salk and Charles Mérieux are known among experts only despite their contribution to global hea...

  17. 上海市浦东新区2009-2010年水痘疫情流行病学分析%Epidemiological analysis on the chickenpox epidemic from 2009 to 2010 in Pudong new area, Shanghai

    Institute of Scientific and Technical Information of China (English)

    刘汉昭; 赵希畅; 肖绍坦

    2012-01-01

    [Objective] To analyze the chickenpox epidemic of Pudong New Area and provide the scientific basis for the prevention and control work. [Methods] 6 032 chickenpox cases were analyzed of 2009 to 2010 in Pudong New Area by Retrospective analysis methods and SPSS 13. 0 statistical tools used to deal with the data (meaningful: P<0. 05), and compared the rate of groups by chi-square test. [Results] A total of 6 032 cases of chickenpox in the Pudong New Area were reported (incidence:64. 73/105). The incidence of local citizens were 79. 19/105 and foreign residents were 44. 40/105. Children below 15 years old accounted for 69. 65% of the total cases. School students accounted for 53. 88%. [Conclusions] The incidence of local citizens is higher than that of foreign residents, the incidence of chickenpox tended to be seasonal. Winter and spring are high-occurrence seasons for this disease. Children below 15 years old are the main infected age and school students are easily to be infected.%[目的]分析上海市浦东新区水痘疫情,为预防控制工作提供科学依据. [方法]将2009-2010年上海市浦东新区6 032例水痘病例采用回顾性分析,通过SPSS 13.0进行统计处理,组间率的比较运用x2检验,以P<0.05为差异有统计学意义. [结果]水痘病例6 032例,发病率为64.73/105,其中本市居民4 312例,发病率79.19/105,外来人员1 720例,发病率为44.40/105;15岁以下人群病例4 201例,占发病总数的69.65%,学生病例3 250例,占发病总数53.88%. [结论]本市居民发病率高于外来人员,发病具有明显的季节性,冬春季为高发季节,以15岁以下年龄为主,学生为主要发病群体.

  18. MMR Vaccine (Measles, Mumps, and Rubella)

    Science.gov (United States)

    Attenuvax® Measles Vaccine ... R-Vax® II (as a combination product containing Measles Vaccine, Rubella Vaccine) ... M-R® II (as a combination product containing Measles Vaccine, Mumps Vaccine, Rubella Vaccine)

  19. Key Facts about Seasonal Flu Vaccine

    Science.gov (United States)

    ... flu is to get vaccinated each year. Flu Vaccination Why should people get vaccinated against the flu? ... Vaccine Benefits What are the benefits of flu vaccination? While how well the flu vaccine works can ...

  20. Pertussis (Whooping Cough) Vaccination

    Science.gov (United States)

    ... Tdap= Tetanus-diphtheria-acellular Pertussis vaccine Pertussis (Whooping Cough) Vaccination Pronounced (per-TUS-iss) Recommend on Facebook Tweet Share Compartir Whooping cough — known medically as pertussis — is a ...

  1. Vaccine Safety Datalink

    Science.gov (United States)

    The Vaccine Safety Datalink is part of the National Immunization Program within the Centers for Disease Control and Prevention and was started in recognition of gaps in the scientific knowledge of rare vaccine side effects.

  2. The HPV Vaccination Crisis

    Science.gov (United States)

    Following the release of a consensus statement from the NCI-Designated Cancer Centers urging HPV vaccination in the United States, Dr. Noel Brewer discusses the country’s low vaccination rates and how clinicians can help to improve them.

  3. Screening Tests and Vaccines

    Science.gov (United States)

    ... Contact Us Text size | Print | Screening Tests and Vaccines This information in Spanish ( en español ) Getting important screening tests and vaccines can save your life. Check this section of ...

  4. Hepatitis B Vaccine

    Science.gov (United States)

    Engerix-B® ... a combination product containing Hepatitis A Vaccine, Hepatitis B Vaccine) ... What is hepatitis B?Hepatitis B is a serious infection that affects the liver. It is caused by the hepatitis B virus.In ...

  5. RECOMBINANT INFLUENZA VACCINES

    OpenAIRE

    Sedova, E.; Shcherbinin, D.; Migunov, A.; Smirnov, Iu; Logunov, D.; Shmarov, M.; Tsybalova, L.; Naroditskiĭ, B.; O. Kiselev; Gintsburg, A.

    2012-01-01

    This review covers the problems encountered in the construction and production of new recombinant influenza vaccines. New approaches to the development of influenza vaccines are investigated; they include reverse genetics methods, production of virus-like particles, and DNA- and viral vector-based vaccines. Such approaches as the delivery of foreign genes by DNA- and viral vector-based vaccines can preserve the native structure of antigens. Adenoviral vectors are a promising gene-delivery pla...

  6. Rotavirus vaccines: an overview.

    OpenAIRE

    Midthun, K; Kapikian, A Z

    1996-01-01

    Rotavirus vaccine development has focused on the delivery of live attenuated rotavirus strains by the oral route. The initial "Jennerian" approach involving bovine (RIT4237, WC3) or rhesus (RRV) rotavirus vaccine candidates showed that these vaccines were safe, well tolerated, and immunogenic but induced highly variable rates of protection against rotavirus diarrhea. The goal of a rotavirus vaccine is to prevent severe illness that can lead to dehydration in infants and young children in both...

  7. Vaccines and global health

    OpenAIRE

    Greenwood, Brian; Salisbury, David; Hill, Adrian V. S.

    2011-01-01

    Vaccines have made a major contribution to global health in recent decades but they could do much more. In November 2011, a Royal Society discussion meeting, ‘New vaccines for global health’, was held in London to discuss the past contribution of vaccines to global health and to consider what more could be expected in the future. Papers presented at the meeting reviewed recent successes in the deployment of vaccines against major infections of childhood and the challenges faced in developing ...

  8. Vaccination during pregnancy

    OpenAIRE

    Bozzo, Pina; Narducci, Andrea; Einarson, Adrienne

    2011-01-01

    Question One of my patients is studying to become a dental hygienist. Owing to the program requirements, she received several vaccinations last week, including measles-mumps-rubella, varicella, and hepatitis B (HB) vaccines, as well as a tetanus booster. However, today a blood test confirmed that she is currently 6 weeks pregnant. What is known about the safety of these vaccines during pregnancy, and are there any general recommendations for vaccines for women who are planning to become pregn...

  9. Vaccine chronicle in Japan

    OpenAIRE

    Nakayama, Tetsuo

    2013-01-01

    The concept of immunization was started in Japan in 1849 when Jenner’s cowpox vaccine seed was introduced, and the current immunization law was stipulated in 1948. There have been two turning points for amendments to the immunization law: the compensation remedy for vaccine-associated adverse events in 1976, and the concept of private vaccination in 1994. In 1992, the regional Court of Tokyo, not the Supreme Court, decided the governmental responsibility on vaccine-associated adverse events, ...

  10. Clinical vaccine development

    OpenAIRE

    Han, Seunghoon

    2015-01-01

    Vaccination is regarded as one of the biggest triumphs in the history of medicine. We are living in the most successful period of vaccine development. The accumulation of multidisciplinary knowledge and the investment of massive funding have enabled the development of vaccines against many infectious diseases as well as other diseases including malignant tumors. The paradigm of clinical vaccine evaluation and licensure has also been modernized based on scientific improvements and historical e...

  11. Vaccines in dermatology

    Directory of Open Access Journals (Sweden)

    Mitali M Shah

    2015-01-01

    Full Text Available A vaccine is a biological preparation that improves immunity to a specific disease. More than two centuries have passed since the first successful vaccine for smallpox was developed. We′ve come a long way since. Today′s vaccines are among the 21 st century′s most successful and cost-effective public health tools for preventing diseases.

  12. A Dengue Vaccine.

    Science.gov (United States)

    Durbin, Anna P

    2016-06-30

    Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year. PMID:27368091

  13. Vaccination: problems and perspectives.

    OpenAIRE

    S. M. Kharit

    2014-01-01

    Massive vaccination had proved its effective morbidity reduction. Today it is necessary to extend vaccination schedule, creation of selective, regional schedules based on epidemiological, clinical, economical substantiation. Development of vaccination needs the profound scientific research, modernization of adverse reaction observing system, betterment training system and awareness of population.

  14. Hepatitis B Vaccine

    Science.gov (United States)

    ... in the same shot with other vaccines.Routine hepatitis B vaccination was recommended for some U.S. adults and children ... 95%, and by 75% in other age groups.Vaccination gives long-term protection from hepatitis B infection, possibly lifelong.

  15. Polysaccharide-Based Vaccines

    Science.gov (United States)

    Santana, Violeta Fernández; Balbin, Yury Valdés; Calderón, Janoi Chang; Icart, Luis Peña; Verez-Bencomo, Vicente

    Capsular polysaccharides (CPS) and lipopolysaccharides from bacteria are employed for the production of vaccines against human diseases. Initial development of CPS as a vaccine was followed by the development and introduction of conjugate polysaccharide-protein vaccines. The principles leading to both developments are reviewed.

  16. EXPERIMENTAL MEASLES VACCINES: A RESEARCH TOOL IN VACCINATION EVENTS

    OpenAIRE

    V. A. Liashenko

    2014-01-01

    Abstract. The review article considers different variants of measles vaccine that may be classified into two groups, i.e., vaccines that do not contain viable measles virus, and attenuated measles vaccines which could be employed in unusual manner.The first group includes DNA-vaccines, recombinant vaccine strains encoding synthesis of measles hemagglutinin and fusion protein, as well as peptide vaccines containing molecular fragments of these proteins. The mentioned variants of vaccines were ...

  17. Importance of vaccination habit and vaccine choice on influenza vaccination among healthy working adults.

    Science.gov (United States)

    Lin, Chyongchiou J; Nowalk, Mary Patricia; Toback, Seth L; Rousculp, Matthew D; Raymund, Mahlon; Ambrose, Christopher S; Zimmerman, Richard K

    2010-11-10

    This randomized cluster trial was designed to improve workplace influenza vaccination rates using enhanced advertising, choice of vaccine type (intranasal or injectable) and an incentive. Workers aged 18-49 years were surveyed immediately following vaccination to determine factors associated with vaccination behavior and choice. The questionnaire assessed attitudes, beliefs and social support for influenza vaccine, demographics, and historical, current, and intentional vaccination behavior. Of the 2389 vaccinees, 83.3% received injectable vaccine and 16.7% received intranasal vaccine. Factors associated with previous influenza vaccination were older age, female sex, higher education and greater support for injectable vaccine (all P<.02). Current influenza vaccination with intranasal vaccine vs. injectable vaccine was associated with higher education, the study interventions, greater support for the intranasal vaccine and nasal sprays, less support of injectable vaccine, more negative attitudes about influenza vaccine, and a greater likelihood of reporting that the individual would not have been vaccinated had only injectable vaccine been offered (all P<.01). Intentional vaccine choice was most highly associated with previous vaccination behavior (P<.001). A key to long term improvements in workplace vaccination is to encourage first time influenza vaccination through interventions that include incentives, publicity and vaccine choice. PMID:20638452

  18. 痰热清注射液治疗成人水痘48例%Tanreqing injection in treatment of 48 adult chickenpox cases

    Institute of Scientific and Technical Information of China (English)

    王轶; 郭文; 方亮; 郑学毅

    2009-01-01

    目的 观察痰热清注射液治疗成人水痘的临床疗效.方法 将48例水痘患者随机分为两组,治疗组在综合治疗的基础上加用痰热清注射液,对照组在综合治疗的基础上加用利巴韦林.两组均治疗5-7d.结果 治疗组加用痰热清注射液能缩短水痘患者体温下降及体温恢复正常时间,缩短皮疹消退时间,能有效缩短疗程,减少传播机会.疗效明显优于对照组(P<0.05).结论 痰热清注射液治疗成人水痘疗效良好,安全性高.%Objective To study the therapeutic effects of tanreqing injection in the treatment of chickenpox.Methods Forty-eight adult patients with ehickenpox were randomly divided into treatment group and control group.The treatment group received tanreqing injection on the base of complex treatment.The control group received ribavirin injection also on the base of complex treatment.Results Tanreqing injection could shorten the time of temperature beginning fall and recovery,skin eruption disappearing.The effective rate of the treatment group was obviously higher than the control group (P<0.05).Conclusions Tanreqing injection is safe and effective for the treatment of chiekenpox.

  19. Vaccine-Associated Uveitis.

    Science.gov (United States)

    Benage, Matthew; Fraunfelder, Frederick W

    2016-01-01

    All of the widely administered vaccines have been reported to cause uveitis. The ocular inflammation is usually temporary and resolves with topical ocular steroids. During a 26-year period, a total of 289 cases of vaccine-associated uveitis were reported to three adverse reaction reporting databases. Hepatitis B vaccine, either alone or administered with other vaccines, appears to be the leading offender. Clinicians are encouraged to report cases of vaccine- or drug-associated ocular adverse reactions to www.eyedrugregistry.com. PMID:27039491

  20. Human Vaccines and Immunotherapeutics: News

    OpenAIRE

    Riedmann, Eva M.

    2013-01-01

    GSK`s Synflorix: Highly effective at preventing invasive pneumococcal disease Positive phase 1 interim results for killed whole-virus HIV vaccine Therapeutic HBV vaccine drives immune responses in liver New tuberculosis vaccine candidate to enter the clinic Novartis receives positive CHMP opinion for MenB vaccine Bexsero New research points way to faster flu vaccines New Meth vaccine shows promise in animals RTS,S malaria vaccine reduces malaria by approximately one-third in African infants

  1. Advances in FIV vaccine technology

    OpenAIRE

    Uhl, Elizabeth W.; Martin, Marcus; Coleman, James K.; Yamamoto, Janet K

    2008-01-01

    Advances in vaccine technology are occurring in the molecular techniques used to develop vaccines and in the assessment of vaccine efficacy, allowing more complete characterization of vaccine-induced immunity correlating to protection. FIV vaccine development has closely mirrored and occasionally surpassed the development of HIV-1 vaccine, leading to first licensed technology. This review will discuss technological advances in vaccine designs, challenge infection assessment, and characterizat...

  2. [Vaccinations for international travelers].

    Science.gov (United States)

    Berens-Riha, N; Alberer, M; Löscher, T

    2014-03-01

    Vaccinations are a prominent part of health preparations before international travel. They can avoid or significantly reduce the risk of numerous infectious diseases. Until recently, vaccination against yellow fever was the only obligatory vaccination. However, according to updated international health regulations, other vaccinations and prophylactic measures may be required at entry from certain countries. For all routine vaccinations as recommended in Germany, necessary revaccination and catch-up of missed vaccinations should be administered before travel. At most destinations the risk of infection is higher than in Germany. Hepatitis A vaccine is generally recommended for travelers to areas of increased risk, polio vaccine for all destinations where eradication is not yet confirmed (Asia and Africa). The indications for other travel vaccines must take into consideration travel destination and itinerary, type and duration of travel, individual risk of exposure as well as the epidemiology of the disease to be prevented. Several vaccines of potential interest for travel medicine, e.g., new vaccines against malaria and dengue fever, are under development. PMID:24519704

  3. Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study

    OpenAIRE

    Langan, Sinéad M.; Liam Smeeth; Margolis, David J.; Thomas, Sara L

    2013-01-01

    Editors' Summary Background Chickenpox is an extremely common childhood infectious disease that is caused by the herpes varicella-zoster virus. Children usually recover quickly from chickenpox, but dormant varicella-zoster virus persists throughout life inside the nervous system. The dormant virus causes no symptoms but if it becomes reactivated, it causes shingles (zoster), a painful skin rash. Anyone who has had chickenpox can develop shingles but shingles is most common and most severe in ...

  4. Vaccines for allergy.

    Science.gov (United States)

    Linhart, Birgit; Valenta, Rudolf

    2012-06-01

    Vaccines aim to establish or strengthen immune responses but are also effective for the treatment of allergy. The latter is surprising because allergy represents a hyper-immune response based on immunoglobulin E production against harmless environmental antigens, i.e., allergens. Nevertheless, vaccination with allergens, termed allergen-specific immunotherapy is the only disease-modifying therapy of allergy with long-lasting effects. New forms of allergy diagnosis and allergy vaccines based on recombinant allergen-derivatives, peptides and allergen genes have emerged through molecular allergen characterization. The molecular allergy vaccines allow sophisticated targeting of the immune system and may eliminate side effects which so far have limited the use of traditional allergen extract-based vaccines. Successful clinical trials performed with the new vaccines indicate that broad allergy vaccination is on the horizon and may help to control the allergy pandemic. PMID:22521141

  5. New tuberculosis vaccines.

    Science.gov (United States)

    Martín Montañés, Carlos; Gicquel, Brigitte

    2011-03-01

    The current tuberculosis (TB) vaccine, bacille Calmette-Guerin (BCG), is a live vaccine used worldwide, as it protects against severe forms of the disease, saving thousands of lives every year, but its efficacy against pulmonary forms of TB, responsible for transmission of the diseases, is variable. For more than 80 years now no new TB vaccines have been successfully developed. Over the last decade the effort of the scientific community has resulted in the design and construction of promising vaccine candidates. The goal is to develop a new generation of vaccines effective against respiratory forms of the disease. We will focus this review on new prophylactic vaccine candidates that aim to prevent TB diseases. Two are the main strategies used to improve the immunity conferred by the current BCG vaccine, by boosting it with new subunit vaccines, and a second strategy is focused on the construction of new more effective live vaccines, capable to replace the current BCG and to be used as prime vaccines. After rigorous preclinical studies in different animal models new TB vaccine candidates enter in clinical trials in humans. First, a small Phase I for safety followed by immunological evaluation in Phase II trials and finally evaluated in large population Phase III efficacy trials in endemic countries. At present BCG prime and boost with different subunit vaccine candidates are the more advanced assessed in Phase II. Two prime vaccines (based on recombinant BCG) have been successfully evaluated for safety in Phase I trials. A short number of live attenuated vaccines are in advance preclinical studies and the candidates ready to enter Phase I safety trials are produced under current good manufacturing practices. PMID:21420568

  6. Chickenpox cases monitoring and epidemic strains gene polymorphism analysis in Ningbo, Zhejiang%浙江省宁波市水痘病例监测及流行株基因多态性分析

    Institute of Scientific and Technical Information of China (English)

    胡逢蛟; 焦素黎; 倪红霞; 马瑞; 潘兴强; 许国章

    2013-01-01

    目的 分析宁波市2009-2011年水痘-带状疱疹病毒(VZV)的流行病学及流行株基因分型特征.方法 收集宁波市突发公共卫生事件报告管理系统的水痘病例发病资料,采集部分水痘病例疱疹液样本,采用PCR法对VZV流行株病毒进行基因分型及限制性内切酶SmaⅠ进行流行株鉴定,用MRC-5细胞进行VZV的分离.结果 2009-2011年宁波市水痘病例的报告发病率分别为23.33/10万、26.24/10万和36.25/10万.7~ 12岁儿童发病率最高,达245.21/10万;5-6月份和11-12月份分别为两个季节性发病高峰.32份水痘患者水疱液样本中25份检出VZV核酸阳性样本,基因分型结果提示为2种不同基因型的毒株,其中2份为M1基因型,其余23份为J基因型毒株.结论 宁波市水痘病例主要发生在春末夏初和秋末冬初季节,以7~12岁学龄儿童为主,J基因型毒株目前为本市流行主要毒株,但也有M1基因型毒株的局部流行.%Objective To analyze the varicella-zoster virus (VZV) epidemiology and the genotype characteristics of epidemic strains in Ningbo from 2009 to 2011.Methods The incidence data of chickenpox cases from Ningbo public health emergency report management system were collected and analyzed.Some vesicle fluid samples from chickenpox cases were collected.The VZV epidemic strains were genotyped by PCR method and the epidemic strains were identified by the restriction enyme Sma Ⅰ.The VZV virus was isolated by MRC-5 cells.Results The reported incidence rates of chickenpox in Ningbo were 23.33/100 000,26.24/100 000 and 36.25/100 000 from 2009 to 2011.Children aged 7-12 years had the highest incidence rate (245.21/100 000).Two seasonal peaks of chickenpox incidence were from May to June and November to December,respectively.The PCR detection result of VZV from 32 vesicle fluid samples showed that 25 samples were positive.Genotype results showed 2 kinds of different genetic types of strain:2 samples were M1 type strains

  7. Vaccine Effectiveness - How Well Does the Seasonal Flu Vaccine Work?

    Science.gov (United States)

    ... flu viruses. What are the benefits of flu vaccination? While how well the flu vaccine works can ... of age and older). How are benefits of vaccination measured? Public health researchers measure how well flu ...

  8. Vaccine process technology.

    Science.gov (United States)

    Josefsberg, Jessica O; Buckland, Barry

    2012-06-01

    The evolution of vaccines (e.g., live attenuated, recombinant) and vaccine production methods (e.g., in ovo, cell culture) are intimately tied to each other. As vaccine technology has advanced, the methods to produce the vaccine have advanced and new vaccine opportunities have been created. These technologies will continue to evolve as we strive for safer and more immunogenic vaccines and as our understanding of biology improves. The evolution of vaccine process technology has occurred in parallel to the remarkable growth in the development of therapeutic proteins as products; therefore, recent vaccine innovations can leverage the progress made in the broader biotechnology industry. Numerous important legacy vaccines are still in use today despite their traditional manufacturing processes, with further development focusing on improving stability (e.g., novel excipients) and updating formulation (e.g., combination vaccines) and delivery methods (e.g., skin patches). Modern vaccine development is currently exploiting a wide array of novel technologies to create safer and more efficacious vaccines including: viral vectors produced in animal cells, virus-like particles produced in yeast or insect cells, polysaccharide conjugation to carrier proteins, DNA plasmids produced in E. coli, and therapeutic cancer vaccines created by in vitro activation of patient leukocytes. Purification advances (e.g., membrane adsorption, precipitation) are increasing efficiency, while innovative analytical methods (e.g., microsphere-based multiplex assays, RNA microarrays) are improving process understanding. Novel adjuvants such as monophosphoryl lipid A, which acts on antigen presenting cell toll-like receptors, are expanding the previously conservative list of widely accepted vaccine adjuvants. As in other areas of biotechnology, process characterization by sophisticated analysis is critical not only to improve yields, but also to determine the final product quality. From a regulatory

  9. Vaccination against seasonal flu

    CERN Multimedia

    2015-01-01

    The Medical Service once again recommends you to get your annual flu vaccination for the year.   Vaccination is the most effective way of avoiding the illness and any serious consequences and protecting those around you. The flu can have especially serious consequences for people with chronic conditions (diabetes, cardio-vascular disease, etc.), pregnant women, infants, and people over 65 years of age. Remember, anyone working on the CERN site who wishes to be vaccinated against seasonal flu should go to the Infirmary (Building 57, ground floor) with their vaccine. The Medical Service will issue a prescription on the day of the vaccination for the purposes of reimbursement by UNIQA. NB: The Medical Service cannot provide this vaccination service for family members or retired members of the personnel. For more information: • The "Seasonal flu" flyer by the Medical Service • Recommendations of the Swiss Federal Office of Public...

  10. Recombinant influenza vaccines.

    Science.gov (United States)

    Sedova, E S; Shcherbinin, D N; Migunov, A I; Smirnov, Iu A; Logunov, D Iu; Shmarov, M M; Tsybalova, L M; Naroditskiĭ, B S; Kiselev, O I; Gintsburg, A L

    2012-10-01

    This review covers the problems encountered in the construction and production of new recombinant influenza vaccines. New approaches to the development of influenza vaccines are investigated; they include reverse genetics methods, production of virus-like particles, and DNA- and viral vector-based vaccines. Such approaches as the delivery of foreign genes by DNA- and viral vector-based vaccines can preserve the native structure of antigens. Adenoviral vectors are a promising gene-delivery platform for a variety of genetic vaccines. Adenoviruses can efficiently penetrate the human organism through mucosal epithelium, thus providing long-term antigen persistence and induction of the innate immune response. This review provides an overview of the practicability of the production of new recombinant influenza cross-protective vaccines on the basis of adenoviral vectors expressing hemagglutinin genes of different influenza strains. PMID:23346377

  11. Vaccines against leptospirosis.

    Science.gov (United States)

    Adler, Ben

    2015-01-01

    Vaccines against leptospirosis followed within a year of the first isolation of Leptospira, with the first use of a killed whole cell bacterin vaccine in guinea pigs published in 1916. Since then, bacterin vaccines have been used in humans, cattle, swine, and dogs and remain the only vaccines licensed at the present time. The immunity elicited is restricted to serovars with related lipopolysaccharide (LPS) antigen. Likewise, vaccines based on LPS antigens have clearly demonstrated protection in animal models, which is also at best serogroup specific. The advent of leptospiral genome sequences has allowed a reverse vaccinology approach for vaccine development. However, the use of inadequate challenge doses and inappropriate statistical analysis invalidates many of the claims of protection with recombinant proteins. PMID:25388138

  12. Vaccine Treatment for Prostate Cancer

    Science.gov (United States)

    ... Preventing and treating prostate cancer spread to bones Vaccine treatment for prostate cancer Sipuleucel-T (Provenge) is ... less advanced prostate cancer. Possible side effects of vaccine treatment Side effects from the vaccine tend to ...

  13. Anthrax vaccination strategies

    OpenAIRE

    Cybulski, Robert J.; Sanz, Patrick; O'Brien, Alison D.

    2009-01-01

    The biological attack conducted through the U.S. postal system in 2001 broadened the threat posed by anthrax from one pertinent mainly to soldiers on the battlefield to one understood to exist throughout our society. The expansion of the threatened population placed greater emphasis on the reexamination of how we vaccinate against Bacillus anthracis. The currently-licensed Anthrax Vaccine, Adsorbed (AVA) and Anthrax Vaccine, Precipitated (AVP) are capable of generating a protective immune res...

  14. Immunobiology of Influenza Vaccines

    OpenAIRE

    Gomez Lorenzo, Margarita M.; Fenton, Matthew J.

    2013-01-01

    Vaccination is the primary strategy for prevention and control of influenza. The surface hemagglutinin (HA) protein of the influenza virus contains two structural elements (head and stalk) that differ in their potential utility as vaccine targets. The head of the HA protein is the primary target of antibodies that confer protective immunity to influenza viruses. The underlying health status, age, and gene polymorphisms of vaccine recipients and, just as importantly, the extent of the antigeni...

  15. Influenza vaccination during pregnancy.

    OpenAIRE

    Goldman, Ran D.; Koren, Gideon

    2002-01-01

    QUESTION: A 27-year-old patient of mine recently learned she is pregnant. She took the influenza vaccine offered at work when she was 7 weeks pregnant. Is her fetus at risk of malformations? ANSWER: No evidence indicates that killed influenza vaccine is teratogenic, even if given during the first trimester. Since 1996, Health Canada's Centre for Disease Control and Prevention has recommended that pregnant women in their second and third trimesters be vaccinated. This should not be interpreted...

  16. Vaccines for allergy

    OpenAIRE

    Linhart, Birgit; Valenta, Rudolf

    2012-01-01

    Vaccines aim to establish or strengthen immune responses but are also effective for the treatment of allergy. The latter is surprising because allergy represents a hyper-immune response based on immunoglobulin E production against harmless environmental antigens, i.e., allergens. Nevertheless, vaccination with allergens, termed allergen-specific immunotherapy is the only disease-modifying therapy of allergy with long-lasting effects. New forms of allergy diagnosis and allergy vaccines based o...

  17. Vaccination against RSV

    OpenAIRE

    Kaaijk, Patricia; Luytjes, Willem; Rots, Nynke Y.

    2013-01-01

    The respiratory syncytial virus (RSV) is the major cause of lower respiratory tract illness (LRI) in infants worldwide. Also persons with heart/lung disease or an immunodeficiency disorder, and the elderly are at increased risk for severe LRI upon RSV infection. Although there is at present no licensed RSV vaccine available, it is a priority target for several vaccine developers. For the implementation of a future RSV vaccination within national immunization schemes, various strategies can be...

  18. Vaccines, our shared responsibility.

    Science.gov (United States)

    Pagliusi, Sonia; Jain, Rishabh; Suri, Rajinder Kumar

    2015-05-01

    The Developing Countries Vaccine Manufacturers' Network (DCVMN) held its fifteenth annual meeting from October 27-29, 2014, New Delhi, India. The DCVMN, together with the co-organizing institution Panacea Biotec, welcomed over 240 delegates representing high-profile governmental and nongovernmental global health organizations from 36 countries. Over the three-day meeting, attendees exchanged information about their efforts to achieve their shared goal of preventing death and disability from known and emerging infectious diseases. Special praise was extended to all stakeholders involved in the success of polio eradication in South East Asia and highlighted challenges in vaccine supply for measles-rubella immunization over the coming decades. Innovative vaccines and vaccine delivery technologies indicated creative solutions for achieving global immunization goals. Discussions were focused on three major themes including regulatory challenges for developing countries that may be overcome with better communication; global collaborations and partnerships for leveraging investments and enable uninterrupted supply of affordable and suitable vaccines; and leading innovation in vaccines difficult to develop, such as dengue, Chikungunya, typhoid-conjugated and EV71, and needle-free technologies that may speed up vaccine delivery. Moving further into the Decade of Vaccines, participants renewed their commitment to shared responsibility toward a world free of vaccine-preventable diseases. PMID:25749248

  19. Rabies vaccines and interferon

    Science.gov (United States)

    Turner, G. S.

    1972-01-01

    Samples of Fermi, Semple, modified Semple, Duck embryo and tissue culture rabies vaccine were inoculated by different routes and in different doses into rabbits, mice and hamsters. The vaccines induced neither detectable interferon nor immediate protection against lethal challenge with CVS rabies virus. Under similar conditions, high but transient levels of interferon were induced in control animals of the same species with the polynucleotide complex Poly I.C. Hamsters but not mice were protected by Poly I.C.-induced interferon. No autointerference by vaccine with challenge virus was established. Vaccine-induced protection in mice was directly related to immune response. PMID:4506993

  20. DNA fusion gene vaccines

    DEFF Research Database (Denmark)

    Holst, Peter Johannes; Bassi, Maria Rosaria; Thomsen, Allan Randrup;

    2010-01-01

    DNA vaccines are versatile and safe, but limited immunogenicity has prevented their use in the clinical setting. Experimentally, immunogenicity may be enhanced by the use of new delivery technologies, by coadministration of cytokines and pathogen-associated molecular patterns, or by fusion...... with these modifications, it is likely that the primary use of DNA vaccines may be as primers for viral-vectored vaccines, rather than as single agents. This review discusses the approaches used to enhance DNA vaccine immunogenicity, with a primary focus on fusion strategies that enhance antigen presentation....

  1. Tetanus, Diphtheria, Pertussis (Tdap) Vaccine

    Science.gov (United States)

    Adacel® (as a combination product containing Diphtheria, Tetanus Toxoids, Acellular Pertussis Vaccine) ... Boostrix® (as a combination product containing Diphtheria, Tetanus Toxoids, Acellular Pertussis Vaccine)

  2. Universal influenza vaccines: Shifting to better vaccines.

    Science.gov (United States)

    Berlanda Scorza, Francesco; Tsvetnitsky, Vadim; Donnelly, John J

    2016-06-01

    Influenza virus causes acute upper and lower respiratory infections and is the most likely, among known pathogens, to cause a large epidemic in humans. Influenza virus mutates rapidly, enabling it to evade natural and vaccine-induced immunity. Furthermore, influenza viruses can cross from animals to humans, generating novel, potentially pandemic strains. Currently available influenza vaccines induce a strain specific response and may be ineffective against new influenza viruses. The difficulty in predicting circulating strains has frequently resulted in mismatch between the annual vaccine and circulating viruses. Low-resource countries remain mostly unprotected against seasonal influenza and are particularly vulnerable to future pandemics, in part, because investments in vaccine manufacturing and stockpiling are concentrated in high-resource countries. Antibodies that target conserved sites in the hemagglutinin stalk have been isolated from humans and shown to confer protection in animal models, suggesting that broadly protective immunity may be possible. Several innovative influenza vaccine candidates are currently in preclinical or early clinical development. New technologies include adjuvants, synthetic peptides, virus-like particles (VLPs), DNA vectors, messenger RNA, viral vectors, and attenuated or inactivated influenza viruses. Other approaches target the conserved exposed epitope of the surface exposed membrane matrix protein M2e. Well-conserved influenza proteins, such as nucleoprotein and matrix protein, are mainly targeted for developing strong cross-protective T cell responses. With multiple vaccine candidates moving along the testing and development pipeline, the field is steadily moving toward a product that is more potent, durable, and broadly protective than previously licensed vaccines. PMID:27038130

  3. Clinical development of Ebola vaccines.

    Science.gov (United States)

    Sridhar, Saranya

    2015-09-01

    The ongoing outbreak of Ebola virus disease in West Africa highlighted the lack of a licensed drug or vaccine to combat the disease and has renewed the urgency to develop a pipeline of Ebola vaccines. A number of different vaccine platforms are being developed by assessing preclinical efficacy in animal models and expediting clinical development. Over 15 different vaccines are in preclinical development and 8 vaccines are now in different stages of clinical evaluation. These vaccines include DNA vaccines, virus-like particles and viral vectors such as live replicating vesicular stomatitis virus (rVSV), human and chimpanzee adenovirus, and vaccinia virus. Recently, in preliminary results reported from the first phase III trial of an Ebola vaccine, the rVSV-vectored vaccine showed promising efficacy. This review charts this rapidly advancing area of research focusing on vaccines in clinical development and discusses the future opportunities and challenges faced in the licensure and deployment of Ebola vaccines. PMID:26668751

  4. Cochlear-Meningitis Vaccination

    Science.gov (United States)

    ... Prevnar 13®) 23-valent pneumococcal polysaccharide (PPSV) (Pneumovax®) Haemophilus influenzae type b conjugate (Hib) Tetravalent (A, C, Y, W-135) ... CDC immunization guidelines for routine meningococcal vaccination. The Haemophilus influenzae type b (Hib) vaccine is not routinely recommended for those ...

  5. Chimeric Pestivirus Experimental Vaccines.

    Science.gov (United States)

    Reimann, Ilona; Blome, Sandra; Beer, Martin

    2016-01-01

    Chimeric pestiviruses have shown great potential as marker vaccine candidates against pestiviral infections. Exemplarily, we describe here the construction and testing of the most promising classical swine fever vaccine candidate "CP7_E2alf" in detail. The description is focused on classical cloning technologies in combination with reverse genetics. PMID:26458840

  6. Lassa fever vaccine.

    Science.gov (United States)

    Fisher-Hoch, Susan P; McCormick, Joseph B

    2004-04-01

    Lassa fever remains a serious challenge to public health in West Africa threatening both local residents in rural areas and those who serve them, particularly medical care providers. Given the ecology of the rodent host and conditions in the endemic area, a vaccine is mandatory for control. The challenge is to overcome the scientific, political and economic obstacles to producing a human use vaccine candidate. There are some scientific issues to resolve. It is known that the G-protein confers protection but we do not know its duration. If the N-protein is also included there may be a better duration of protection but it is unclear whether the N-protein as a vaccine may possibly enhance the infection. The original vaccinia vector must be replaced by new vectors, chimeras or by delivering DNA in some format. A live vaccine is attractive because it can confer protection in a single shot. A killed vaccine is more stable, particularly for distribution in the tropics but usually requires repeated shots. For practical reasons a live vaccine format should probably be pursued, which could then be combined with a yellow fever vaccine, using the same cold chains, since this disease occupies the same endemic areas in West Africa. Lassa vaccine initiatives have suffered from a lack of funding in the past but bioterrorism has brought new resources to Lassa virus science. Adequate funding and applications of new vaccine technologies give hope that we may soon see a vaccine in clinical trials. However, the difficulty of conducting trials in endemic areas and lack of political stability remain serious problems. PMID:15056044

  7. Vaccination practices of Quebec family physicians. Influenza vaccination status and professional practices for influenza vaccination.

    Directory of Open Access Journals (Sweden)

    Milord F

    2001-11-01

    Full Text Available OBJECTIVE: To assess influenza vaccination status and influenza vaccination practices of family physicians in Quebec. DESIGN: Mail survey of a random sample of 1000 family physicians. SETTING: Family practices in the province of Quebec. PARTICIPANTS: Of 1000 Quebec family physicians sent questionnaires, 550 responded. After excluding physicians who worked only in institutions, had no patients older than 65 years, or did clinical work less than 20% of the time, 379 respondents were eligible for the study. MAIN OUTCOME MEASURES: Vaccination status of family physicians in 1996 and professional practices based on six clinical and administrative activities pertaining to influenza vaccination. RESULTS: Prevalence of vaccination was 35.5% (95% confidence interval 30.8% to 40.4% among responding physicians and was higher among those 60 years and older, those with a chronic condition, and those perceiving high peer pressure to get vaccinated. Most respondents frequently assessed the current influenza vaccination status of their patients, risk factors for influenza-related complications, and contraindications to the vaccine. They also frequently provided education about influenza and its vaccine, recommended vaccination, and administered the vaccine. Only a few reported assessing prior influenza vaccinations or recording vaccination status regularly. Finally, vaccinated physicians recommended the vaccine more frequently to their patients than unvaccinated physicians did. CONCLUSION: Promotion programs focusing on peer influence could increase vaccination of family physicians. This could in turn improve vaccination coverage of elderly patients.

  8. Parental knowledge of paediatric vaccination

    Directory of Open Access Journals (Sweden)

    Borràs Eva

    2009-05-01

    Full Text Available Abstract Background Although routine vaccination is a major tool in the primary prevention of some infectious diseases, there is some reluctance in a proportion of the population. Negative parental perceptions of vaccination are an important barrier to paediatric vaccination. The aim of this study was to investigate parental knowledge of paediatric vaccines and vaccination in Catalonia. Methods A retrospective, cross-sectional study was carried out in children aged Results An association was observed between greater vaccination coverage of the 4:4:4:3:1 schedule (defined as: 4 DTPa/w doses, 4 Hib doses, 4 OPV doses, 3 MenC doses and 1 MMR dose and maternal age >30 years (OR: 2.30; 95% CI: 1.20–4.43 and with a knowledge of vaccination score greater than the mean (OR: 0.45; 95% CI: 0.28–0.72. The score increased with maternal educational level and in parents of vaccinated children. A total of 20.47% of parents stated that vaccines could have undesirable consequences for their children. Of these, 23.26% had no specific information and 17.83% stated that vaccines can cause adverse reactions and the same percentage stated that vaccines cause allergies and asthma. Conclusion Higher vaccination coverage is associated with older maternal age and greater knowledge of vaccination. Vaccination coverage could be raised by improving information on vaccines and vaccination.

  9. Mumps - Vaccine Q and A

    Science.gov (United States)

    ... CDC.gov . Vaccines and Immunizations Share Compartir Mumps - Vaccine Q&A For Parents Is there a vaccine to prevent mumps? Yes. Two doses of mumps- ... 12 years old. UPDATED July 2010 Is the vaccine effective/does it work? One dose of mumps ...

  10. [Current events in vaccination].

    Science.gov (United States)

    Aubert, M; Aumaître, H; Beytout, J; Bloch, K; Bouhour, D; Callamand, P; Chave, C; Cheymol, J; Combadière, B; Dahlab, A; Denis, F; De Pontual, L; Dodet, B; Dommergues, M-A; Dufour, V; Gagneur, A; Gaillat, J; Gaudelus, J; Gavazzi, G; Gillet, Y; Gras-le-Guen, C; Haas, H; Hanslik, T; Hau-Rainsard, I; Larnaudie, S; Launay, O; Lorrot, M; Loulergue, P; Malvy, D; Marchand, S; Picherot, G; Pinquier, D; Pulcini, C; Rabaud, C; Regnier, F; Reinert, P; Sana, C; Savagner, C; Soubeyrand, B; Stephan, J-L; Strady, C

    2011-11-01

    The annual meeting of the Infectious Disease Society of America (IDSA) ; which brought together nearly 5000 participants from over 80 countries in Vancouver, Canada, October 21 to 24, 2010 ; provided a review of the influenza (H1N1) 2009 pandemic, evaluated vaccination programmes and presented new vaccines under development. With 12,500 deaths in the United States in 2009-2010, the influenza (H1N1) 2009 pandemic was actually less deadly than the seasonal flu. But it essentially hit the young, and the toll calculated in years of life lost is high. The monovalent vaccines, whether live attenuated or inactivated with or without adjuvants, were well tolerated in toddlers, children, adults and pregnant women. In order to protect infants against pertussis, family members are urged to get their booster shots. The introduction of the 13-valent Pneumococcal conjugated vaccine in the beginning of 2010 may solve - but for how long ? - the problem of serotype replacement, responsible for the re-increasing incidence of invasive Pneumococcal infections observed in countries that had introduced the 7-valent vaccine. The efficacy of a rotavirus vaccine has been confirmed, with a reduction in hospitalization in the United States and a reduction in gastroenteritis-related deaths in Mexico. In the United States, vaccination of pre-adolescents against human papillomavirus (HPV) has not resulted in any specific undesirable effects. Routine vaccination against chicken pox, recommended since 1995, has not had an impact on the evolution of the incidence of shingles. Vaccination against shingles, recommended in the United States for subjects 60 years and over, shows an effectiveness of 55 %, according to a cohort study (Kaiser Permanente, Southern California). Although some propose the development of personalized vaccines according to individual genetic characteristics, the priority remains with increasing vaccine coverage, not only in infants but also in adults and the elderly. Vaccine

  11. DNA vaccine: the miniature miracle

    Directory of Open Access Journals (Sweden)

    Karthik Kaliaperumal

    2013-08-01

    Full Text Available DNA, the essential part of the life is making way in to new vaccine technology. Plasmid vectors from the bacteria have revolutionized the world of vaccine design by its new technology – DNA vaccines. Small portion of the nucleotides from the pathogen held under the control of promoter in a plasmid vector can be used as a vaccine. DNA vaccines alleviate the odds of the other vaccines by having good hold on both the faces of the immunity. The key to the success of DNA vaccine lies in the route of administration of the vaccine which can be done in many ways. Prime boost strategy is an approach used to boost the action of DNA vaccine. To date there are only four DNA vaccine available in the market. [Vet World 2013; 6(4.000: 228-232

  12. Flu vaccination in pregnancy

    Directory of Open Access Journals (Sweden)

    Maria Siettou

    2012-04-01

    Full Text Available In periods of seasonal influenza, during pandemic flu in the past and from recent experience that we have the emergence of influenza A (H1N1, pregnant compared with non-pregnant women are at increased risk to get sick and to develop serious complications up to mortality. Purpose: This paper examines the risks that arise for pregnant from contamination with the flu virus and the safety of influenza vaccination in pregnancy. Method: The method involves searching review and research studies in Pubmed data base mainly of the 2000 until 2009 and the words were used is pregnancy, flu vaccination, complications of the flu vaccination at the period of pregnancy. Results: Morbidity during periods of seasonal influenza in pregnant women is increased, while in times of pandemic are recorded fatalities. Based on this, specific recommendations have been made for a flu vaccination in pregnant women, both from the CDC, the American College of Obstetricians and Gynecologists in the U.S. and other official bodies like the World Health Organization, according to that the constitution of influenza vaccine in the pregnancy is necessary, given that the probability of morbidity in this period is increased at 10%. Conclusions: The studies so far to influenza vaccination in pregnancy, do not record serious complications for pregnant women and infants. However more research needs to be done on the safety of influenza vaccination in pregnancy.

  13. [Vaccinations in respiratory medicine].

    Science.gov (United States)

    Lode, H M; Stahlmann, R

    2015-09-01

    Vaccinations are the most successful and cost-effective measures for prevention of infections. Important pathogens of respiratory tract infections (e.g. influenza viruses and pneumococci) can be effectively treated by vaccinations. The seasonal trivalent and recently now quadrivalent influenza vaccines include antigens from influenza A and B type viruses, which have to be modified annually oriented to the circulating strains. The effective protection by influenza vaccination varies considerably (too short protection time, mismatch); therefore, administration late in the year is the best approach (November/December). Two pneumococcal vaccines are recommended for adults: the over 30-year-old 23-valent polysaccharide vaccine (PPV23) and the 4-year-old 13-valent conjugate vaccine (PCV13). The immunological and clinical efficacy of PPV23 is controversially discussed; however, a moderate reduction of invasive pneumococcal infections is widely accepted. The PCV13 stimulates a T-cell response and has currently demonstrated its clinical efficacy in an impressive study (CAPiTA). The problem of PCV13 is the relatively limited coverage of only 47% of the currently circulating invasive pneumococcal serotypes. PMID:26330051

  14. Reasons for non-vaccination

    OpenAIRE

    Dannetun, Eva

    2006-01-01

    Vaccines are among the most effective public health interventions used today. Population based vaccination programmes are mainly aimed at protecting against common childhood diseases, but other population groups are also the targets for different recommendations. The objectives of this thesis were to assess coverage and reasons for non-vaccination for three of vaccination programmes recommended by the National Board of Health and Welfare: influenza vaccine for the elderly, ...

  15. Vaccine acceptance: The UK perspective

    OpenAIRE

    Ford, John A; Mahgoub, Hamid; Shankar, Ananda Giri

    2013-01-01

    The United Kingdom has had a long history with vaccine acceptability dating back to Edward Jenner’s theory of small pox vaccination. More recently, the discredited, Wakefield study published in 1998 continues to cause MMR skepticism. In pregnant women pertussis vaccination has been considerably more successful than influenza vaccination. Influenza vaccine uptake in healthcare workers remains poor. The media, politicians, and health reforms have contributed to the mixed coverage for these vacc...

  16. Vaccination against Klebsiella aerogenes.

    OpenAIRE

    Roe, E. A.; Jones, R J

    1984-01-01

    Klebsiella vaccine was prepared from strains of Klebsiella aerogenes with capsular types K1, K36, K44 and K Cross (a type which cross-reacts in vitro with sera from many klebsiella capsular types). The vaccine was extracted by dialysis and ultrafiltration from capsular material released during growth of the bacteria in a five-day batch culture. Mice given one dose of vaccine from K1a (1.0 microgram/mouse) survived lethal intraperitoneal challenge of 11/11 homologous klebsiella strains four da...

  17. Research toward Malaria Vaccines

    Science.gov (United States)

    Miller, Louis H.; Howard, Russell J.; Carter, Richard; Good, Michael F.; Nussenzweig, Victor; Nussenzweig, Ruth S.

    1986-12-01

    Malaria exacts a toll of disease to people in the Tropics that seems incomprehensible to those only familiar with medicine and human health in the developed world. The methods of molecular biology, immunology, and cell biology are now being used to develop an antimalarial vaccine. The Plasmodium parasites that cause malaria have many stages in their life cycle. Each stage is antigenically distinct and potentially could be interrupted by different vaccines. However, achieving complete protection by vaccination may require a better understanding of the complexities of B- and T-cell priming in natural infections and the development of an appropriate adjuvant for use in humans.

  18. Therapeutic HIV Peptide Vaccine

    DEFF Research Database (Denmark)

    Fomsgaard, Anders

    2015-01-01

    Therapeutic vaccines aim to control chronic HIV infection and eliminate the need for lifelong antiretroviral therapy (ART). Therapeutic HIV vaccine is being pursued as part of a functional cure for HIV/AIDS. We have outlined a basic protocol for inducing new T cell immunity during chronic HIV-1...... infection directed to subdominant conserved HIV-1 epitopes restricted to frequent HLA supertypes. The rationale for selecting HIV peptides and adjuvants are provided. Peptide subunit vaccines are regarded as safe due to the simplicity, quality, purity, and low toxicity. The caveat is reduced immunogenicity...

  19. Hepatitis B vaccination.

    Science.gov (United States)

    Romanò, Luisa; Paladini, Sara; Galli, Cristina; Raimondo, Giovanni; Pollicino, Teresa; Zanetti, Alessandro R

    2015-01-01

    Hepatitis B virus is a worldwide leading cause of acute and chronic liver disease including cirrhosis and hepatocellular carcinoma. Effective vaccines have been available since the early '80s and vaccination has proved highly successful in reducing the disease burden, the development of the carrier state and the HB-related morbidity and mortality in the countries where vaccination has been implemented.   Neutralizing (protective) antibodies (anti-HBs) induced by vaccination are targeted largely towards the amino acid hydrophilic region, referred to as the common a determinant which is present on the outer protein coat or surface antigen (HBsAg), spanning amino acids 124-149. This provides protection against all HBV genotypes (from A to H) and is responsible for the broad immunity afforded by hepatitis B vaccination. Thus, alterations of residues within this region of the surface antigen may determine conformational changes that can allow replication of the mutated HBV in vaccinated people. An important mutation in the surface antigen region was identified in Italy some 25 years ago in infants born to HBsAg carrier mothers who developed breakthrough infections despite having received HBIG and vaccine at birth. This virus had a point mutation from guanosine to adenosine at nucleotide position 587, resulting in aa substitution from glycine (G) to arginine (R) at position 145 in the a determinant. Since the G145R substitution alters the projecting loop (aa 139-147) of the a determinant, the neutralizing antibodies induced by vaccination are no longer able to recognize the mutated epitope. Beside G145R, other S-gene mutations potentially able to evade neutralizing anti-HBs and infect vaccinated people have been described worldwide. In addition, the emergence of Pol mutants associated with resistance to treatment with nucleos(t)ide analogues can select viruses with crucial changes in the overlapping S-gene, potentially able to alter the S protein immunoreactivity. Thus

  20. Alphavirus-Based Vaccines.

    Science.gov (United States)

    Lundstrom, Kenneth

    2016-01-01

    Alphavirus vectors based on Semliki Forest virus, Sindbis virus, and Venezuelan equine encephalitis virus have been widely applied for vaccine development. Naked RNA replicons, recombinant viral particles, and layered DNA vectors have been subjected to immunization in preclinical animal models with antigens for viral targets and tumor antigens. Moreover, a limited number of clinical trials have been conducted in humans. Vaccination with alphavirus vectors has demonstrated efficient immune responses and has showed protection against challenges with lethal doses of virus and tumor cells, respectively. Moreover, vaccines have been developed against alphaviruses causing epidemics such as Chikungunya virus. PMID:27076308

  1. Cellular based cancer vaccines

    DEFF Research Database (Denmark)

    Hansen, Morten; Met, O; Svane, I M;

    2012-01-01

    Cancer vaccines designed to re-calibrate the existing host-tumour interaction, tipping the balance from tumor acceptance towards tumor control holds huge potential to complement traditional cancer therapies. In general, limited success has been achieved with vaccines composed of tumor...... in vitro migration via autocrine receptor-mediated endocytosis of CCR7. In the current review, we discuss optimal design of DC maturation focused on pre-clinical as well as clinical results from standard and polarized dendritic cell based cancer vaccines....

  2. Vaccines: Engineering immune evasion

    Science.gov (United States)

    Mascola, John R.

    2006-05-01

    One obstacle to realizing the promise of viral vectors for vaccine delivery is pre-existing immunity to such vectors. An adroit application of structure-based design points to a way around that problem.

  3. Human Papillomavirus (HPV) Vaccines

    Science.gov (United States)

    ... Prevention Overview–for health professionals Research Human Papillomavirus (HPV) Vaccines On This Page What are human papillomaviruses? Which cancers are caused by HPV? Who gets HPV infections? Can HPV infections be ...

  4. Hepatitis B Vaccination Protection

    Science.gov (United States)

    Fact Sheet Hepatitis B Vaccination Protection Hepatitis B virus (HBV) is a pathogenic microorganism that can cause potentially life- threatening disease in humans. HBV infection is transmitted through exposure ...

  5. Antibacterials: A sweet vaccine

    Science.gov (United States)

    Bundle, David

    2016-03-01

    Vaccination with a synthetic glycoconjugate, in combination with the administration of an inhibitor that blocks capsular polysaccharide synthesis in bacteria, could offer an alternative route to combat bacterial infections.

  6. Tetanus, Diphtheria (Td) Vaccine

    Science.gov (United States)

    Tenivac® (as a combination product containing Diphtheria, Tetanus Toxoids) ... Why get vaccinated?Tetanus and diphtheria are very serious diseases. They are rare in the United States today, but people who do become ...

  7. Tetanus, Diphtheria (Td) Vaccine

    Science.gov (United States)

    Tenivac® (as a combination product containing Diphtheria, Tetanus Toxoids) ... Why get vaccinated?Tetanus and diphtheria are very serious diseases. They are rare in the United States today, but people who do become infected often have severe ...

  8. Ingredients of Vaccines

    Science.gov (United States)

    ... is packaged. Monosodium glutamate ( MSG ) and 2-phenoxy-ethanol which are used as stabilizers in a few ... mercury, aluminum, formaldehyde, human serum albumin, antibiotics, and yeast proteins in vaccines have not been found to ...

  9. Governments, off-patent vaccines, smallpox and universal childhood vaccination.

    Science.gov (United States)

    Music, Stanley

    2010-01-22

    WHO is now celebrating more than 30 years of freedom from smallpox. What was originally seen as a victory over an ancient scourge can now be viewed as an epidemiologically driven programme to overcome governmental inertia and under-achievement in delivering an off-patent vaccine. Though efforts are accelerating global vaccine use, a plea is made to push the world's governments to commit to universal childhood vaccination via a proposed new programme. The latter should begin by exploiting a long list of ever more affordable off-patent vaccines, vaccines that can virtually eliminate the bulk of the world's current vaccine-preventable disease burden. PMID:19699330

  10. Fundamentals of Vaccine Immunology

    OpenAIRE

    Angela S Clem

    2011-01-01

    From a literature review of the current literature, this article provides an introduction to vaccine immunology including a primer on the components of the immune system, passive vs. active immunization, the mechanism(s) by which immunizations stimulate(s) immunity, and the types of vaccines available. Both the innate and adaptive immune subsystems are necessary to provide an effective immune response to an immunization. Further, effective immunizations must induce long-term stimulation of bo...

  11. Rotavirus vaccines Review

    OpenAIRE

    KURUGÖL, Zafer

    2007-01-01

    Rotavirus is a major cause of acute gastroenteritis worldwide and infects almost all children in the first 5 years of life with severe dehydrating gastroenteritis occurring primarily among children 4 to 36 months of age Rotavirus causes an estimated 600 000 deaths and more than 2 million hospitalizations each year A tetravalent rhesus human reassortant rotavirus vaccine Rotashield was licensed in 1998 for routine immunization of infants in the United States However the vaccine was subsequentl...

  12. Next Generation Pneumococcal Vaccines

    OpenAIRE

    Kristin L Moffitt; Malley, Richard

    2011-01-01

    Currently licensed pneumococcal vaccines are based on the generation of antibodies to the pneumococcal polysaccharide, of which there are more than 90 different types. While these vaccines are highly effective against the serotypes included, their high cost and limited serotype coverage limits their usefulness worldwide, particularly in low resources areas. Thus alternative or adjunctive options are being actively pursued. This review will present these various approaches, including variation...

  13. Vaccines for Pandemic Influenza

    OpenAIRE

    Luke, Catherine J.; Subbarao, Kanta

    2006-01-01

    Recent outbreaks of highly pathogenic avian influenza in Asia and associated human infections have led to a heightened level of awareness and preparation for a possible influenza pandemic. Vaccination is the best option by which spread of a pandemic virus could be prevented and severity of disease reduced. Production of live attenuated and inactivated vaccine seed viruses against avian influenza viruses, which have the potential to cause pandemics, and their testing in preclinical studies and...

  14. Advances in influenza vaccination

    OpenAIRE

    Reperant, Leslie A.; Rimmelzwaan, Guus F.; Osterhaus, Albert D. M. E.

    2014-01-01

    Influenza virus infections yearly cause high morbidity and mortality burdens in humans, and the development of a new influenza pandemic continues to threaten mankind as a Damoclean sword. Influenza vaccines have been produced by using egg-based virus growth and passaging techniques that were developed more than 60 years ago, following the identification of influenza A virus as an etiological agent of seasonal influenza. These vaccines aimed mainly at eliciting neutralizing antibodies targetin...

  15. Vaccination in Elite Athletes

    OpenAIRE

    Gärtner, Barbara C.; de Meyer, Tim

    2014-01-01

    Public health vaccination guidelines cannot be easily transferred to elite athletes. An enhanced benefit from preventing even mild diseases is obvious but stronger interference from otherwise minor side effects has to be considered as well. Thus, special vaccination guidelines for adult elite athletes are required. In most of them, protection should be strived for against tetanus, diphtheria, pertussis, influenza, hepatitis A, hepatitis B, measles, mumps and varicella. When living or travelin...

  16. Anti-addiction vaccines

    OpenAIRE

    Shen, Xiaoyun; Orson, Frank M.; Kosten, Thomas R.

    2011-01-01

    Despite intensive efforts to eradicate it, addiction to both legal and illicit drugs continues to be a major worldwide medical and social problem. Anti-addiction vaccines can produce the antibodies to block the effects of these drugs on the brain, and have great potential to ameliorate the morbidity and mortality associated with illicit drug intoxications. This review provides a current overview of anti-addiction vaccines that are under clinical trial and pre-clinical research evaluation. It ...

  17. Meningococcal vaccines Review

    OpenAIRE

    Kurugöl, Zafer

    2007-01-01

    Meningococcal disease presenting primarily as meningococcemia and meningitis continues to be a devastating problem around the world In the past 200 years several meningococcal epidemics have been noted in Europe Africa Asia and the United States Annually 500 000 cases of invasive meningococcal disease occur still worldwide of which 8805;50 000 result in death Therefore vaccine development has been undertaken in earnest for the prevention of this disease Polysaccharide vaccines have been avail...

  18. Nieuw vaccin tegen campylobacter

    OpenAIRE

    Wagenaar, J.A.

    2008-01-01

    Het vaccin dat de kip moet beschermen tegen de bacterie Campylobacter werkt in het laboratorium. Dat wil bacterioloog Jaap Wagenaar wel kwijt. Wanneer het er komt en zelfs of het er komt, daarover laat Wagenaar zich niet uit. "Het is een hele klus om het immuunsysteem van kippen effectief op te laten treden tegen Campylobacter", zegt Wagenaar die werkt bij het CVI en hoogleraar is aan de Universiteit Utrecht. "Geen van de vaccins die onderzoekers tot nu hebben uitgeprobeerd werken"

  19. [Influenza vaccine and adjuvant].

    Science.gov (United States)

    Nakayama, Tetsuo

    2011-01-01

    Adjuvant is originated from the Latin word "adjuvare" which means "help" in English to enhance the immunological responses when given together with antigens. The beginning of adjuvant was mineral oil which enhanced the immune response when it was given with inactivated Salmonella typhimurium. Aluminium salt was used to precipitate diphtheria toxoid and increased level of antibody response was demonstrated when administered with alum-precipitated antigens. Since 1930, aluminium salt has been used as DTaP (diphtheria-tetanus-acellular pertussis vaccine) adjuvant. Many candidates were tested for adjuvant activity but only aluminum salt is allowed to use for human vaccines. New adjuvant MF59, oil-in-water emulsion type, was developed for influenza vaccine for elderly (Fluad) and series of AS adjuvant are used for hepatitis B, pandemic flue, and human papiloma virus vaccines. Oil-adjuvanted influenza pandemic vaccines induced higher antibody response than alum-adjuvanted vaccine with higher incidence of adverse events, especially for local reactions. Alum-adjuvanted whole virion inactivated H5N1 vaccine was developed in Japan, and it induced relatively well immune responses in adults. When it applied for children, febrile reaction was noted in approximately 60% of the subjects, with higher antibodies. Recent investigation on innate immunity demonstrates that adjuvant activity is initiated from the stimulation on innate immunity and/or inflammasome, resulting in cytokine induction and antigen uptake by monocytes and macrophages. The probable reason for high incidence of febrile reaction should be investigated to develop a safe and effective influenza vaccine. PMID:22129866

  20. Current status of rotavirus vaccines

    Institute of Scientific and Technical Information of China (English)

    Ching-Min Wang; Shou-Chien Chen; Kow-Tong Chen

    2015-01-01

    Background: Rotaviruses remain the major cause of childhood diarrheal disease worldwide and of diarrheal deaths of infants and children in developing countries. The huge burden of childhood rotavirus-related diarrhea in the world continues to drive the remarkable pace of vaccine development. Data sources: Research articles were searched using terms "rotavirus" and "rotavirus vaccine" in MEDLINE and PubMed. Articles not published in the English language, articles without abstracts, and opinion articles were excluded from the review. After preliminary screening, all articles were reviewed and synthesized to provide an overview of current vaccines and vaccination programs. Results: In this review of the global rotavirus vaccines and vaccination programs, the principles of rotavirus vaccine development and the efficacy of the currently licensed vaccines from both developed and developing countries were summarized. Conclusions: Rotavirus is a common cause of diarrhea in children in both developed and developing countries. Rotavirus vaccination is a cost-effective measure to prevent rotavirus diarrhea.

  1. HPV vaccines: a controversial issue?

    Directory of Open Access Journals (Sweden)

    A.F. Nicol

    2016-01-01

    Full Text Available Controversy still exists over whether the benefits of the available HPV vaccines outweigh the risks and this has suppressed uptake of the HPV vaccines in comparison to other vaccines. Concerns about HPV vaccine safety have led some physicians, healthcare officials and parents to withhold the recommended vaccination from the target population. The most common reason for not administering the prophylactic HPV vaccines are concerns over adverse effects. The aim of this review is the assessment of peer-reviewed scientific data related to measurable outcomes from the use of HPV vaccines throughout the world with focused attention on the potential adverse effects. We found that the majority of studies continue to suggest a positive risk-benefit from vaccination against HPV, with minimal documented adverse effects, which is consistent with other vaccines. However, much of the published scientific data regarding the safety of HPV vaccines appears to originate from within the financially competitive HPV vaccine market. We advocate a more independent monitoring system for vaccine immunogenicity and adverse effects to address potential conflicts of interest with regular systematic literature reviews by qualified individuals to vigilantly assess and communicate adverse effects associated with HPV vaccination. Finally, our evaluation suggests that an expanded use of HPV vaccine into more diverse populations, particularly those living in low-resource settings, would provide numerous health and social benefits.

  2. HPV vaccines: a controversial issue?

    Science.gov (United States)

    Nicol, A F; Andrade, C V; Russomano, F B; Rodrigues, L L S; Oliveira, N S; Provance, D W

    2016-01-01

    Controversy still exists over whether the benefits of the available HPV vaccines outweigh the risks and this has suppressed uptake of the HPV vaccines in comparison to other vaccines. Concerns about HPV vaccine safety have led some physicians, healthcare officials and parents to withhold the recommended vaccination from the target population. The most common reason for not administering the prophylactic HPV vaccines are concerns over adverse effects. The aim of this review is the assessment of peer-reviewed scientific data related to measurable outcomes from the use of HPV vaccines throughout the world with focused attention on the potential adverse effects. We found that the majority of studies continue to suggest a positive risk-benefit from vaccination against HPV, with minimal documented adverse effects, which is consistent with other vaccines. However, much of the published scientific data regarding the safety of HPV vaccines appears to originate from within the financially competitive HPV vaccine market. We advocate a more independent monitoring system for vaccine immunogenicity and adverse effects to address potential conflicts of interest with regular systematic literature reviews by qualified individuals to vigilantly assess and communicate adverse effects associated with HPV vaccination. Finally, our evaluation suggests that an expanded use of HPV vaccine into more diverse populations, particularly those living in low-resource settings, would provide numerous health and social benefits. PMID:27074168

  3. Prophylactic HPV vaccines

    Directory of Open Access Journals (Sweden)

    Mandić Aljoša

    2009-01-01

    Full Text Available Human papillomavirus (HPV is one of the most common sexually transmitted diseases worldwide. Cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis are HPV associated diseases. Prophylactic HPV vaccines are composed of HPV L1 capsid protein that self-assemble into virus-like particles (VLPs when expressed in recombinant systems. Two types of prophylactic vaccines are designed as a bivalent vaccine to protect against high-risk HPV types 16 and 18 and a quadrivalent vaccine designed to protect against HPV 16 and 18, and low-risk, genital wart-causing HPV 6 and 11. Proof-of-principle trials have suggested that intramuscular injections of VLPs result in strong adaptive immune responses that are capable of neutralizing subsequent natural infections. Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results with nearly 100% efficacy in preventing the development of persistent infections and cervical precancerous lesions in vaccinated individuals.

  4. Immunology of BVDV vaccines.

    Science.gov (United States)

    Ridpath, Julia F

    2013-01-01

    Providing acquired immune protection against infection with bovine viral diarrhea viruses (BVDV) is challenging due to the heterogeneity that exists among BVDV strains and the ability of the virus to infect the fetus and establish persistent infections. Both modified live and killed vaccines have been shown to be efficacious under controlled conditions. Both humoral and cellular immune responses are protective. Following natural infection or vaccination with a modified live vaccine, the majority of the B cell response (as measured by serum antibodies) is directed against the viral proteins E2 and NS2/3, with minor responses against the Erns and E1 proteins. Vaccination with killed vaccines results in serum antibodies directed mainly at the E2 protein. It appears that the major neutralizing epitopes are conformational and are located within the N-terminal half of the E2 protein. While it is thought that the E2 and NS2/3 proteins induce protective T cell responses, these epitopes have not been mapped. Prevention of fetal infections requires T and B cell response levels that approach sterilizing immunity. The heterogeneity that exists among circulating BVDV strains, works against establishing such immunity. Vaccination, while not 100% effective in every individual animal, is effective at the herd level. PMID:22883306

  5. Therapeutic Cancer Vaccines.

    Science.gov (United States)

    Ye, Zhenlong; Li, Zhong; Jin, Huajun; Qian, Qijun

    2016-01-01

    Cancer is one of the major leading death causes of diseases. Prevention and treatment of cancer is an important way to decrease the incidence of tumorigenesis and prolong patients' lives. Subversive achievements on cancer immunotherapy have recently been paid much attention after many failures in basic and clinical researches. Based on deep analysis of genomics and proteomics of tumor antigens, a variety of cancer vaccines targeting tumor antigens have been tested in preclinical and human clinical trials. Many therapeutic cancer vaccines alone or combination with other conventional treatments for cancer obtained spectacular efficacy, indicating the tremendously potential application in clinic. With the illustration of underlying mechanisms of cancer immune regulation, valid, controllable, and persistent cancer vaccines will play important roles in cancer treatment, survival extension and relapse and cancer prevention. This chapter mainly summarizes the recent progresses and developments on cancer vaccine research and clinical application, thus exploring the existing obstacles in cancer vaccine research and promoting the efficacy of cancer vaccine. PMID:27240458

  6. Vaccinations for Adults with Hepatitis C Infection

    Science.gov (United States)

    Vaccinations for Adults with Hepatitis C Infection This table shows which vaccinations you should have to protect your health if ... sure you and your healthcare provider keep your vaccinations up to date. Vaccine Do you need it? ...

  7. Vaccinations for Adults with HIV Infection

    Science.gov (United States)

    Vaccinations for Adults with HIV Infection The table below shows which vaccinations you should have to protect your health if ... sure you and your healthcare provider keep your vaccinations up to date. Vaccine Do you need it? ...

  8. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... MP3 :60-second unbranded MP3 Video PSAs for Web :30-second branded FLV | MP4/QuickTime | WMV :30- ... MPEG-2 Full-Length Videos Full-length branded, web FLV | MP4/QuickTime | WMV Full-length unbranded, web ...

  9. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... pkids.org is for educational purposes only and should not be considered to be medical advice . It ... for your child. All medical advice and information should be considered to be incomplete without a physical ...

  10. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... not meant to replace the advice of the physician who cares for your child. All medical advice ... is not possible without a visit to your doctor. Immunizations stop disease from spreading. Check with your ...

  11. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... advice of the physician who cares for your child. All medical advice and information should be considered to be incomplete without a physical exam, which is not possible without a visit to your doctor. ... us sitemap ...

  12. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... only and should not be considered to be medical advice . It is not meant to replace the ... the physician who cares for your child. All medical advice and information should be considered to be ...

  13. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... organizations wishing to create their own end slates. Right-click any link to download to your computer. ... you could benefit. Copyright 1996 - by PKIDs. All rights reserved. home tools experts donate contact us sitemap ...

  14. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... of formats and lengths for use by your organization free-of-charge. Branded videos contain the "PKIDs.ORG" end slate; unbranded videos are provided for organizations wishing to create their own end slates. Right- ...

  15. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... Transcripts Full-length transcript PDF Important disclaimer : The information on pkids.org is for educational purposes only ... cares for your child. All medical advice and information should be considered to be incomplete without a ...

  16. One Family's Struggle with Chickenpox

    Medline Plus

    Full Text Available ... formats and lengths for use by your organization free-of-charge. Branded videos contain the "PKIDs.ORG" ... be considered to be incomplete without a physical exam, which is not possible without a visit to ...

  17. 9 CFR 113.318 - Pseudorabies Vaccine.

    Science.gov (United States)

    2010-01-01

    ... 9 Animals and Animal Products 1 2010-01-01 2010-01-01 false Pseudorabies Vaccine. 113.318 Section... Virus Vaccines § 113.318 Pseudorabies Vaccine. Pseudorabies Vaccine shall be prepared from virus-bearing... be used for preparing seeds for vaccine production. All serials of vaccine shall be prepared from...

  18. A brief history of vaccines & vaccination in India

    OpenAIRE

    Chandrakant Lahariya

    2014-01-01

    The challenges faced in delivering lifesaving vaccines to the targeted beneficiaries need to be addressed from the existing knowledge and learning from the past. This review documents the history of vaccines and vaccination in India with an objective to derive lessons for policy direction to expand the benefits of vaccination in the country. A brief historical perspective on smallpox disease and preventive efforts since antiquity is followed by an overview of 19 th century efforts to replace ...

  19. Vaccine hesitancy: Definition, scope and determinants.

    Science.gov (United States)

    MacDonald, Noni E

    2015-08-14

    The SAGE Working Group on Vaccine Hesitancy concluded that vaccine hesitancy refers to delay in acceptance or refusal of vaccination despite availability of vaccination services. Vaccine hesitancy is complex and context specific, varying across time, place and vaccines. It is influenced by factors such as complacency, convenience and confidence. The Working Group retained the term 'vaccine' rather than 'vaccination' hesitancy, although the latter more correctly implies the broader range of immunization concerns, as vaccine hesitancy is the more commonly used term. While high levels of hesitancy lead to low vaccine demand, low levels of hesitancy do not necessarily mean high vaccine demand. The Vaccine Hesitancy Determinants Matrix displays the factors influencing the behavioral decision to accept, delay or reject some or all vaccines under three categories: contextual, individual and group, and vaccine/vaccination-specific influences. PMID:25896383

  20. 75 FR 48712 - Proposed Vaccine Information Materials for Influenza Vaccine

    Science.gov (United States)

    2010-08-11

    ... autism in children. In 2004 the Institute of Medicine reviewed many studies looking into this theory and... the vaccine. 5. What are the risks from inactivated influenza vaccine? A vaccine, like any medicine... palsy) that can lead to breathing or swallowing problems. Anyone with a weakened immune system....

  1. 42 CFR 410.57 - Pneumococcal vaccine and flu vaccine.

    Science.gov (United States)

    2010-10-01

    ... 42 Public Health 2 2010-10-01 2010-10-01 false Pneumococcal vaccine and flu vaccine. 410.57 Section 410.57 Public Health CENTERS FOR MEDICARE & MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES MEDICARE PROGRAM SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS Medical and Other Health Services § 410.57 Pneumococcal vaccine and flu...

  2. 广州市番禺区2008-2010年学校水痘暴发疫情分析%Analysis on chickenpox outbreak in schools of PanYu distract during 2008 to 2010

    Institute of Scientific and Technical Information of China (English)

    黎燕君; 郭甜妹; 王凤梅

    2012-01-01

    目的 了解广州市番禺区2008 - 2010年学校水痘疫情的流行情况,为制订学校水痘疫情防制措施提供科学依据.方法 对2008 - 2010年广州市番禺区学校水痘疫情进行描述性流行病学分析.结果 番禺区2008- 2010年中小学校和幼托园共报告水痘暴发疫情11起,累计发病237例,无死亡病例,累计罹患率3.70%.小学及幼儿园水痘暴发疫情10起,占总数的90.91%;暴发疫情主要集中在3~5月、10 ~ 12月.暴发疫情时间持续最长47d,最短4d,平均6d(中位数).大部分病例无水痘免疫史.结论 2008 -2010年番禺区报告的中小学校和幼托园水痘暴发疫情有逐年减少趋势,水痘暴发疫情防控较理想,但小学幼儿园仍是水痘暴发疫情控制的重点人群聚集场所,需采取针对性的控制措施.%Objective To understand the epidemic status of chickenpox outbreak in schools of Panyu during 2008 to 2010, and provide scientific evidences for marking preventive and control measures. Method Descriptive epidemiology method was performed on analyzing the epidemic of chickenpox outbreak in schools of Panyu during 2008 to 2010. Results 11 incidents and 237 cases were reported in middle schools and primary schools and infant' s schools during 2008 to 2010, no death cases, the accumulative total attack rate was 3. 70%. 10 of 11 incidents happened in primary schools and infant' s schools, it was about 90. 57 %. Most outbreak incidents happened in Mar to May and Oct to Dec. The epidemic time lasted for 47 days at the longest and 4 days at the shortest, the average was 6 days. Most of patients were without immunization history. Conclusions The chickenpox epidemic of schools which reported in Panyu during 2008 to 2010 showed downward trend year by year, and the epidemic situation was controlled, but the primary schools and infant' s schools were still the key people to control the disease, at the same time, we need to take the pertinent control measures.

  3. Answers about HIV Vaccine Research

    Science.gov (United States)

    ... trial participation by people of all races/ethnicities, genders and socioeconomic backgrounds. • Support vaccine volunteers and/or ... preventive HIV vaccines. These include leading universities, biotechnology companies, pharmaceutical firms and government agencies such as NIAID. • ...

  4. Update on Veterinary Tuberculosis Vaccines

    Science.gov (United States)

    Educational Objective: At the conclusion of this presentation, the participant will know the current status of veterinary tuberculosis vaccine research and development, and understand the challenges which remain for the future introduction of tuberculosis vaccines intended for wildlife and livestock...

  5. Liver Disease and Adult Vaccination

    Science.gov (United States)

    ... and click "GO" or visit Healthmap Vaccine Finder . Liver Disease and Adult Vaccination Recommend on Facebook Tweet ... critical for people with health conditions such as liver disease. If you have chronic liver disease, talk ...

  6. The Flu Vaccine and Pregnancy

    Science.gov (United States)

    ... Education & Events Advocacy For Patients About ACOG The Flu Vaccine and Pregnancy Home For Patients Search FAQs ... Pamphlets - Spanish FAQ189, October 2015 PDF Format The Flu Vaccine and Pregnancy Pregnancy What is influenza (the ...

  7. Measles Vaccination: Who Needs It?

    Science.gov (United States)

    ... Resources News Newsletters Events Measles Vaccination: Who Needs It? Recommend on Facebook Tweet Share Compartir Vaccine Measles ... it is eliminated from the body. Who Needs It? Children Children should get 2 doses of MMR ...

  8. Vaccination against seasonal influenza

    CERN Multimedia

    GS Department

    2010-01-01

    This year, as usual, the Medical Service is helping to promote vaccination against seasonal influenza. Vaccination against seasonal flu is especially recommended for anyone who suffers from chronic pulmonary, cardio-vascular or kidney disease or diabetes, is recovering from a serious illness or major surgery, or is over 65 years of age. The flu virus is transmitted through the air and through contact with contaminated surfaces, so frequent hand-washing with soap and/or an antiseptic hand wash is of great importance. As soon as the first symptoms appear (fever above 38°, shivering, coughing, muscle and/or joint pains, generalised weakness), you are strongly recommended to stay at home to avoid spreading the virus. Anyone working on the CERN site who wishes to be vaccinated against seasonal flu should go to the Infirmary (Building 57, ground floor), with their dose of vaccine. The Medical Service will issue a prescription on the day of the vaccination for the purposes of reimbursement through UNIQA...

  9. Technical Transformation of Biodefense Vaccines

    OpenAIRE

    Lu, Shan; Wang, Shixia

    2009-01-01

    Biodefense vaccines are developed against a diverse group of pathogens. Vaccines were developed for some of these pathogens a long time ago but they are facing new challenges to move beyond the old manufacturing technologies. New vaccines to be developed against other pathogens have to determine whether to follow traditional vaccination strategies or to seek new approaches. Advances in basic immunology and recombinant DNA technology have fundamentally transformed the process of formulating a ...

  10. Current scenario of Malaria Vaccine

    OpenAIRE

    Malik, SS; Gupta, MC; Braich, JS

    2012-01-01

    Malaria, one of the deadliest infectious diseases, affects millions of people worldwide including India. As an addition to chemoprophylaxis and other antimalarial interventions malaria vaccine is under extensive research since decades. The vaccine development is more difficult to predict than drug development and presents a unique challenge as there has never before been a vaccine effective against a parasite. Effective malaria vaccine could help eliminate and eradicate malaria. There are cur...

  11. Current scenario of malaria vaccine

    OpenAIRE

    Jarnail Singh Braich; Surinder Singh Malik

    2012-01-01

    Malaria is one of the deadliest infectious diseases that affects millions of people worldwide including India. As an addition to chemoprophylaxis and other antimalarial interventions malaria vaccine is under extensive research since decades. The vaccine development is more difficult to predict than drug development and presents a unique challenge as already there has been no vaccine effective against a parasite. Effective malaria vaccine could help eliminate and eradicate malaria; there are c...

  12. Rotaviruses: from pathogenesis to vaccination

    OpenAIRE

    Greenberg, Harry B.; Estes, Mary K.

    2009-01-01

    Rotaviruses cause life-threatening gastroenteritis in children worldwide; the enormous disease burden has focused efforts to develop vaccines and led to the discovery of novel mechanisms of gastrointestinal virus pathogenesis and host responses to infection. Two live-attenuated vaccines for gastroenteritis (Rotateq and Rotarix) have been licensed in many countries. This review summarizes the latest data on these vaccines, their effectiveness and challenges to global vaccination. Recent insigh...

  13. A brief history of vaccines & vaccination in India

    Directory of Open Access Journals (Sweden)

    Chandrakant Lahariya

    2014-01-01

    Full Text Available The challenges faced in delivering lifesaving vaccines to the targeted beneficiaries need to be addressed from the existing knowledge and learning from the past. This review documents the history of vaccines and vaccination in India with an objective to derive lessons for policy direction to expand the benefits of vaccination in the country. A brief historical perspective on smallpox disease and preventive efforts since antiquity is followed by an overview of 19 th century efforts to replace variolation by vaccination, setting up of a few vaccine institutes, cholera vaccine trial and the discovery of plague vaccine. The early twentieth century witnessed the challenges in expansion of smallpox vaccination, typhoid vaccine trial in Indian army personnel, and setting up of vaccine institutes in almost each of the then Indian States. In the post-independence period, the BCG vaccine laboratory and other national institutes were established; a number of private vaccine manufacturers came up, besides the continuation of smallpox eradication effort till the country became smallpox free in 1977. The Expanded Programme of Immunization (EPI (1978 and then Universal Immunization Programme (UIP (1985 were launched in India. The intervening events since UIP till India being declared non-endemic for poliomyelitis in 2012 have been described. Though the preventive efforts from diseases were practiced in India, the reluctance, opposition and a slow acceptance of vaccination have been the characteristic of vaccination history in the country. The operational challenges keep the coverage inequitable in the country. The lessons from the past events have been analysed and interpreted to guide immunization efforts.

  14. 阿昔洛韦与更昔洛韦治疗成人水痘的疗效比较%Comparison of Therapeutic Efficacy of Acyclovir and Ganciciovir in the Treatment of Adult Chickenpox

    Institute of Scientific and Technical Information of China (English)

    陈孝虹; 林敏

    2011-01-01

    OBJECTIVE: To compare the therapeutic efficacy of acyclovir vs. Ganciclovir in the treatment of adult chickenpox. METHODS: 140 patients with chickenpox in our hospital were randomly divided into acyclovir group and ganciclovir group, according to odd and even days of hospitalization. They were given acyclovir and ganciclovir 10 mg·kg-1, bid, iv.gtt. The average defervescence time, the time for herpes forming a scab, total effective rate and adverse drug reaction were observed in 2 groups. RESULTS: The defervescence time of ganciclovir group was significantly shorter in acyclovir group, the difference was statistically significant (P 0.05); Total effective rte of ganciclovir group was significantly higher than that of acyclovir group, the difference was statistically significant (p<0.05). No adverse drug reaction was found in 2 groups during the treatment. CONCLUSIONS: The therapeutic efficacy of ganciclovir in the treatment of adult varicella is significantly better than acyclovir, and the defervescence time of ganciclovir is shorter than acyclovir.%目的:比较阿昔洛韦与更昔洛韦治疗成人水痘的疗效.方法:将我院140例水痘患者,按住院单双日随机均分为阿昔洛韦组与更昔洛韦组,分别给予阿昔洛韦与更昔洛韦10 mg·kg-1,bid,静脉滴注.观察并记录2组患者的退热时间、皮疹结痂时间、总有效率和不良反应.结果:更昔洛韦组患者的退热时间明显短于阿昔洛韦组,2组比较差异有统计学意义(P<0.05);2组的皮疹结痂时间比较,差异无统计学意义(P>0.05);更昔洛韦组的总有效率明显高于阿昔洛韦组(P<0.05).2组治疗过程中,均未见不良反应发生.结论:更昔洛韦治疗成人水痘的疗效显著优于阿昔洛韦,且退热时间短于阿昔洛韦.

  15. Vaccination: An Act of Love

    Science.gov (United States)

    ... SPOTS! AH’M SICK, MA! AH CAIN’T GIT NO VACCINE T’DAY! 13 OH, SON! HOW’ ... D TELL HIS FOLKS HE WAS GOIN’ T’GIT VACCINATED AN’ HE’D GO SWIMMIN’! "” ” HE DIDN’ ... T’THE HEALTH CLINIC! HEH! HEH! AH GOTTA GIT THET VACCINE! WAIT! WE’LL GO WITH YOU! ...

  16. ERM immersion vaccination and adjuvants

    DEFF Research Database (Denmark)

    Skov, J.; Chettri, J. K.; Jaafar, R. M.;

    2015-01-01

    Two candidate adjuvants were tested with a commercial ERM dip vaccine (AquaVac™ Relera, MSD Animal Health) for rainbow trout in an experimental design compatible with common vaccination practices at farm level, i.e. immersion of fish in vaccine (±adjuvant) for 30 s. The adjuvants were the...

  17. Current scenario of malaria vaccine

    Directory of Open Access Journals (Sweden)

    Jarnail Singh Braich

    2012-04-01

    Full Text Available Malaria is one of the deadliest infectious diseases that affects millions of people worldwide including India. As an addition to chemoprophylaxis and other antimalarial interventions malaria vaccine is under extensive research since decades. The vaccine development is more difficult to predict than drug development and presents a unique challenge as already there has been no vaccine effective against a parasite. Effective malaria vaccine could help eliminate and eradicate malaria; there are currently 63 vaccine candidates, 41 in preclinical and clinical stages of development. Vaccines are being designed to target pre-erythrocytic stages, erythrocytic stage or the sexual stages of Plasmodium taken up by a feeding mosquito, or the multiple stages. Two vaccines in preclinical and clinical development target P. falciparum; and the most advanced candidate is the pre-erythrocytic vaccine RTS,S which is in phase-III clinical trials. It is likely that world's first malaria vaccine will be available by 2015 at the country level. More efficacious second generation malaria vaccines are on the way to development. Safety, efficacy, cost and provision of the vaccine to all communities are major concerns in malaria vaccine issue. [Int J Basic Clin Pharmacol 2012; 1(2.000: 60-66

  18. Fundamentals of vaccine immunology

    Directory of Open Access Journals (Sweden)

    Angela S Clem

    2011-01-01

    Full Text Available From a literature review of the current literature, this article provides an introduction to vaccine immunology including a primer on the components of the immune system, passive vs. active immunization, the mechanism(s by which immunizations stimulate(s immunity, and the types of vaccines available. Both the innate and adaptive immune subsystems are necessary to provide an effective immune response to an immunization. Further, effective immunizations must induce long-term stimulation of both the humoral and cell-mediated arms of the adaptive system by the production of effector cells and memory cells. At least seven different types of vaccines are currently in use or in development that produce this effective immunity and have contributed greatly to the prevention of infectious disease around the world.

  19. Vaccination against seasonal influenza

    CERN Multimedia

    DG Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not pr...

  20. Controversies in vaccine mandates.

    Science.gov (United States)

    Lantos, John D; Jackson, Mary Anne; Opel, Douglas J; Marcuse, Edgar K; Myers, Angela L; Connelly, Beverly L

    2010-03-01

    Policies that mandate immunization have always been controversial. The controversies take different forms in different contexts. For routine childhood immunizations, many parents have fears about both short- and long-term side effects. Parental worries change as the rate of vaccination in the community changes. When most children are vaccinated, parents worry more about side effects than they do about disease. Because of these worries, immunization rates go down. As immunization rates go down, disease rates go up, and parents worry less about side effects of vaccination and more about the complications of the diseases. Immunization rates then go up. For teenagers, controversies arise about the criteria that should guide policies that mandate, rather than merely recommend and encourage, certain immunizations. In particular, policy makers have questioned whether immunizations for human papillomavirus, or other diseases that are not contagious, should be required. For healthcare workers, debates have focused on the strength of institutional mandates. For years, experts have recommended that all healthcare workers be immunized against influenza. Immunizations for other infections including pertussis, measles, mumps, and hepatitis are encouraged but few hospitals have mandated such immunizations-instead, they rely on incentives and education. Pandemics present a different set of problems as people demand vaccines that are in short supply. These issues erupt into controversy on a regular basis. Physicians and policy makers must respond both in their individual practices and as advisory experts to national and state agencies. The articles in this volume will discuss the evolution of national immunization programs in these various settings. We will critically examine the role of vaccine mandates. We will discuss ways that practitioners and public health officials should deal with vaccine refusal. We will contrast responses of the population as a whole, within the

  1. The relationship between influenza vaccination habits and location of vaccination.

    Directory of Open Access Journals (Sweden)

    Lori Uscher-Pines

    Full Text Available Although use of non-medical settings for vaccination such as retail pharmacies has grown in recent years, little is known about how various settings are used by individuals with different vaccination habits. We aimed to assess the relationship between repeated, annual influenza vaccination and location of vaccination.We conducted a cross-sectional survey of 4,040 adults in 2010.We fielded a nationally representative survey using an online research panel operated by Knowledge Networks. The completion rate among sampled panelists was 73%.39% of adults reported that they have never received a seasonal influenza vaccination. Compared to those who were usually or always vaccinated from year to year, those who sometimes or rarely received influenza vaccinations were significantly more likely to be vaccinated in a medical setting in 2009-2010.RESULTS indicate that while medical settings are the dominant location for vaccination overall, they play an especially critical role in serving adults who do not regularly receive vaccinations. By exploring vaccination habits, we can more appropriately choose among interventions designed to encourage the initiation vs. maintenance of desired behaviors.

  2. Smallpox vaccines for biodefense.

    Science.gov (United States)

    Kennedy, Richard B; Ovsyannikova, Inna; Poland, Gregory A

    2009-11-01

    Few diseases can match the enormous impact that smallpox has had on mankind. Its influence can be seen in the earliest recorded histories of ancient civilizations in Egypt and Mesopotamia. With fatality rates up to 30%, smallpox left its survivors with extensive scarring and other serious sequelae. It is estimated that smallpox killed 500 million people in the 19th and 20th centuries. Given the ongoing concerns regarding the use of variola as a biological weapon, this review will focus on the licensed vaccines as well as current research into next-generation vaccines to protect against smallpox and other poxviruses. PMID:19837292

  3. Vaccines for Canine Leishmaniasis

    Directory of Open Access Journals (Sweden)

    Faeze Foroughi-Parvar

    2014-01-01

    Full Text Available Leishmania infantum is the obligatory intracellular parasite of mammalian macrophages and causes zoonotic visceral leishmaniasis (ZVL. The presence of infected dogs as the main reservoir host of ZVL is regarded as the most important potential risk for human infection. Thus the prevention of canine visceral leishmaniasis (CVL is essential to stop the current increase of the Mediterranean visceral leishmaniasis. Recently considerable advances in achieving protective immunization of dogs and several important attempts for achieving an effective vaccine against CVL lead to attracting the scientists trust in its important role for eradication of ZVL. This paper highlights the recent advances in vaccination against canine visceral leishmaniasis from 2007 until now.

  4. Japanese encephalitis vaccines: current vaccines and future prospects.

    Science.gov (United States)

    Monath, T P

    2002-01-01

    Vaccination against JE ideally should be practiced in all areas of Asia where the virus is responsible for human disease. The WHO has placed a high priority on the development of a new vaccine for prevention of JE. Some countries in Asia (Japan, South Korea, North Korea, Taiwan, Vietnam, Thailand, and the PRC) manufacture JE vaccines and practice childhood immunization, while other countries suffering endemic or epidemic disease (India, Nepal, Laos, Cambodia, Bangladesh, Myanmar, Malaysia, Indonesia and the Philippines) have no JE vaccine manufacturing or policy for use. With the exception of the PRC, all countries practicing JE vaccination use formalin inactivated mouse brain vaccines, which are relatively expensive and are associated with rare but clinically significant allergic and neurological adverse events. New inactivated JE vaccines manufactured in Vero cells are in advanced preclinical or early clinical development in Japan, South Korea, Taiwan, and the PRC. An empirically derived, live attenuated vaccine (SA14-14-2) is widely used in the PRC. Trials in the PRC have shown SA14-14-2 to be safe and effective when administered in a two-dose regimen, but regulatory concerns over manufacturing and control have restricted international distribution. The genetic basis of attenuation of SA14-14-2 has been partially defined. A new live attenuated vaccine (ChimeriVax-JE) that uses a reliable flavivirus vaccine--yellow fever 17D--as a live vector for the envelope genes of SA14-14-2 virus is in early clinical trials and appears to be well tolerated and immunogenic after a single dose. Vaccinia and avipox vectored vaccines have also been tested clinically, but are no longer being pursued due to restricted effectiveness mediated by anti-vector immunity. Other approaches to JE vaccines--including naked DNA, oral vaccination, and recombinant subunit vaccines--have been reviewed. PMID:12082985

  5. Neurological complications of rabies vaccines.

    Science.gov (United States)

    Tullu, Millind S; Rodrigues, Sean; Muranjan, Mamta N; Bavdekar, Sandeep B; Kamat, Jaishree R; Hira, Priya R

    2003-02-01

    The rabies vaccines containing neural elements are used in some countries including India. We report three cases that presented with various neurological complications following the use of these vaccines. The presenting manifestations included those of encephalitis, radiculitis and acute inflammatory demyelinating polyradiculoneuropathy. These neurological complications are highlighted so that scientific evidence compels the community to discontinue the use of the neural tissue rabies vaccines. Newer generation cell culture rabies vaccines should be preferred over the neural tissue rabies vaccines for post-exposure prophylaxis. PMID:12626831

  6. Experience with registered mucosal vaccines.

    Science.gov (United States)

    Dietrich, Guido; Griot-Wenk, Monika; Metcalfe, Ian C; Lang, Alois B; Viret, Jean-François

    2003-01-30

    Most pathogens gain access to their host through mucosal surfaces. It is therefore desirable to develop vaccination strategies that lead to mucosal immune responses. Ideally, a vaccine should be administered mucosally in order to elicit mucosal protection. Several attenuated live viral and bacterial pathogens are registered as oral vaccines for human use, including the oral polio vaccine (Sabin) as well as attenuated strains of Salmonella typhi and Vibrio cholerae. These attenuated bacterial live vaccines-S. typhi Ty21a as well as V. cholerae CVD 103-HgR-are employed as vaccines against typhoid and cholera, respectively. In this manuscript, we review the immune responses that are induced by these vaccines, with a focus on mucosal immunity. PMID:12531339

  7. Vaccination scars in HIV infected patients – does vaccinia vaccination confer protection against HIV?

    DEFF Research Database (Denmark)

    Jespersen, Sanne; Hønge, Bo Langhoff; Medina, Candida;

    Vaccination scars in HIV infected patients – does vaccinia vaccination confer protection against HIV?......Vaccination scars in HIV infected patients – does vaccinia vaccination confer protection against HIV?...

  8. Alphavirus-Based Vaccines

    Directory of Open Access Journals (Sweden)

    Kenneth Lundstrom

    2014-06-01

    Full Text Available Alphavirus vectors have demonstrated high levels of transient heterologous gene expression both in vitro and in vivo and, therefore, possess attractive features for vaccine development. The most commonly used delivery vectors are based on three single-stranded encapsulated alphaviruses, namely Semliki Forest virus, Sindbis virus and Venezuelan equine encephalitis virus. Alphavirus vectors have been applied as replication-deficient recombinant viral particles and, more recently, as replication-proficient particles. Moreover, in vitro transcribed RNA, as well as layered DNA vectors have been applied for immunization. A large number of highly immunogenic viral structural proteins expressed from alphavirus vectors have elicited strong neutralizing antibody responses in multispecies animal models. Furthermore, immunization studies have demonstrated robust protection against challenges with lethal doses of virus in rodents and primates. Similarly, vaccination with alphavirus vectors expressing tumor antigens resulted in prophylactic protection against challenges with tumor-inducing cancerous cells. As certain alphaviruses, such as Chikungunya virus, have been associated with epidemics in animals and humans, attention has also been paid to the development of vaccines against alphaviruses themselves. Recent progress in alphavirus vector development and vaccine technology has allowed conducting clinical trials in humans.

  9. Immunology of BVDV vaccines

    Science.gov (United States)

    The use of vaccination to control bovine viral diarrhea virus (BVDV) infections presents exceptional challenges due to the nature of the virus, the unique interaction of the virus with the immune system, and its ability to establish persistent infections. The lack of proof reading function during th...

  10. Vaccines Help Protect Us

    Centers for Disease Control (CDC) Podcasts

    2013-04-23

    In this podcast for kids, the Kidtastics talk about the importance of vaccines and how they work.  Created: 4/23/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/23/2013.

  11. Developments in rabies vaccines.

    Science.gov (United States)

    Hicks, D J; Fooks, A R; Johnson, N

    2012-09-01

    The development of vaccines that prevent rabies has a long and distinguished history, with the earliest preceding modern understanding of viruses and the mechanisms of immune protection against disease. The correct application of inactivated tissue culture-derived vaccines is highly effective at preventing the development of rabies, and very few failures are recorded. Furthermore, oral and parenteral vaccination is possible for wildlife, companion animals and livestock, again using inactivated tissue culture-derived virus. However, rabies remains endemic in many regions of the world and causes thousands of human deaths annually. There also remain no means of prophylaxis for rabies once the virus enters the central nervous system (CNS). One reason for this is the poor immune response within the CNS to infection with rabies virus (RABV). New approaches to vaccination using modified rabies viruses that express components of the innate immune system are being applied to this problem. Preliminary reports suggest that direct inoculation of such viruses could trigger an effective anti-viral response and prevent a fatal outcome from RABV infection. PMID:22861358

  12. Genetically modified tumour vaccines

    Czech Academy of Sciences Publication Activity Database

    Bubeník, Jan

    2005-01-01

    Roč. 3, Suppl. 1 (2005), S7. ISSN 1214-021X. [Cells VI - Biological Days /18./. 24.10.2005-26.10.2005, České Budějovice] Institutional research plan: CEZ:AV0Z50520514 Keywords : tumour vaccines * HPV16 Subject RIV: EC - Immunology

  13. Dissecting Cancer Vaccines

    Institute of Scientific and Technical Information of China (English)

    Jennifer Couzin; 丁东

    2004-01-01

    @@ If there's one thing cancer vaccine developers would like to know, it's why only a handful of patients respond strongly to their inventions. Now at an immunology② meeting here, a team of scientists reported that a set of patients with metastatic melanoma③ may be revealing an answer to that mysterious question.

  14. Polio vaccine and retroviruses.

    OpenAIRE

    Beale, J; Horaud, F.

    2001-01-01

    In this paper we consider the main steps in the process of manufacture of oral polio vaccine and assess the probable clearance factor for HIV retrovirus at each step. We conclude that the processes employed would have eliminated retrovirus contamination for all practical purposes.

  15. Vaccine Adverse Events

    Science.gov (United States)

    ... about data collection Información en español acerca del Sistema para Reportar Reacciones Adversas a las Vacunas (VAERS) ( ... by Product Area Product Areas back Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & ...

  16. Stabilization of live Mycoplasma gallisepticum vaccines during vaccination with second generation Spray-Vac® vaccine stabilizer

    Science.gov (United States)

    Dilutions and application of live Mycoplasma gallisepticum vaccines without the use of vaccine stabilizing compounds may lead to significant loss of vaccine viability and loss of vaccine efficacy. Vaccine viability may decreases due to osmotic lysis of the mycoplasma as well as the presence of chlo...

  17. Analysis of occurrence of adverse reactions and causes after injection of chickenpox vaccine%水痘疫苗注射后发病情况及原因探讨

    Institute of Scientific and Technical Information of China (English)

    赵秀云

    2007-01-01

    目的 调查水痘疫苗注射后的发病情况,明确发病者的流行病学意义,为制定预防控制措施提高科学依据.方法 采用酶联免疫吸附试验(ELISA),对2~20岁人群接种水痘疫苗后出现发热、出疹等症状者进行血清学检查,IGM抗体阳性者,予以确诊.结果 共接种8 827人,上报疑似病例165例,确诊165例,免疫后发病率为1.87%.结论 水痘疫苗免疫后发病较高,应对其原因加以研究,确保疫苗免疫安全有效.

  18. An Analysis of the Clinical Features of Chickenpox after Children Inoculated Live Attenuated Varicella Vaccine%接种水痘减毒活疫苗后发生水痘的临床特征分析

    Institute of Scientific and Technical Information of China (English)

    范篆玲

    2014-01-01

    目的 探讨接种水痘减毒活疫苗对儿童的保护作用及意义.方法 将同一流行期内的33例儿童水痘分为已接种水痘疫苗组和未接种水痘疫苗组,从临床特征、愈后情况进行对比分析.结果 接种水痘疫苗组患儿较未接种水痘疫苗组临床症状轻,患儿体温基本均正常,水疱数目明显少,且合并上呼吸道感染症状明显减少,出疹及脱痂时间、病程和疗程明显缩短,差异有统计学意义(P<0.05).结论 水痘减毒活疫苗具有免疫保护作用,儿童应及时接种,同时建议完善水痘免疫策略以提高其免疫持久性.

  19. Swine flu vaccination for patients with cancers

    OpenAIRE

    Viroj Wiwanitkit

    2011-01-01

    In oncology, vaccination is accepted as an important preventive measure. As a tertiary prevention protocol, several vaccines are recommended for the oncology patients. The newest vaccine in medicine is swine flu vaccine which is developed for prevention of novel H1N1 influenza virus infection. In this paper, the author will briefly discuss on swine flu vaccination for oncology patients.

  20. Vaccine against human Papilloma Virus

    Directory of Open Access Journals (Sweden)

    Julio Cesar Reina

    2014-11-01

    Full Text Available At present two prophylactic human papilloma virus (HPV vaccines are commercially available. The Tetravalent vaccine against infection with four VPH types (6, 11, 16, and 18 distributed in the national program in Colombia and the Bivalent vaccine against the VPH types 16 and 18, respectively.  The efficacy and safety of both vaccines has periodically been assessed and they have been declared efficacious and safe by the health authorities of several countries and the Global Advisory Committee on Vaccine Safety ( GACVS of the World’s Health Organization (WHO.In its report of March 2014 the GACVS analyzed the evidence of the relationship between the  Human Papillomavirus Vaccine with  >175 million of doses distributed worldwide and autoimmune diseases, particularly Multiple Sclerosis, Aluminum as adjuvant, Vasculitis caused by vaccine DNA fragments and the Complex Regional Pain Syndrome described in Japan.   The Committee ratified the strict vaccine safety control and based on a thorough examination of existing evidence, reaffirmed that the risk-benefit profile remains favorable. The case of the children of Carmen de Bolivar in Colombia has been described by several authors in other countries as "Massive Psychogenic Event", which has absolute no relationship with the vaccine but its high media dissemination resulted into disastrous consequences for the national vaccination program

  1. Experimental rabies vaccines for humans.

    Science.gov (United States)

    McGettigan, James P

    2010-10-01

    Rabies remains a global public health threat that kills more than 55,000 people per year. Rabies disproportionately affects children and, therefore, is ranked the seventh most important infectious disease due to years lost. Prevention of human rabies is accomplished by controlling rabies in domestic and wild animals, including the use of vaccination programs. The usefulness of human rabies vaccines is hampered by high cost, complicated vaccination regimens and lack of compliance, especially in areas of Africa and Asia where human rabies infections are endemic. A single-dose vaccine would greatly benefit efforts to combat this global health threat. However, a single-dose vaccine based on current inactivated vaccines does not appear feasible and other approaches are needed. Technology has advanced since modern human rabies vaccines were developed over 40 years ago. In addition, our understanding of immunological principles that influence the outcome of vaccination has increased. This article describes the current status of inactivated rabies virus vaccines and recent developments arising from the use of reverse genetics technologies designed to develop replication-deficient or single-cycle live rabies virus-based vectors for use as a single-dose rabies vaccine for humans. PMID:20923268

  2. Parasite vaccines--a reality?

    Science.gov (United States)

    Dalton, J P; Mulcahy, G

    2001-07-12

    Over the last decade, the anti-parasitics market has been the fastest growing sector of the overall $18 billion animal health market. While drugs for the treatment of parasites of livestock still dominate this sector and will continue to be developed or re-formulated, because of consumer demands for chemical-free food and of concerns regarding the environment and animal welfare there is a growing interest in the development of safe and effective vaccines. There is also a call for vaccines in the lucrative $3 billion-plus companion animal market. These demands for vaccines will add a greater impetus to an area that has seen tremendous success in the last 15 years. A number of anti-parasite vaccines have been developed, e.g. the recombinant 45w and EG95 oncosphere proteins against Taenia ovis and Echinococcus granulosis, respectively, and the Bm86 vaccine against Boophilus microplus. In addition, the cathepsin L vaccines against the liver fluke, Fasciola hepatica, and the H11 vaccine against Haemonchus contortus are progressing well. There are also many additional vaccine candidates for H. contortus and for other nematodes such as Ostertagia and Trichostrongylus spp. that may ultimately lead to broad-spectrum gastrointestinal worm vaccines. Live or attenuated-live vaccines are available for the control of avian coccidiosis, toxplasmosis in sheep and anaplasmosis in cattle, although molecular vaccines against protozoans are still proving elusive. The wealth of information in genomics, proteomics and immunology that has been forthcoming together will new methods of vaccine production and delivery should see many new vaccines reach the marketplace in the near future. PMID:11516584

  3. The Safety of Adjuvanted Vaccines Revisited: Vaccine-Induced Narcolepsy.

    Science.gov (United States)

    Ahmed, S Sohail; Montomoli, Emanuele; Pasini, Franco Laghi; Steinman, Lawrence

    2016-01-01

    Despite the very high benefit-to-risk ratio of vaccines, the fear of negative side effects has discouraged many people from getting vaccinated, resulting in the reemergence of previously controlled diseases such as measles, pertussis and diphtheria. This fear has been amplified more recently by multiple epidemiologic studies that confirmed the link of an AS03-adjuvanted pandemic influenza vaccine (Pandemrix, GlaxoSmithKline Biologicals, Germany) used in Europe during the 2009 H1N1 influenza pandemic [A(H1N1) pdm09] with the development of narcolepsy, a chronic sleep disorder, in children and adolescents. However, public misperceptions of what adjuvants are and why they are used in vaccines has created in some individuals a closed "black box" attitude towards all vaccines. The focus of this review article is to revisit this "black box" using the example of narcolepsy associated with the European AS03-adjuvanted pandemic influenza vaccine. PMID:27228647

  4. Distempter Vaccination of Dogs: Factors Which Could Cause Vaccine Failure

    OpenAIRE

    Povey, R. Charles

    1986-01-01

    Distemper vaccination failures are uncommon. A number of factors which could cause such failure are discussed. The blocking effect of maternal antibody can be expected in 50% of pups at six weeks but is not important after 12 weeks. Among intercurrent infections, the immunosuppressive effect of parvovirus has the potential to precipitate vaccine-induced distemper. Corticosteroids at levels up to 10 mg/kg do not interfere with successful distemper vaccination. Anesthesia or surgery has little ...

  5. Undesired consequences of vaccination and faults in vaccination

    OpenAIRE

    Prodanov Jasna; Došen Radoslav; Lalić Milan; Gagrčin Mladen; Orlić Dušan B.

    2002-01-01

    Different diseases in domestic animals require the application of different methods of immunological protection, depending on the type of vaccine manner of application and type of adjuvant. The objective of the work was to consider general principles and the basic requirements for efficient vaccination. It points out existing faults in practice which lead to the occurrence of mistakes made during vaccination and the appearance of resulting undesired consequences. There are many reasons why va...

  6. Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines.

    Science.gov (United States)

    Scriba, Thomas J; Kaufmann, Stefan H E; Henri Lambert, Paul; Sanicas, Melvin; Martin, Carlos; Neyrolles, Olivier

    2016-09-01

    Live attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress. PMID:27247343

  7. Tetravalent DNA vaccine product as a vaccine candidate against dengue.

    Science.gov (United States)

    Porter, Kevin R; Teneza-Mora, Nimfa; Raviprakash, Kanakatte

    2014-01-01

    Dengue is the most important arbovirus worldwide and is the virus that causes dengue fever and the more severe dengue hemorrhagic fever. There are four serotypes of dengue with each possessing the ability to cause disease. Developing a preventive vaccine is the most efficient and effective way to prevent these diseases, and because immunity to one serotype does not protect against the other serotypes, a vaccine must provide tetravalent protection. We used DNA immunization as a platform to develop a tetravalent vaccine. In this chapter, we describe the laboratory, regulatory, and clinical methodology for evaluating a candidate tetravalent vaccine in a Phase 1 clinical trial. PMID:24715294

  8. Targeting vaccines to dendritic cells

    DEFF Research Database (Denmark)

    Foged, Camilla; Sundblad, Anne; Hovgaard, Lars

    2002-01-01

    be far superior to that of B-cells and macrophages. DC are localized at strategic places in the body at sites used by pathogens to enter the organism, and are thereby in an optimal position to capture antigens. In general, vaccination strategies try to mimic the invasiveness of the pathogens. DC are...... considered to play a central role for the provocation of primary immune responses by vaccination. A rational way of improving the potency and safety of new and already existing vaccines could therefore be to direct vaccines specifically to DC. There is a need for developing multifunctional vaccine drug...... delivery systems (DDS) with adjuvant effect that target DC directly and induce optimal immune responses. This paper will review the current knowledge of DC physiology as well as the progress in the field of novel vaccination strategies that directly or indirectly aim at targeting DC....

  9. Preventing Cervical Cancer with HPV Vaccines

    Science.gov (United States)

    Cervical cancer can be prevented with HPV vaccines. NCI-supported researchers helped establish HPV as a cause of cervical cancer. They also helped create the first HPV vaccines, were involved in the vaccine trials, and contribute to ongoing studies.

  10. Meningococcal Vaccines: What You Need to Know

    Science.gov (United States)

    ... Español Text Size Email Print Share Meningococcal ACWY Vaccines: What You Need to Know (VIS) Page Content ... to help protect against serogroup B . Meningococcal ACWY Vaccines There are two kinds of meningococcal vaccines licensed ...

  11. Vaccines: What You Need to Know

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Diseases and Vaccinations Vaccines: What You Need to Know Past Issues / ... b), and Varicella (protects against chicken pox). The vaccination charts that follow offer a simple overview of ...

  12. Validation of an aseptic process for live attenuated varicella vaccine%水痘减毒活疫苗的无菌生产工艺验证

    Institute of Scientific and Technical Information of China (English)

    马相虎; 陈哲文; 晏子厚

    2015-01-01

    Objective To validate the effectiveness of the aseptic production process of live attenuated varicella vaccine (chickenpox vaccine) by media fill test.Methods The aseptic filling of the vaccine was simulated using Trypticase Soy Broth (TSB,3.2%),with filling volume of 0.6 ml per vial.The vials were incubated after filling,and the sterility of current production process was evaluated by the contamination situation of the media inside the vials.Results The filling batch numbers of 3 media fill tests were 10 160,10 181 and 10 175 vials,respectively.After successive incubation at 20-25 ℃ and 30-35 ℃,contamination rates of TSB all were 0.≥0.5μm airborne particulates were less than 70 per cubic meter at each sampling point in the production area.No ≥ 5.0 μm airborne particulate was detected.There was no colony of settle plate and surface microbial.The growth promotion test and microbial challenging test of TSB were both qualified.Conclusion The aseptic production process of chickenpox vaccine is conformed with good manufacture practice,which can assure its sterility.%目的 通过培养基模拟灌装试验,验证水痘减毒活疫苗(水痘疫苗)无菌生产工艺的有效性.方法 模拟水痘疫苗的无菌灌装工艺,对胰酪胨大豆肉汤培养基(TSB)按0.6 ml/瓶进行模拟灌装,对灌装后小瓶进行培养,根据小瓶内培养基的污染情况,评估现行水痘疫苗无菌生产工艺的有效性.结果 3次TSB模拟灌装试验的灌装批量分别为10 160、10 181和10 175瓶,经20~25℃和30~35℃先后培养后,均未出现TSB污染.在水痘疫苗生产区域的各监测点,≥0.5μm悬浮粒子均≤70粒/m3,≥5.0 μm悬浮粒子均为0;沉降菌和表面微生物的菌落计数均为0;培养基灵敏度检查和微生物挑战试验均合格.结论 水痘疫苗的无菌生产工艺符合药品生产质量管理规范的要求,可确保产品的无菌性.

  13. Statistical physics of vaccination

    CERN Document Server

    Wang, Zhen; Bhattacharyya, Samit; d'Onofrio, Alberto; Manfredi, Piero; Perc, Matjaz; Perra, Nicola; Salathé, Marcel; Zhao, Dawei

    2016-01-01

    Historically, infectious diseases caused considerable damage to human societies, and they continue to do so today. To help reduce their impact, mathematical models of disease transmission have been studied to help understand disease dynamics and inform prevention strategies. Vaccination - one of the most important preventive measures of modern times - is of great interest both theoretically and empirically. And in contrast to traditional approaches, recent research increasingly explores the pivotal implications of individual behavior and heterogeneous contact patterns in populations. Our report reviews the developmental arc of theoretical epidemiology with emphasis on vaccination, as it led from classical models assuming homogeneously mixing (mean-field) populations and ignoring human behavior, to recent models that account for behavioral feedback and/or population spatial/social structure. Many of the methods used originated in statistical physics, such as lattice and network models, and their associated ana...

  14. Reproductive toxicity testing of vaccines

    International Nuclear Information System (INIS)

    Vaccines play a major role in the prevention of human birth defects by protecting the pregnant woman from teratogenic or otherwise harmful infections. Until now, it has not been common practice to perform preclinical developmental toxicity tests for new vaccines. Despite the excellent safety record of vaccines, increased attention is now being given to the feasibility of screening new vaccines for developmental hazards in animals before their use in humans. Contrary to previous assumptions, many vaccines are now given to potentially pregnant women. Any new components of the vaccine formulation (adjuvants, excipients, stabilisers, preservatives, etc...) could also be tested for influences on development, although based on past experience the risks are limited by the very low dosages used. The conferred immunity following vaccination lasts for several years. Therefore, the developing conceptus may theoretically be exposed to the induced antibodies and/or sensitised T-cells, even if the pregnant woman was last vaccinated during childhood (particularly if she encounters the antigen during pregnancy through exposure to infection). However, it should be kept in mind that viral or bacterial infections represent a higher risk for a pregnant woman than the potential adverse effects related to vaccination or the associated immune response. Non-clinical safety studies may be employed as an aid for hazard identification. In these studies interactions of the vaccine with the maternal immune system or with the developmental systems of the offspring are considered. Post-natal examinations are necessary to detect all possible manifestations of developmental toxicity, such as effects on the immune system. Species selection for the preclinical studies is based on immunogenicity to the vaccine and the relative timing and rate of transfer of maternal antibodies to the offspring. A single study design is proposed for the pre- and post-natal developmental assessments of vaccines in

  15. DNA vaccines for aquacultured fish

    DEFF Research Database (Denmark)

    Lorenzen, Niels; LaPatra, S.E.

    2005-01-01

    fully addressed, although inherently the risks should not be any greater than with the commercial fish vaccines that are currently used. Present classification systems lack clarity in distinguishing DNA-vaccinated animals from genetically modified organisms (GMOs), which could raise issues in terms of...... licensing and public acceptance of the technology. The potential benefits of DNA vaccines for farmed fish include improved animal welfare, reduced environmental impacts of aquaculture activities, increased food quality and quantity, and more sustainable production. Testing under commercial production...

  16. Hepatitis B vaccination in prisons.

    OpenAIRE

    Awofeso Niyi

    2002-01-01

    The opportunities and problems for hepatitis B vaccination programmes in prison settings are discussed. In particular, the advantages of modelling are stressed and an active case-finding approach is advocated. Measures for maintaining good case-holding are also discussed, and a 0, 1, 2 months vaccination regimen with 20 microg doses of vaccine is advocated for prison settings. A higher reference level for inferring adequate immunization is also recommended, with booster injections for inmates...

  17. A perspective on malaria vaccines

    OpenAIRE

    Desowitz, R S; Miller, L. H.

    1980-01-01

    The data obtained with adjuvant—antigen vaccines against asexual malaria parasites in different host—parasite systems are reviewed. From these data the problems associated with antimalarial vaccine development and testing are considered. The requirement for an adjuvant to induce immunity and the type of adjuvant required depends primarily on the host. Since the immune response of man to malaria vaccines is unknown, it is impossible to predict which animal infection is most likely to be a fait...

  18. Progress with new malaria vaccines.

    OpenAIRE

    2003-01-01

    Malaria is a parasitic disease of major global health significance that causes an estimated 2.7 million deaths each year. In this review we describe the burden of malaria and discuss the complicated life cycle of Plasmodium falciparum, the parasite responsible for most of the deaths from the disease, before reviewing the evidence that suggests that a malaria vaccine is an attainable goal. Significant advances have recently been made in vaccine science, and we review new vaccine technologies a...

  19. Experimental rabies vaccines for humans

    OpenAIRE

    McGettigan, James P.

    2010-01-01

    Rabies remains a global public health threat that kills more than 55,000 people per year. Rabies disproportionately affects children and, therefore, is ranked the seventh most important infectious disease due to years lost. Prevention of human rabies is accomplished by controlling rabies in domestic and wild animals, including the use of vaccination programs. The usefulness of human rabies vaccines is hampered by high cost, complicated vaccination regimens and lack of compliance, especially i...

  20. Effective Vaccine for Lassa Fever

    OpenAIRE

    Fisher-Hoch, S P; Hutwagner, L.; Brown, B.; McCormick, J. B.

    2000-01-01

    Lassa fever has been estimated to cause 5,000 deaths annually in West Africa. Recently, war in the zone where Lassa fever is hyperendemic has severely impeded control and treatment. Vaccination is the most viable control measure. There is no correlation between antibody levels and outcome in human patients, and inactivated vaccines produce high titers of antibodies to all viral proteins but do not prevent virus replication and death in nonhuman primates. Accordingly, we vaccinated 44 macaques...

  1. Identifying and Addressing Vaccine Hesitancy

    OpenAIRE

    Kestenbaum, Lori A.; Feemster, Kristen A

    2015-01-01

    In the 20th century, the introduction of multiple vaccines significantly reduced childhood morbidity, mortality, and disease outbreaks. Despite, and perhaps because of, their public health impact, an increasing number of parents and patients are choosing to delay or refuse vaccines. These individuals are described as vaccine hesitant. This phenomenon has developed due to the confluence of multiple social, cultural, political and personal factors. As immunization programs continue to expand, u...

  2. Considerations in vaccine patent protection.

    Science.gov (United States)

    Brazell, Lorna

    2010-12-01

    This feature article discusses the basic principles of patentability as related to vaccine research, and outlines recent cases in the US and EU in which vaccine patents have been considered. Issues regarding eligibility for supplementary protection, as currently being considered by the Court of Justice of the EU, are also outlined, as well as the implications of such issues in protecting future vaccine research. PMID:21154148

  3. Flu vaccination in pregnancy

    OpenAIRE

    Maria Siettou; Maria Saridi

    2012-01-01

    In periods of seasonal influenza, during pandemic flu in the past and from recent experience that we have the emergence of influenza A (H1N1), pregnant compared with non-pregnant women are at increased risk to get sick and to develop serious complications up to mortality. Purpose: This paper examines the risks that arise for pregnant from contamination with the flu virus and the safety of influenza vaccination in pregnancy. Method: The method involves searching review and research studies in ...

  4. Rationally designed tularemia vaccines

    OpenAIRE

    Mann, Barbara J.; Ark, Nicole M

    2009-01-01

    Tularemia, caused by the Gram-negative bacterium Francisella tularensis, can be contracted by the bite of an arthropod vector or by inhalation. This disease occurs relatively infrequently but can be severe and even life-threatening if untreated. Until recently, there were few laboratories studying this organism; however, concerns over its potential use as a biological weapon have led to renewed attention to F. tularensis research, particularly in the area of vaccine development. Advances in t...

  5. Vaccination against seasonal influenza

    CERN Multimedia

    SC Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not provide protection against the...

  6. Vaccine-derived polioviruses.

    Science.gov (United States)

    Burns, Cara C; Diop, Ousmane M; Sutter, Roland W; Kew, Olen M

    2014-11-01

    The attenuated oral poliovirus vaccine (OPV) has many properties favoring its use in polio eradication: ease of administration, efficient induction of intestinal immunity, induction of durable humoral immunity, and low cost. Despite these advantages, OPV has the disadvantage of genetic instability, resulting in rare and sporadic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically divergent vaccine-derived polioviruses (VDPVs). Whereas VAPP is an adverse event following exposure to OPV, VDPVs are polioviruses whose genetic properties indicate prolonged replication or transmission. Three categories of VDPVs are recognized: (1) circulating VDPVs (cVDPVs) from outbreaks in settings of low OPV coverage, (2) immunodeficiency-associated VDPVs (iVDPVs) from individuals with primary immunodeficiencies, and (3) ambiguous VDPVs (aVDPVs), which cannot be definitively assigned to either of the first 2 categories. Because most VDPVs are type 2, the World Health Organization's plans call for coordinated worldwide replacement of trivalent OPV with bivalent OPV containing poliovirus types 1 and 3. PMID:25316847

  7. HPV vaccine acceptability among Kenyan women

    OpenAIRE

    Becker-Dreps, Sylvia; Otieno, Walter Agingu; Brewer, Noel T.; Agot, Kawango; Smith, Jennifer S.

    2010-01-01

    As human papillomavirus (HPV) vaccines become available in less developed countries, understanding women’s attitudes towards HPV vaccines can help guide approaches to immunization programs. We assessed knowledge and interest in prophylactic HPV vaccines among Kenyan women seeking women’s health services (N=147). They knew little about cervical cancer or HPV vaccine. Most women (95%, 95% confidence interval [CI]: 92%, 99%), however, were willing to have their daughters vaccinated with a vaccin...

  8. Understanding vaccines: a public imperative.

    Science.gov (United States)

    Federman, Ross S

    2014-12-01

    Though once a discovery greatly celebrated by the nation, the vaccine has come under fire in recent decades from skeptics, critics, and a movement set into motion by fraudulent scientists and fueled by frustrated parents looking for answers to the autism conundrum. There is enough denialist resistance to vaccination to bring upon renewed fear of young children and infants becoming infected with diseases, the threats of which had been functionally eradicated from the United States. In more recent years, the surge in independent online journalism and blogging has invited many to rapidly share their opinions with millions of readers and, importantly, has appeared to open the door for opinion to be portrayed as fact. As a result, many parents are inundated with horror stories of vaccine dangers, all designed to eat away at them emotionally while the medical and scientific communities have mounted their characteristic response by sharing the facts, the data, and all of the reliable peer-reviewed and well-cited research to show that vaccines are safe and effective. It has become clear to me that facts are no match for emotion, but perhaps an understanding behind vaccine methodology will help parents overcome these fears of vaccinating. By helping those who doubt vaccines better understand what vaccines really are and how they work in such an incredibly engineered fashion, we may have a stronger weapon than we realize in battling the emotional arsenal that comes from the fear and skepticism of vaccinating. PMID:25506276

  9. The March Toward Malaria Vaccines.

    Science.gov (United States)

    Hoffman, Stephen L; Vekemans, Johan; Richie, Thomas L; Duffy, Patrick E

    2015-12-01

    In 2013 there were an estimated 584,000 deaths and 198 million clinical illnesses due to malaria, the majority in sub-Saharan Africa. Vaccines would be the ideal addition to the existing armamentarium of anti-malaria tools. However, malaria is caused by parasites, and parasites are much more complex in terms of their biology than the viruses and bacteria for which we have vaccines, passing through multiple stages of development in the human host, each stage expressing hundreds of unique antigens. This complexity makes it more difficult to develop a vaccine for parasites than for viruses and bacteria, since an immune response targeting one stage may not offer protection against a later stage, because different antigens are the targets of protective immunity at different stages. Furthermore, depending on the life cycle stage and whether the parasite is extra- or intra-cellular, antibody and/or cellular immune responses provide protection. It is thus not surprising that there is no vaccine on the market for prevention of malaria, or any human parasitic infection. In fact, no vaccine for any disease with this breadth of targets and immune responses exists. In this limited review, we focus on four approaches to malaria vaccines, (1) a recombinant protein with adjuvant vaccine aimed at Plasmodium falciparum (Pf) pre-erythrocytic stages of the parasite cycle (RTS,S/AS01), (2) whole sporozoite vaccines aimed at Pf pre-erythrocytic stages (PfSPZ Vaccine and PfSPZ-CVac), (3) prime boost vaccines that include recombinant DNA, viruses and bacteria, and protein with adjuvant aimed primarily at Pf pre-erythrocytic, but also asexual erythrocytic stages, and (4) recombinant protein with adjuvant vaccines aimed at Pf and Plasmodium vivax sexual erythrocytic and mosquito stages. We recognize that we are not covering all approaches to malaria vaccine development, or most of the critically important work on development of vaccines against P. vivax, the second most important cause of

  10. HPV Vaccine and Adolescent Males

    OpenAIRE

    Reiter, Paul L.; McRee, Annie-Laurie; KADIS, JESSICA A.; Brewer, Noel T.

    2011-01-01

    In 2009, the United States approved quadrivalent HPV vaccine for males 9–26 years old, but data on vaccine uptake are lacking. We determined HPV vaccine uptake among adolescent males, as well as stage of adoption and vaccine acceptability to parents and their sons. A national sample of parents of adolescent males ages 11–17 years (n=547) and their sons (n=421) completed online surveys during August and September 2010. Analyses used multivariate linear regression. Few sons (2%) had received an...

  11. [Diarrhea and vaccines: current developments].

    Science.gov (United States)

    Landry, P

    2006-05-10

    Diarrhoea is a main concern for travellers, populations of developing countries and children. Causative pathogens are numerous. An efficient vaccine against cholera is available, also offering a 50% cross-protection against E. Coli enterotoxin (ETEC), however its efficacy is only 23% against all-causes traveller's diarrhoea. Rotavirus can be responsible for severe diarrhoea in infants but rarely causes traveller's diarrhoea. Two new vaccines being under development appear effective and well-tolerated but too expensive for developing countries which most need them. To date, the live oral Ty21a vaccine remains frequently prescribed in Switzerland, with limited indications and suboptimal efficacy. A new oral vaccine is under development. PMID:16767878

  12. Oral vaccination of dogs with recombinant rabies virus vaccines.

    Science.gov (United States)

    Rupprecht, Charles E; Hanlon, Cathleen A; Blanton, Jesse; Manangan, Jamie; Morrill, Patricia; Murphy, Staci; Niezgoda, Michael; Orciari, Lillian A; Schumacher, Carolin L; Dietzschold, Bernhard

    2005-07-01

    Oral rabies virus (RV) vaccines are used to immunize a diversity of mammalian carnivores, but no single biological is effective for all major species. Recently, advances in reverse genetics have allowed the design of recombinant RV for consideration as new vaccines. The objective of this experiment was to examine the safety, immunogenicity and efficacy of recombinant RV vaccines administered to captive dogs by the oral route, compared to a commercial vaccinia-rabies glycoprotein (V-RG) recombinant virus vaccine. Animals consisted of naive purpose-bred beagles of both sexes, and were 6 months of age or older. Dogs were randomly assigned to one of six groups, and received either diluent or vaccine (PBS; V-RG; RV SN10-333; RV SPBN-Cyto c; RV SPBNGA; RV SPBNGAGA), with at least six animals per group. On day 0, 1 ml of each vaccine (or PBS) was administered to the oral cavity of each dog, at an approximate concentration of 10(8) to 10(9) TCID50. After vaccination, dogs were observed daily and bled weekly, for 5 weeks, prior to RV challenge. No signs of illness related to vaccination were detected during the observation period. Excluding the controls, RV neutralizing antibodies were detected in the majority of animals within 1-2 weeks of primary vaccination. Thereafter, all dogs were inoculated in the masseter muscle with a street virus of canine origin. All control animals developed rabies, but no vaccinates succumbed, with the exception of a single dog in the V-RG group. Review of these preliminary data demonstrates the non-inferiority of recombinant RV products, as concerns both safety and efficacy, and supports the suggestion that these vaccines may hold promise for future development as oral immunogens for important carnivore species, such as dogs. PMID:15896409

  13. Influenza Vaccinations, Fall 2009: Model School-Located Vaccination Clinics

    Science.gov (United States)

    Herl Jenlink, Carolyn; Kuehnert, Paul; Mazyck, Donna

    2010-01-01

    The 2009 H1N1 influenza virus presented a major challenge to health departments, schools, and other community partners to effectively vaccinate large numbers of Americans, primarily children. The use of school-located vaccination (SLV) programs to address this challenge led health departments and schools to become creative in developing models for…

  14. 75 FR 48706 - Proposed Vaccine Information Materials for Rotavirus Vaccine

    Science.gov (United States)

    2010-08-11

    ... these materials is included in a December 17, 1999 Federal Register notice (64 FR 70914). Proposed... HUMAN SERVICES Centers for Disease Control and Prevention Proposed Vaccine Information Materials for Rotavirus Vaccine AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and...

  15. Studies using multiple vaccinated animals

    International Nuclear Information System (INIS)

    The serological responses in vaccinated and multiple vaccinated cattle against non-structural proteins (NSP) of foot-and-mouth disease (FMD) virus were measured using four commercially available assays. Vaccines were concentrated using polyethylene glycol to contain higher antigenic payloads that those routinely used. Animals received up to five doses of polyvalent oil vaccines over six months, administered by the intra-muscular route on d 0, 90, 130, 160 and 200. Serum samples were taken 30-40 d after each vaccination. At 60 d post vaccination the antibody response to each of the vaccine strains showed high levels of antibodies against structural proteins that correlated with protection against challenge above 81%. The detection of antibodies against NSP was made with two ELISAs using expressed 3ABC as antigen; one ELISA using peptides from 3B and an enzyme-immunotransfer blot assay (EITB). Locally produced ELISA-3ABC reagents and agar gel immunodiffusion using VIAA, were also evaluated. After four doses of vaccine, animals were negative in all the assays. After the fifth immunization, two of seventeen animals were reactive in one ELISA kit, but these samples proved negative by confirmatory tests. Antibodies against NSP were not detected in primo-vaccinated cattle used for potency tests using three batches of standard vaccine. The principle of the NSP ELISA as screening test for large sero surveys in South America is established and this paper emphasises the importance using vaccines that have no demonstrated interference with NSP ELISAs and the advantages of reducing the number of false-positives that would require further confirmation by other assays. (author)

  16. Delivery systems for intradermal vaccination.

    Science.gov (United States)

    Kim, Y C; Jarrahian, C; Zehrung, D; Mitragotri, S; Prausnitz, M R

    2012-01-01

    Intradermal (ID) vaccination can offer improved immunity and simpler logistics of delivery, but its use in medicine is limited by the need for simple, reliable methods of ID delivery. ID injection by the Mantoux technique requires special training and may not reliably target skin, but is nonetheless used currently for BCG and rabies vaccination. Scarification using a bifurcated needle was extensively used for smallpox eradication, but provides variable and inefficient delivery into the skin. Recently, ID vaccination has been simplified by introduction of a simple-to-use hollow microneedle that has been approved for ID injection of influenza vaccine in Europe. Various designs of hollow microneedles have been studied preclinically and in humans. Vaccines can also be injected into skin using needle-free devices, such as jet injection, which is receiving renewed clinical attention for ID vaccination. Projectile delivery using powder and gold particles (i.e., gene gun) have also been used clinically for ID vaccination. Building off the scarification approach, a number of preclinical studies have examined solid microneedle patches for use with vaccine coated onto metal microneedles, encapsulated within dissolving microneedles or added topically to skin after microneedle pretreatment, as well as adapting tattoo guns for ID vaccination. Finally, technologies designed to increase skin permeability in combination with a vaccine patch have been studied through the use of skin abrasion, ultrasound, electroporation, chemical enhancers, and thermal ablation. The prospects for bringing ID vaccination into more widespread clinical practice are encouraging, given the large number of technologies for ID delivery under development. PMID:21472533

  17. Improved ERM vaccination efficacy using combined vaccine administration methods

    DEFF Research Database (Denmark)

    Buchmann, Kurt; Desmukh, Sidhartha; Chettri, Jiwan Kumar;

    2012-01-01

    We have previously shown that immersion vaccination (30 sec) using the Aquavac Relera vaccine (containing formalin killed Yersinia ruckeri serotype O1 of both biotypes 1 and 2) provides the best protection (when compared to other commercial ERM vaccines on the Danish market) against infection...... following i. p. challenge using Y. ruckeri O1, biotype 2, which at present is the main bacterial pathogen in fingerling trout production in Denmark. Despite a significant protection conferred by this vaccine (immersion) some mortality could be observed following challenge. We have therefore performed a...... study in order to elucidate if different vaccine administration methods (using Aquavac Relera) can improve protection and reduce mortality of exposed trout following challenge with this particular pathogen. Rainbow trout (mean weight 7.8 g) reared at the Bornholm Salmon Hatchery under pathogen free...

  18. Biotechnology and DNA vaccines for aquatic animals

    Science.gov (United States)

    Kurath, G.

    2008-01-01

    Biotechnology has been used extensively in the development of vaccines for aquaculture. Modern molecular methods such as polymerase chain reaction (PCR), cloning and microarray analysis have facilitated antigen discovery, construction of novel candidate vaccines, and assessments of vaccine efficacy, mode of action, and host response. This review focuses on DNA vaccines for finfish to illustrate biotechnology applications in this field. Although DNA vaccines for fish rhabdoviruses continue to show the highest efficacy, DNA vaccines for several other viral and bacterial fish pathogens have now been proven to provide significant protection against pathogen challenge. Studies of the fish rhabdovirus DNA vaccines have elucidated factors that affect DNA vaccine efficacy as well as the nature of the fish innate and adaptive immune responses to DNA vaccines. As tools for managing aquatic animal disease emergencies, DNA vaccines have advantages in speed, flexibility, and safety, and one fish DNA vaccine has been licensed.

  19. Challenges for cancer vaccine development.

    Science.gov (United States)

    Tabi, Z; Man, S

    2006-10-01

    The first generation of human cancer vaccines has been tested in phase III clinical trials, but only a few of these have demonstrated sufficient efficacy to be licensed for clinical use. This article reviews some of the mechanisms that could contribute to these limited clinical responses, and highlights the challenges faced for development of future vaccines. PMID:16979786

  20. Diabetes and Hepatitis B Vaccination

    Science.gov (United States)

    Diabetes and Hepatitis B Vaccination Information for Diabetes Educators What is hepatitis B? Hepatitis B is a contagious liver disease that results from ... Immunization Practices (ACIP) released new guidelines that recommend hepatitis B vaccination for all unvaccinated adults with diabetes who are ...

  1. Adolescent Attitudes toward Influenza Vaccination and Vaccine Uptake in a School-Based Influenza Vaccination Intervention: A Mediation Analysis

    Science.gov (United States)

    Painter, Julia E.; Sales, Jessica M.; Pazol, Karen; Wingood, Gina M.; Windle, Michael; Orenstein, Walter A.; DiClemente, Ralph J.

    2011-01-01

    Background: School-based vaccination programs may provide an effective strategy to immunize adolescents against influenza. This study examined whether adolescent attitudes toward influenza vaccination mediated the relationship between receipt of a school-based influenza vaccination intervention and vaccine uptake. Methods: Participants were…

  2. DNA vaccines for aquacultured fish

    DEFF Research Database (Denmark)

    Lorenzen, Niels; LaPatra, S.E.

    2005-01-01

    in various animal species as well as in humans, the vaccines against rhabdovirus diseases in fish have given some of the most promising results. A single intramuscular (IM) injection of microgram amounts of DNA induces rapid and long-lasting protection in farmed salmonids against economically important...... viruses such as infectious haematopoietic necrosis virus (IHNV) and viral haemorrhagic septicaemia virus (VHSV). DNA vaccines against other types of fish pathogens, however, have so far had limited success. The most efficient delivery route at present is IM injection, and suitable delivery strategies...... for mass vaccination of small fish have yet to be developed. In terms of safety, no adverse effects in the vaccinated fish have been observed to date. As DNA vaccination is a relatively new technology, various theoretical and long-term safety issues related to the environment and the consumer remain...

  3. Development of a schistosomiasis vaccine.

    Science.gov (United States)

    Molehin, Adebayo J; Rojo, Juan U; Siddiqui, Sabrina Z; Gray, Sean A; Carter, Darrick; Siddiqui, Afzal A

    2016-05-01

    Schistosomiasis is a neglected tropical disease (NTD) of public health importance. Despite decades of implementation of mass praziquantel therapy programs and other control measures, schistosomiasis has not been contained and continues to spread to new geographic areas. A schistosomiasis vaccine could play an important role as part of a multifaceted control approach. With regards to vaccine development, many biological bottlenecks still exist: the lack of reliable surrogates of protection in humans; immune interactions in co-infections with other diseases in endemic areas; the potential risk of IgE responses to antigens in endemic populations; and paucity of appropriate vaccine efficacy studies in nonhuman primate models. Research is also needed on the role of modern adjuvants targeting specific parts of the innate immune system to tailor a potent and protective immune response for lead schistosome vaccine candidates with the long-term aim to achieve curative worm reduction. This review summarizes the current status of schistosomiasis vaccine development. PMID:26651503

  4. Phacilitate vaccine forum Barcelona 2009.

    Science.gov (United States)

    Silman, Nigel J; Rivera, Liza M; Wheat, Jenifer

    2009-10-01

    The Phacilitate Vaccine Forum comprised numerous plenary sessions and panel discussions. The highlights of the meeting were the discussion of new adjuvant technologies able to specifically target the immune system to drive the response down the required route. Also of topical interest was a session on the challenges of the current influenza pandemic, and strategies for vaccination and control of the disease. Finally, the session covering vaccines for tropical and emerging infectious diseases highlighted some of the niche vaccines that are being developed, in particular those for dengue and West Nile viruses, which show great promise. In addition to scientific promise, the value proposition for vaccine development in a risk-averse economy was outlined, citing expected growth in the worldwide market of more than US$25 billion within 5 years. This proposition was supported by the overviews of disposable and 'flex factory' manufacturing technologies, providing cost and time efficiencies in product development, which are especially critical for the emerging markets. PMID:19803754

  5. A New Decade of Vaccines

    LENUS (Irish Health Repository)

    Murphy, JFA

    2011-09-01

    The call for a new decade of vaccines was made in December 2010. The aims are to secure the further discovery, development and delivery of vaccination. The first challenge is the acquisition of funds for the research and development of 20 new vaccines1. The Gates Foundation has pledged $10 billion for this venture. The other major players are WHO, UNICEF and the US National Institute of Allergy and Infectious Diseases. The top priorities are TB, AIDS and Malaria. It is hoped that a Malaria vaccine will available in 3 years. The ambitious target of saving the lives of over 7 million children has been set. The programme must also address the need for vaccines in insulin dependent diabetes, cancers and degenerative diseases2.

  6. Vaccine strategies against schistosomiasis

    Directory of Open Access Journals (Sweden)

    A. Capron

    1992-01-01

    Full Text Available Schistosomiasis, the second major parasitic disease in the world after malaria affects at least 200 million people, 500 million being exposed to the risk of infection. It is widely agreed that a vaccine strategy wich could lead to the induction of effector mechanisms reducing the level of reinfection and ideally parasite fecundity would deeply affect the incidence of pathological manifestations as well as the parasite transmission potentialities. Extensive studies performed in the rat model have allowed the identification of novel effector mechanisms involving IgE antibodies and various inflammatory cell populations (eosinophils, macrophages and platelets whereas regulation of immune response by blocking antibodies has been evidencial. Recent epidemiological studies have now entirely confirmed in human populations the the role of IgE antibodies in the acquisition of resistance and the association of IgG4 blocking antibodies with increased susceptibility. On the basis of these concepts, several schistosome glutathion S-transferase (Sm 28 GST appears as a pronising vaccine candidate. Immunization experiments have shown that two complementary goals can be achieved: (a a partial but significant reduction of the worm population (up to 60//in rats; (b a significant reduction of parasite fecundity (up in the mice and 85//in cattle and egg viability (up to 80//. At least two distinct immunological mechanisms account for these two effects. IgE antibodies appear as a major humoral component of acquired resistance whereas IgA antibodies appear as a major humoral factor affecting parasite fecundity. These studies seem to represent a parasite diseases through the identification of potentially protective antigens and of the components of the immune response which vaccination should aim at inducing.

  7. Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative.

    Science.gov (United States)

    Lim, Jacqueline Kyungah; Lee, Yong-Seok; Wilder-Smith, Annelies; Thiry, Georges; Mahoney, Richard; Yoon, In-Kyu

    2016-04-01

    Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries. In anticipation of the first dengue vaccine candidate to be licensed, Dengue Vaccine Initiative (DVI) and, its predecessor, Pediatric Dengue Vaccine Initiative (PDVI) have been working on points for consideration to accelerate evidence-based dengue vaccine introduction, once a vaccine becomes available. In this paper, we review the history of PDVI and its successor, the DVI, and elaborate on the points of consideration for dengue vaccine introduction. PMID:26651238

  8. BCG vaccine in Korea

    OpenAIRE

    Joung, Sun Myung; Ryoo, Sungweon

    2013-01-01

    The anti-tuberculosis Bacille de Calmette et Guérin (BCG) vaccine was developed between 1905 and 1921 at Pasteur Institutes of Lille in France, and was adopted by many countries. BCG strains comprise natural mutants of major virulence factors of Mycobacterium tuberculosis and that BCG sub-strains differ markedly in virulence levels. The tuberculosis became endemic in Korea after the Korean War (1950s). The BCG strain, which was donated by Pasteur Institutes, was brought to Korea in 1955, and ...

  9. HPV Vaccine PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-01-15

    In this 30 second public service announcement, a mother talks about the importance of protecting 11-12 year-old boys and girls with HPV vaccination. (Una madre habla sobre la importancia de proteger a los niños y las niñas de 11 a 12 años con la vacuna contra el VPH.).  Created: 1/15/2014 by National Center for Immunizations and Respiratory Diseases (NCIRD).   Date Released: 1/15/2014.

  10. 广州地区92例成人水痘患者流行病学、临床及实验室特征分析%Epidemiologic, clinical and laboratory characteristics of 92 adult patients with chickenpox in Guangzhou area

    Institute of Scientific and Technical Information of China (English)

    周颖; 林思炜; 廖宝林; 熊红品

    2013-01-01

    Objective To investigate the epidemiologic, clinical and laboratory characteristics of adult patients with chickenpox in Guangzhou area. Methods We retrospectively enrolled 92 adult patients with chickenpox, collected and analyzed their epidemiologic, clinical and laboratory data. We also chose 30 child patients with chickenpox from same period for comparison. Results Adult patients with chickenpox in Guangzhou area were mostly found in seasons of autumn and winter (61.9%), and in Baiyun district (40.2%). They were mainly consisted of students (42.4%). Patients in adult group (n = 84) had significantly longer fever (P = 0.033), as well as higher frequencies of throat pain, blister with infection and involved in oral mucosa than those in child group (P = 0.001, 0.005, 0.041), and most of their rash were not centrally distribution (P = 0.006). Patients in adult group had higher frequency of hepatitis than those in childe group (54.8% vs 10.0%, P < 0.001). Conclusion Clinical symptoms in adult patients with chickenpox are not typical and more severe, attentions must be paid to prevent and treat their complications.%目的:了解广州地区成人水痘患者流行病学、临床和实验室检查特征。方法回顾性分析92例成人水痘患者的流行病学、临床和实验室资料,选取同期30例儿童水痘患者作为对照。结果广州成人水痘患者多发生于秋冬季节(61.9%),白云区例数最多(40.2%),以学生为主(42.4%)。成人组(n =84)热程较长(P =0.033),咽痛、水泡伴发感染与累及口腔黏膜发生率均较儿童组明显升高(P =0.001、0.005、0.041),且皮疹以非向心性分布为主(P =0.006)。成人组合并肝炎发生率较儿童组高(54.8% vs 10.0%,P <0.001)。结论成人水痘患者临床表现不典型且病情较重,需注意并发症的防治。

  11. Status of vaccine research and development of vaccines for malaria.

    Science.gov (United States)

    Birkett, Ashley J

    2016-06-01

    Despite recent progress in reducing deaths attributable to malaria, it continues to claim approximately 500,000 lives per year and is associated with approximately 200 million infections. New tools, including safe and effective vaccines, are needed to ensure that the gains of the last 15 years are leveraged toward achieving the ultimate goal of malaria parasite eradication. In 2015, the European Medicines Agency announced the adoption of a positive opinion for the malaria vaccine candidate most advanced in development, RTS,S/AS01, which provides modest protection against clinical malaria; in early 2016, WHO recommended large-scale pilot implementations of RTS,S in settings of moderate-to-high malaria transmission. In alignment with these advancements, the community goals and preferred product characteristics for next-generation vaccines have been updated to inform the development of vaccines that are highly efficacious in preventing clinical malaria, and those needed to accelerate parasite elimination. Next-generation vaccines, targeting all stages of the parasite lifecycle, are in early-stage development with the most advanced in Phase 2 trials. Importantly, progress is being made in the definition of feasible regulatory pathways to accelerate timelines, including for vaccines designed to interrupt transmission of parasites from humans to mosquitoes. The continued absence of financially lucrative, high-income markets to drive investment in malaria vaccine development points to continued heavy reliance on public and philanthropic funding. PMID:26993333

  12. Status of vaccine research and development of vaccines for tuberculosis.

    Science.gov (United States)

    Evans, Thomas G; Schrager, Lew; Thole, Jelle

    2016-06-01

    TB is now the single pathogen that causes the greatest mortality in the world, at over 1.6 million deaths each year. The widely used the 90 year old BCG vaccine appears to have minimal impact on the worldwide incidence despite some efficacy in infants. Novel vaccine development has accelerated in the past 15 years, with 15 candidates entering human trials; two vaccines are now in large-scale efficacy studies. Modeling by three groups has consistently shown that mass vaccination that includes activity in the latently infected population, especially adolescents and young adults, will likely have the largest impact on new disease transmission. At present the field requires better validated animal models, better understanding of a correlate of immunity, new cost-effective approaches to Proof of Concept trials, and increased appreciation by the public health and scientific community for the size of the problem and the need for a vaccine. Such a vaccine is likely to also play a role in the era of increasing antibiotic resistance. Ongoing efforts and studies are working to implement these needs over the next 5 years, which will lead to an understanding that will increase the likelihood of a successful TB vaccine. PMID:26973073

  13. Anthrax vaccine associated deaths in miniature horses

    OpenAIRE

    Wobeser, Bruce K.

    2015-01-01

    During a widespread anthrax outbreak in Canada, miniature horses were vaccinated using a live spore anthrax vaccine. Several of these horses died from an apparent immune-mediated vasculitis temporally associated with this vaccination. During the course of the outbreak, other miniature horses from different regions with a similar vaccination history, clinical signs, and necropsy findings were found.

  14. Anthrax vaccine associated deaths in miniature horses.

    Science.gov (United States)

    Wobeser, Bruce K

    2015-04-01

    During a widespread anthrax outbreak in Canada, miniature horses were vaccinated using a live spore anthrax vaccine. Several of these horses died from an apparent immune-mediated vasculitis temporally associated with this vaccination. During the course of the outbreak, other miniature horses from different regions with a similar vaccination history, clinical signs, and necropsy findings were found. PMID:25829553

  15. Meningococcal Education: More than Just a Vaccine

    Science.gov (United States)

    Kuenzi, Lana

    2004-01-01

    The administration of meningitis vaccinations to the college population has recently been the topic of much discussion. Much of the controversy has surrounded the promotion of widespread vaccinations or educational campaigns about the vaccine for incoming freshman students. Recommendations about the use of meningococcal vaccines for college…

  16. Meningococcal Group B Vaccine (MenB)

    Science.gov (United States)

    ... problems, or severe scars from skin grafts. Meningococcal group B (MenB) vaccine can help prevent meningococcal disease ... What are meningococcal group B vaccines?Two meningococcal group B vaccines have been licensed by the Food and Drug Administration. These vaccines are ...

  17. Human Papillomavirus (HPV) Vaccine (Gardasil-9)

    Science.gov (United States)

    What is HPV vaccine?Gardasil-9 is one of three FDA-approved HPV vaccines. It is recommended for both males and females. ... Who should not get HPV vaccine or should wait?Anyone who has had a severe, life-threatening allergic reaction to a dose of HPV vaccine should ...

  18. Advances in vaccine stability monitoring technology.

    Science.gov (United States)

    Zweig, Stephen E

    2006-08-14

    Electronic time-temperature indicator (eTTI) monitors can be programmed to exactly follow the stability characteristics of vaccines with a high degree of realism. The monitors have a visual output, enabling vaccine status to be assessed at a glance, and can also output more detailed statistical data. When packaged with vaccine vials in groups of about 10 vials per box, the eTTI can remain with a vaccine throughout most of the vaccine's lifetime. The monitors can detect essentially all cold-chain breaks, and can detect issues, such as inadvertent freezing, that are presently not detected by other vaccine stability monitors such as Vaccine Vial Monitors (VVM). PMID:16759766

  19. Immune response in cattle vaccinated against rabies

    Directory of Open Access Journals (Sweden)

    Oliveira Alexandre Nunes de

    2000-01-01

    Full Text Available In order to determine the best type of rabies vaccine to use as a booster, 78 serological samples from singly vaccinated cattle were analyzed by counterimmunoelectrophoresis technique. The animals were divided into several groups, received the first vaccine dose with modified live virus vaccine (ERA strain and were revaccinated with inactivated virus or modified live virus vaccines. Boosters were given at 2, 4, 8, 12 and 16 weeks following first vaccination. Results showed high titres in the cases of booster with inactivated vaccine. In all cases, however, detectable antibody titres declined quickly.

  20. Rethinking vaccine policy making in an era of vaccine hesitancy

    Science.gov (United States)

    Opel, Douglas J; Marcuse, Edgar K

    2013-01-01

    Recently in this journal, David Ropeik argued for imposing additional burdens upon individuals who refused vaccines for themselves or for their children. Specifically, Ropeik advocated for policies that would decrease the ease of claiming vaccine exemptions and restricting unvaccinated children participation in social activities. We argue that, in order to derive the optimal societal benefit from modern vaccinology in an era of vaccine hesitancy, we need to consider doing more than conventional remodeling of current policies. We may need to fundamentally redesign and rebuild. PMID:24084386

  1. Timeliness vaccination of measles containing vaccine and barriers to vaccination among migrant children in East China.

    Directory of Open Access Journals (Sweden)

    Yu Hu

    Full Text Available BACKGROUND: The reported coverage rates of first and second doses of measles containing vaccine (MCV are almost 95% in China, while measles cases are constantly being reported. This study evaluated the vaccine coverage, timeliness, and barriers to immunization of MCV1 and MCV2 in children aged from 8-48 months. METHODS: We assessed 718 children aged 8-48 months, of which 499 children aged 18-48 months in September 2011. Face to face interviews were administered with children's mothers to estimate MCV1 and MCV2 coverage rate, its timeliness and barriers to vaccine uptake. RESULTS: The coverage rates were 76.9% for MCV1 and 44.7% for MCV2 in average. Only 47.5% of surveyed children received the MCV1 timely, which postpone vaccination by up to one month beyond the stipulated age of 8 months. Even if coverage thus improves with time, postponed vaccination adds to the pool of unprotected children in the population. Being unaware of the necessity for vaccination and its schedule, misunderstanding of side-effect of vaccine, and child being sick during the recommended vaccination period were significant preventive factors for both MCV1 and MCV2 vaccination. Having multiple children, mother's education level, household income and children with working mothers were significantly associated with delayed or missing MCV1 immunization. CONCLUSIONS: To avoid future outbreaks, it is crucial to attain high coverage levels by timely vaccination, thus, accurate information should be delivered and a systematic approach should be targeted to high-risk groups.

  2. [Vaccination by the pharmacist: practical guidelines].

    Science.gov (United States)

    Freney, J

    2012-11-01

    It appears to be entirely appropriate for pharmacists to administer vaccinations if restricted to a limited number of vaccines and a well-defined set of recipients. Recommended types of vaccines would be inert vaccines with no contraindications, including flu vaccines, booster shots for diphtheria, tetanus, pertussis, and polio, and HPV vaccines for the prevention of cervical cancer. Recipients targeted for these types of vaccinations would only be adults and adolescents. In addition, pharmacist-administered vaccinations would not be recommended for pregnant women, people with immunodeficiencies, chronic diseases, or cystic fibrosis, people under treatment (anticoagulants) or with known allergies, and haemophiliacs. They would not be recommended either when needed in the context of employment and for traveling abroad. Training is essential to manage the successful implementation of a pharmacist-administered vaccination program (maintaining cold storage, monitoring, space allocation, vaccination administration process, preventive measures, quick recognition and management of anaphylactic chock…). PMID:23177558

  3. The Evolution of Poxvirus Vaccines

    Directory of Open Access Journals (Sweden)

    Lucas Sánchez-Sampedro

    2015-04-01

    Full Text Available After Edward Jenner established human vaccination over 200 years ago, attenuated poxviruses became key players to contain the deadliest virus of its own family: Variola virus (VARV, the causative agent of smallpox. Cowpox virus (CPXV and horsepox virus (HSPV were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia virus (VACV, which was used in the final campaigns aimed to eradicate the disease, an endeavor that was accomplished by the World Health Organization (WHO in 1980. Ever since, naturally evolved strains used for vaccination were introduced into research laboratories where VACV and other poxviruses with improved safety profiles were generated. Recombinant DNA technology along with the DNA genome features of this virus family allowed the generation of vaccines against heterologous diseases, and the specific insertion and deletion of poxvirus genes generated an even broader spectrum of modified viruses with new properties that increase their immunogenicity and safety profile as vaccine vectors. In this review, we highlight the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.

  4. Review of enterovirus 71 vaccines.

    Science.gov (United States)

    Chong, Pele; Liu, Chia-Chyi; Chow, Yen-Hung; Chou, Ai-Hsiang; Klein, Michel

    2015-03-01

    Enterovirus 71 (EV71) and coxsackieviruses are the major causative agents of hand, foot, and mouth disease (HFMD) outbreaks worldwide and have a significant socioeconomic impact, particularly in Asia. Formalin-inactivated (FI) EV71 vaccines evaluated in human clinical trials in China, Taiwan, and Singapore were found to be safe and to elicit strong neutralizing antibody responses against EV71 currently circulating in Asia. The results from 3 different phase 3 clinical trials performed in young children (6-60 months) indicate that the efficacy of FI-EV71 vaccines is >90% against EV71-related HFMDs and >80% against EV71-associated serious diseases, but the vaccines did not protect against coxsackievirus A16 infections. Here we discuss the critical factors affecting EV71 vaccine product registration, including clinical epidemiology, antigenic shift issues in cross-protection and vaccine strain selection, standardized animal models for potency testing, and cost-effective manufacturing processes for potential incorporation of FI-EV71 vaccine into Expanded Programme on Immunization vaccines. PMID:25352588

  5. A stable live bacterial vaccine.

    Science.gov (United States)

    Kunda, Nitesh K; Wafula, Denis; Tram, Meilinn; Wu, Terry H; Muttil, Pavan

    2016-06-01

    Formulating vaccines into a dry form enhances its thermal stability. This is critical to prevent administering damaged and ineffective vaccines, and to reduce its final cost. A number of vaccines in the market as well as those being evaluated in the clinical setting are in a dry solid state; yet none of these vaccines have achieved long-term stability at high temperatures. We used spray-drying to formulate a recombinant live attenuated Listeria monocytogenes (Lm; expressing Francisella tularensis immune protective antigen pathogenicity island protein IglC) bacterial vaccine into a thermostable dry powder using various sugars and an amino acid. Lm powder vaccine showed minimal loss in viability when stored for more than a year at ambient room temperature (∼23°C) or for 180days at 40°C. High temperature viability was achieved by maintaining an inert atmosphere in the storage container and removing oxygen free radicals that damage bacterial membranes. Further, in vitro antigenicity was confirmed by infecting a dendritic cell line with cultures derived from spray dried Lm and detection of an intracellularly expressed protective antigen. A combination of stabilizing excipients, a cost effective one-step drying process, and appropriate storage conditions could provide a viable option for producing, storing and transporting heat-sensitive vaccines, especially in regions of the world that require them the most. PMID:27020530

  6. Public awareness regarding children vaccination in Jordan.

    Science.gov (United States)

    Masadeh, Majed M; Alzoubi, Karem H; Al-Azzam, Sayer I; Al-Agedi, Hassan S; Abu Rashid, Baraa E; Mukattash, Tariq L

    2014-01-01

    Immunization can contribute to a dramatic reduction in number of vaccine-preventable diseases among children. The aim of this study is to investigate mothers' awareness about child vaccines and vaccination in Jordan. This study was a community-based, cross-sectional study that was performed at public places in Irbid City. Data was collected from 506 mothers. After verbal approval, mothers were interviewed to assess their knowledge, attitudes, and practice toward vaccination. Results show that majority of mothers had acceptable knowledge and positive attitude toward vaccination. Most of mothers (94.7-86.8%) were able to identify vaccines that are mandatory as per the national vaccination program. Lower knowledge was observed among mothers (71.6%) for HIB vaccination being mandatory. Most mothers (97.2%) had vaccination card for their baby form the national vaccination programs. Vaccination delay was reported by about 36.6% of mothers and was shown to be associated with significantly (P = 0.001) lower vaccination knowledge/attitude score. Additionally, mothers who reported to be regularly offered information about vaccination during visits and those who identified medical staff members as their major information source had significantly higher vaccination knowledge/attitude score (P = 0.002). In conclusion, vaccination coverage rate is high; however, some aspects of knowledge, attitudes, and practice of vaccination need to be improved. Knowledge and attitudes of mothers were directly associated with their practice of vaccination. Medical staff education about vaccination during each visit seems to be the most effective tool that directly reflects on better practice of vaccination such as reducing the possibility for vaccination delay. PMID:24732060

  7. Vaccines for Malaria: How Close Are We?

    OpenAIRE

    Thera, Mahamadou A.; Plowe, Christopher V.

    2011-01-01

    Vaccines are the most powerful public health tools mankind has created, but malaria parasites are bigger, more complicated, and wilier than the viruses and bacteria that have been conquered or controlled with vaccines. Despite decades of research toward a vaccine for malaria, this goal has remained elusive. Nevertheless, recent advances justify optimism that a licensed malaria vaccine is within reach. A subunit recombinant protein vaccine that affords in the neighborhood of 50% protective eff...

  8. Stability of influenza vaccine coated onto microneedles

    OpenAIRE

    Choi, Hyo-Jick; Yoo, Dae-Goon; Bondy, Brian J.; Quan, Fu-Shi; Compans, Richard W.; Kang, Sang-Moo; Mark R Prausnitz

    2012-01-01

    A microneedle patch coated with vaccine simplifies vaccination by using a patch-based delivery method and targets vaccination to the skin for superior immunogenicity compared to intramuscular injection. Previous studies of microneedles have demonstrated effective vaccination using freshly prepared microneedles, but the issue of long-term vaccine stability has received only limited attention. Here, we studied the long-term stability of microneedles coated with whole inactivated influenza vacci...

  9. Recent update in HIV vaccine development

    OpenAIRE

    Shin, So Youn

    2016-01-01

    Despite the tremendous efforts to develop a successful human immunodeficiency virus (HIV) vaccine, the quest for a safe and effective HIV vaccine seems to be remarkably long and winding. Disappointing results from previous clinical trials of VaxGen's AIDSVAXgp120 vaccine and MRKAd5 HIV-1 Gag/Pol/Nef vaccine emphasize that understanding the correlates of immune protection in HIV infection is the key to solve the puzzle. The modest vaccine efficacy from RV144 trial and the successive results ob...

  10. Novel vaccines to human rabies.

    Directory of Open Access Journals (Sweden)

    Hildegund C J Ertl

    Full Text Available Rabies, the most fatal of all infectious diseases, remains a major public health problem in developing countries, claiming the lives of an estimated 55,000 people each year. Most fatal rabies cases, with more than half of them in children, result from dog bites and occur among low-income families in Southeast Asia and Africa. Safe and efficacious vaccines are available to prevent rabies. However, they have to be given repeatedly, three times for pre-exposure vaccination and four to five times for post-exposure prophylaxis (PEP. In cases of severe exposure, a regimen of vaccine combined with a rabies immunoglobulin (RIG preparation is required. The high incidence of fatal rabies is linked to a lack of knowledge on the appropriate treatment of bite wounds, lack of access to costly PEP, and failure to follow up with repeat immunizations. New, more immunogenic but less costly rabies virus vaccines are needed to reduce the toll of rabies on human lives. A preventative vaccine used for the immunization of children, especially those in high incidence countries, would be expected to lower fatality rates. Such a vaccine would have to be inexpensive, safe, and provide sustained protection, preferably after a single dose. Novel regimens are also needed for PEP to reduce the need for the already scarce and costly RIG and to reduce the number of vaccine doses to one or two. In this review, the pipeline of new rabies vaccines that are in pre-clinical testing is provided and an opinion on those that might be best suited as potential replacements for the currently used vaccines is offered.

  11. Novel vaccines to human rabies.

    Science.gov (United States)

    Ertl, Hildegund C J

    2009-01-01

    Rabies, the most fatal of all infectious diseases, remains a major public health problem in developing countries, claiming the lives of an estimated 55,000 people each year. Most fatal rabies cases, with more than half of them in children, result from dog bites and occur among low-income families in Southeast Asia and Africa. Safe and efficacious vaccines are available to prevent rabies. However, they have to be given repeatedly, three times for pre-exposure vaccination and four to five times for post-exposure prophylaxis (PEP). In cases of severe exposure, a regimen of vaccine combined with a rabies immunoglobulin (RIG) preparation is required. The high incidence of fatal rabies is linked to a lack of knowledge on the appropriate treatment of bite wounds, lack of access to costly PEP, and failure to follow up with repeat immunizations. New, more immunogenic but less costly rabies virus vaccines are needed to reduce the toll of rabies on human lives. A preventative vaccine used for the immunization of children, especially those in high incidence countries, would be expected to lower fatality rates. Such a vaccine would have to be inexpensive, safe, and provide sustained protection, preferably after a single dose. Novel regimens are also needed for PEP to reduce the need for the already scarce and costly RIG and to reduce the number of vaccine doses to one or two. In this review, the pipeline of new rabies vaccines that are in pre-clinical testing is provided and an opinion on those that might be best suited as potential replacements for the currently used vaccines is offered. PMID:19787033

  12. Vaccines for preventing Japanese encephalitis

    DEFF Research Database (Denmark)

    Schiøler, Karin Linda; Samuel, Miny; Wai, Kim Lay

    2007-01-01

    acceptance and uptake. OBJECTIVES: To evaluate vaccines for preventing Japanese encephalitis in terms of effectiveness, adverse events, and immunogenicity. SEARCH STRATEGY: In March 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue 1......, fever, headache, and nausea were reported in less than 6% of children receiving inactivated vaccine compared to 0.6% of unvaccinated controls. One cluster-RCT compared the live-attenuated SA14-14-2 vaccine (widely used in China) with no intervention measuring adverse events. Fever was reported in 2...

  13. Universal varicella vaccine immunization in Japan.

    Science.gov (United States)

    Yoshikawa, Tetsushi; Kawamura, Yoshiki; Ohashi, Masahiro

    2016-04-01

    In 1974, Japanese scientists developed a live attenuated varicella vaccine based on the Oka strain. The efficacy of the vaccine for the prevention of varicella has been primarily demonstrated in studies conducted in the United States following the adoption of universal immunization using the Oka strain varicella vaccine in 1996. Although the vaccine was developed by Japanese scientists, until recently, the vaccine has been administered on a voluntary basis in Japan resulting in a vaccine coverage rate of approximately 40%. Therefore, Japan initiated universal immunization using the Oka strain varicella vaccine in November 2014. Given the transition from voluntary to universal immunization in Japan, it will also be important to monitor the epidemiology of varicella and herpes zoster. The efficacy and safety of co-administration of the varicella vaccine and measles, mumps, and rubella vaccine have been demonstrated in many countries; however, there was no data from Japan. In order to adopt the practice of universal immunization using the Oka strain varicella vaccine in Japan, data demonstrating the efficacy and safety of co-administration of varicella vaccine and measles and rubella (MR) vaccine were required. Additionally, we needed to elucidate the appropriate time interval between the first and second administrations of the vaccine. It is also important to differentiate between wild type and Oka vaccine type strains in herpes zoster patient with past history of varicella vaccine. Thus, there are many factors to consider regarding the adoption of universal immunization in Japan to control varicella zoster virus (VZV) infections. PMID:26944711

  14. Introducing dengue vaccine: Implications for diagnosis in dengue vaccinated subjects.

    Science.gov (United States)

    Alagarasu, Kalichamy

    2016-05-27

    Diagnosis of dengue virus infections is complicated by preference for different diagnostic tests in different post onset days of illness and the presence of multiple serotypes leading to secondary and tertiary infections. The sensitivity of the most commonly employed diagnostic assays such as anti dengue IgM capture (MAC) ELISA and non structural protein (NS) 1 capture ELISA are lower in secondary and subsequent infections. Introduction of dengue vaccine in endemic regions will affect the way how dengue is diagnosed in vaccinated subjects. This viewpoint article discusses implications of introduction of dengue vaccine on the diagnosis of dengue infections in vaccinated subjects and the strategies that are needed to tackle the issue. PMID:27142330

  15. Interactions of conjugate vaccines and co-administered vaccines.

    Science.gov (United States)

    Findlow, H; Borrow, R

    2016-01-01

    Conjugate vaccines play an important role in the prevention of infectious diseases such as those caused by the bacteria Haemophilus influenzae (Hi) type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae. Vaccines developed against these 3 pathogens utilize 3 main carrier proteins, non-toxic mutant of diphtheria toxin (CRM197), diphtheria toxoid (DT) and tetanus toxoid (TT). Current pediatric immunisation schedules include the administration of several vaccines simultaneously, therefore increasing the potential for immune interference (both positively and negatively) to the antigens administered. Knowledge of vaccine interactions is principally derived from clinical trials, these are reviewed here to explore immune interference which may result of from carrier-specific T-cell helper interactions, bystander interference and carrier induced epitopic suppression. PMID:26619353

  16. Novel Vaccine against Venezuelan Equine Encephalitis Combines Advantages of DNA Immunization and a Live Attenuated Vaccine

    OpenAIRE

    Tretyakova, Irina; Lukashevich, Igor S; Glass, Pamela; Wang, Eryu; Weaver, Scott; Pushko, Peter

    2012-01-01

    DNA vaccines combine remarkable genetic and chemical stability with proven safety and efficacy in animal models, while remaining less immunogenic in humans. In contrast, live-attenuated vaccines have the advantage of inducing rapid, robust, long-term immunity after a single-dose vaccination. Here we describe novel iDNA vaccine technology that is based on an infectious DNA platform and combines advantages of DNA and live attenuated vaccines. We applied this technology for vaccination against i...

  17. A game dynamic model for vaccine skeptics and vaccine believers: measles as an example

    OpenAIRE

    Shim, Eunha; Grefenstette, John J.; Albert, Steven M.; Cakouros, Brigid E.; Burke, Donald S.

    2011-01-01

    Widespread avoidance of Measles-Mumps-Rubella vaccination (MMR), with a consequent increase in the incidence of major measles outbreaks, demonstrates that the effectiveness of vaccination programs can be thwarted by the public misperceptions of vaccine risk. By coupling game theory and epidemic models, we examine vaccination choice among populations stratified into two behavioral groups: vaccine skeptics and vaccine believers. The two behavioral groups are assumed to be heterogeneous with res...

  18. Is a low dose of hepatitis B vaccine enough for a rapid vaccination scheme?

    Institute of Scientific and Technical Information of China (English)

    Ru-Xiang Wang; Jan van Hattum; Gijsbert C. de Gast; Greet Boland; Ying Guo; Shao-Ping Lei; Chang-Hong Yang; Juan Chen; Jie Tian; Jin-Ying Wen; Ke-Hong Du

    2003-01-01

    AIM: To determine whether or not a low dose of HB vaccine can be effectively used in the rapid vaccination.METHODS: Rapid vaccination (0, 1, 2 months) with low dose (5 μg) or routine dose (10 μg) HB vaccine was studied in 250 subjects (130 school children and 120 university students). Serum from all the participants was tested for HBsAg, anti-HBs and anti-HBc at 1, 3 and 7 months after the first dose of vaccination and all subjects were serum HBV marks negative before the vaccination. Non-responders to a complete initial vaccination from university students were given an additional vaccination with 10 μg of HB vaccine and their serum anti-HBs was tested again one month later.RESULTS: One month after the third dose of vaccination (third month) sero-conversion rates and geometric mean titer (GMTs) were significantly (P<0.01) higher in the routine dose (resp. 89 % and 106.8) than in the low dose group (resp. 72 % and 59.5). Sero-conversion rates and GMTs were maintained stable for another 4 months in both groups.After an additional vaccination to non-responders with 10 μg HB vaccine, 17/23 subjects (13/15 from those vaccinated with 5 μg vaccine and 4/8 from those vaccinated with 10 μg vaccine) became anti-HBs positive, yielding similar seroconversion rates for both dose groups.CONCLUSION: Higher sero-conversion rates and GMTs were reached in those vaccinated with 10 μg HB vaccine than in those vaccinated with 5 μg HB vaccine after a comp~te vaccination with a 0, 1, 2 month scheme. But the subjects vaccinated with 5 μg vaccine can also reach the similar sero-conversion rate after an additional vaccination.

  19. THE AUSTRIAN VACCINATION PARADOX: TICK-BORNE ENCEPHALITIS VACCINATION VERSUS INFLUENZA VACCINATION.

    Science.gov (United States)

    Kunze, Ursula; Kunze, Michael

    2015-09-01

    This paper describes a paradoxical situation in Austria. The vaccination rate against tick-borne encephalitis (TBE) in the general population is 82%, which is the highest worldwide, whereas the vaccination rate against influenza is about 8% and is among the lowest worldwide. A high awareness of TBE among the Austrian population achieved by an annual social marketing programme and the wide use of effective and well-tolerated vaccines have led to a successful containment of that disease. The vaccination coverage increased from 6% in 1980 to 82% in 2013 and exceeds 90% in some high-risk areas. This has led to a steady decline in the number of TBE cases from several hundred cases to 50 to 100 cases per year. The situation in regard to influenza vaccination is the opposite. Although Austria has issued one of the most extensive recommendations for influenza vaccination worldwide, the vaccination rate of the general population is extremely low. The possible reasons for the failure in the implementation of recommendations are ignorance, lack of social marketing and the predominance of a distinct discordance within the health system in general, and the Austrian medical fraternity in particular. PMID:26615654

  20. Status of vaccine research and development of vaccines for leishmaniasis.

    Science.gov (United States)

    Gillespie, Portia M; Beaumier, Coreen M; Strych, Ulrich; Hayward, Tara; Hotez, Peter J; Bottazzi, Maria Elena

    2016-06-01

    A number of leishmaniasis vaccine candidates are at various stages of pre-clinical and clinical development. Leishmaniasis is a vector-borne neglected tropical disease (NTD) caused by a protozoan parasite of the genus Leishmania and transmitted to humans by the bite of a sand fly. Visceral leishmaniasis (VL, kala-azar) is a high mortality NTD found mostly in South Asia and East Africa, while cutaneous leishmaniasis (CL) is a disfiguring NTD highly endemic in the Middle East, Central Asia, North Africa, and the Americas. Estimates attribute 50,000 annual deaths and 3.3 million disability-adjusted life years to leishmaniasis. There are only a few approved drug treatments, no prophylactic drug and no vaccine. Ideally, an effective vaccine against leishmaniasis will elicit long-lasting immunity and protect broadly against VL and CL. Vaccines such as Leish-F1, F2 and F3, developed at IDRI and designed based on selected Leishmania antigen epitopes, have been in clinical trials. Other groups, including the Sabin Vaccine Institute in collaboration with the National Institutes of Health are investigating recombinant Leishmania antigens in combination with selected sand fly salivary gland antigens in order to augment host immunity. To date, both VL and CL vaccines have been shown to be cost-effective in economic modeling studies. PMID:26973063

  1. Mucin-Based Vaccines

    Science.gov (United States)

    Richardson, Jonathan P.; MacMillan, Derek

    Mucins are heavily O-glycosylated cell surface and secreted glycoproteins . In addition to orchestrating cell-extracellular matrix and cell-cell interactions in healthy organisms mucins are also the major carriers of altered glycosylation in carcinomas. Tumor-associated antigens displayed by cancer cells comprise oligosaccharide and glycopeptide motifs not encountered in the same locale or at the same frequency in healthy cells, and potentially confer a selective advantage to the tumor. Frequently tumor-associated antigens are under-glycosylated and prematurely sialylated, and it is these relatively simple saccharide and glycopeptide structures that have been targeted to serve as drug candidates in most cases. A major goal is to assemble glycopeptide vaccine candidates based on partial mucin sequences and displaying tumor-associated antigens that can mount a potent immunological tumor-specific response when, in reality, the tumor has already coerced the immune system into a state of co-existence.

  2. Vaccins contre les schistosomoses

    OpenAIRE

    D. Boulanger

    2000-01-01

    L'utilisation d'un vaccin faisant intervenir la mémoire immunitaire permettrait, d'une part, de contourner les problèmes posés par la chimiothérapie notamment la résistance au praziquantel et, d'autre part, d'espacer les interventions de contrôle. Les cibles théoriques sont la larve infestante, le ver adulte, l'oeuf ou le granulome inflammatoire, c'est-à-dire la réponse de l'hôte lors de la pénétration de la bilharzie dans les tissus. Des quatre candidats actuels, celui qui est le plus avancé...

  3. Immunogenicity of recombinant hepatitis B vaccine: comparison of two different vaccination schedules

    OpenAIRE

    Agladioglu, S.; Beyazova, U.; Camurdan, A. D.; Sahin, F.; Atak, A.

    2010-01-01

    Background Neonatal immunization with hepatitis B (HB) vaccine induces protective levels of antibody (anti-HBs ≥10 IU/L) in a majority of vaccines. However, the duration of protection after HB vaccination in infants is unknown. A smaller proportion of children vaccinated beginning at birth with three doses of HB vaccine were found to have protective titers 5–10 years after initial vaccination. Long-term efficacy of HB vaccine depends mainly on peak antibody levels after vaccination, and subje...

  4. Vaccine-related internet search activity predicts H1N1 and HPV vaccine coverage: implications for vaccine acceptance.

    Science.gov (United States)

    Kalichman, Seth C; Kegler, Christopher

    2015-01-01

    The Internet is a primary source for health-related information, and Internet search activity is associated with infectious disease outbreaks. The authors hypothesized that Internet search activity for vaccine-related information would predict vaccination coverage. They examined Internet search activity for H1N1 and human papilloma virus (HPV) disease and vaccine information in relation to H1N1 and HPV vaccine uptake. Google Insight for Search was used to assess the volume of Internet search queries for H1N1- and vaccine-related terms in the United States in 2009, the year of the H1N1 pandemic. Vaccine coverage data were also obtained from the Centers for Disease Control and Prevention at the state level for H1N1 vaccinations in 2009. These same measures were collected at the state level for HPV- and vaccine-related search terms in 2010 as well as HPV vaccine uptake in that year. Analyses showed that the search terms H1N1 and vaccine were correlated with H1N1 vaccine uptake; ordinal regression found the H1N1 search term was independently associated with H1N1 vaccine coverage. Similarly, the correlation between vaccine search volume and HPV coverage was significant; ordinal regression showed the search term vaccine independently predicted HPV vaccination coverage. This is among the first studies to show that Internet search activity is associated with vaccination coverage. The Internet should be exploited as an opportunity to dispel vaccine misinformation by providing accurate information to support vaccine decision making. PMID:25222149

  5. 儿童期急性白血病合并水痘的特点及其高危预后因素的临床分析%Clinical features of chickenpox and high risk factors of prognosis in childhood cases with acute lymphocytic leukemia

    Institute of Scientific and Technical Information of China (English)

    曾慧慧; 程澄; 陈志海; 李兴旺

    2015-01-01

    目的:分析儿童期急性淋巴细胞白血病(ALL)合并水痘的临床特点,探讨与预后相关的高危临床因素。方法对2008年1月1日~2014年12月31日首都医科大学附属北京地坛医院感染中心收治的儿童期ALL合并水痘的患儿及同期随机普通水痘患儿的临床资料进行回顾性对照分析。结果仅5例(31.25%)儿童期ALL患儿合并水痘有明确水痘接触史。13例(81.25%)儿童期ALL患儿合并水痘临床表现为高热,较普通水痘患儿热程长,为(7.38±3.32)d(t =5.575,P <0.05);皮疹结痂时间较长,为(10.92±2.50)d(t=4.928,P<0.05)。100%患儿出现骨髓抑制,其中10例(62.50%)患儿出现粒细胞缺乏,7例(43.75%)出现血小板减少;8例(50.00%)患儿肝功能异常。儿童期ALL患儿合并水痘经抗病毒、对症支持等治疗,临床治愈11例,自动出院4例,死亡1例。儿童期ALL患儿合并水痘临床表现危重和最终死亡者,具有应用静脉药物化疗方案治疗、化疗中或完成静脉化疗1周内罹患水痘、所有病例均出现骨髓抑制粒细胞缺乏且持续较长时间[(10.08±2.77) d]等特点。结论儿童期ALL患儿合并水痘具有临床症状持续时间长、并发骨髓抑制粒细胞减少等特点,经积极抗病毒及对症支持治疗后预后良好。应用静脉药物化疗中或完成化疗1周内罹患水痘、持续性粒细胞缺乏是与儿童期ALL患儿并发水痘预后不良的临床相关因素。%Objective To investigate the clinical features of chickenpox and the high risk factors of the prognosis in childhood patients with acute lymphocytic leukemia (ALL). Methods The clinical characteristics of chickenpox in childhood ALL patients hospitalized in Beijing Ditan Hospital, Capital Medical University, from January 1st, 2008 to December 31st, 2014 were studied, retrospectively, and the features of random ordinary children onset chickenpox

  6. Neurologic Complications of Smallpox Vaccination

    Directory of Open Access Journals (Sweden)

    J Gordon Millichap

    2003-06-01

    Full Text Available Smallpox and smallpox vaccination is reviewed from the Departments of Neurology, Yale University School of Medicine, New Haven, CT, and University of New Mexico School of Medicine, Albuquerque.

  7. Synthetic vaccines: Immunity without harm

    Science.gov (United States)

    Acharya, Abhinav P.; Murthy, Niren

    2011-03-01

    Multilamellar lipid vesicles with crosslinked walls carrying protein antigens in the vesicle core and immunostimulatory drugs in the vesicle walls generate immune responses comparable to the strongest live vector vaccines.

  8. HPV Vaccine - Questions and Answers

    Science.gov (United States)

    ... and Media Resources News Newsletters Events Redirect for HPV Vaccine FAQ Recommend on Facebook Tweet Share Compartir ... to the address below. http://www.cdc.gov/hpv/parents/questions-answers.html File Formats Help: How ...

  9. What Vaccinations Do You Need?

    Science.gov (United States)

    ... I have more questions? If you have additional questions about vaccinations, speak to your doctor and health care team. You may also be interested in reading What You Should Know About Infectious Diseases: A ...

  10. Veterinary vaccines against Toxoplasma gondii

    Directory of Open Access Journals (Sweden)

    Elisabeth A Innes

    2009-03-01

    Full Text Available Toxoplasma gondii has a very wide intermediate host range and is thought to be able to infect all warm blooded animals. The parasite causes a spectrum of different diseases and clinical symptoms within the intermediate hosts and following infection most animals develop adaptive humoral and cell-mediated immune responses. The development of protective immunity to T. gondii following natural infection in many host species has led researchers to look at vaccination as a strategy to control disease, parasite multiplication and establishment in animal hosts. A range of different veterinary vaccines are required to help control T. gondii infection which include vaccines to prevent congenital toxoplasmosis, reduce or eliminate tissue cysts in meat producing animals and to prevent oocyst shedding in cats. In this paper we will discuss some of the history, challenges and progress in the development of veterinary vaccines against T. gondii.

  11. Pneumococcal Vaccination: Who Needs It?

    Science.gov (United States)

    ... Resources News Newsletters Events Pneumococcal Vaccination: Who Needs It? Recommend on Facebook Tweet Share Compartir There are ... healthy, do not need to get PPSV23 because it is not effective against those conditions. For additional ...

  12. Addressing viral resistance through vaccines

    Science.gov (United States)

    Laughlin, Catherine; Schleif, Amanda; Heilman, Carole A

    2015-01-01

    Antimicrobial resistance is a serious healthcare concern affecting millions of people around the world. Antiviral resistance has been viewed as a lesser threat than antibiotic resistance, but it is important to consider approaches to address this growing issue. While vaccination is a logical strategy, and has been shown to be successful many times over, next generation viral vaccines with a specific goal of curbing antiviral resistance will need to clear several hurdles including vaccine design, evaluation and implementation. This article suggests that a new model of vaccination may need to be considered: rather than focusing on public health, this model would primarily target sectors of the population who are at high risk for complications from certain infections. PMID:26604979

  13. Vaccine Therapy for Unresectable Chordoma

    Science.gov (United States)

    In this phase II clinical trial, adult patients with inoperable chordoma who are scheduled to undergo radiation therapy will be randomly assigned to receive a yeast-based vaccine that targets a protein called brachyury or a placebo injection.

  14. Melanoma vaccines: trials and tribulations

    Directory of Open Access Journals (Sweden)

    Dillman RO

    2013-10-01

    Full Text Available Robert O Dillman1,21Hoag Cancer Institute and Hoag Institute for Research and Education, Newport Beach, CA, USA; 2University of California Irvine, Irvine, CA, USAAbstract: Metastatic melanoma has been a target of immunotherapy for more than 4 decades. Three immunotherapeutics have received regulatory approval for treating melanoma: interferon-alpha, interleukin-2, and ipilimumab. The antitumor mechanisms of these products depend on enhancing existing immune responses, including autoimmune effects. The combination of autologous, cytotoxic T-lymphocytes plus high-dose interleukin-2 is a promising patient-specific therapy, but has limited clinical application. Other approaches include vaccines targeting melanoma-associated antigens, and patient-specific vaccines that utilize autologous tumor. Non-patient-specific vaccine approaches target melanocyte differentiation antigens (eg, tyrosinase, Melan-A, gp100, antigens identified by cytotoxic T-lymphocytes (eg, NY-Eso-1, Melan-A/Mart-1, Mage-3, and antigens originally identified by murine monoclonal antibodies (gangliosides, gp97, gp225. Self-renewing cells in tumor cell lines may represent tumor stem cells, but vaccines derived from allogeneic tumor cell lines have yielded disappointing results in randomized trials. Patient-specific vaccines can be derived from bulk autologous tumor or autologous tumor cell lines, and intratumoral injections of immunostimulatory fusion products have shown promise. While technically more complex to manufacture, patient-specific vaccines derived from autologous tumor cell lines have the potential to target tumor stem cells and overcome interpatient tumor cell heterogeneity. This article reviews sources of melanoma-associated antigens, costimulatory agents, and clinical trial results for various melanoma vaccines. Comparing Phase II trials is difficult because of the wide range of vaccine strategies and the differences in study patient populations; therefore, randomized

  15. Vaccination Confidence and Parental Refusal/Delay of Early Childhood Vaccines

    Science.gov (United States)

    Gilkey, Melissa B.; McRee, Annie-Laurie; Magnus, Brooke E.; Reiter, Paul L.; Dempsey, Amanda F.; Brewer, Noel T.

    2016-01-01

    Objective To support efforts to address parental hesitancy towards early childhood vaccination, we sought to validate the Vaccination Confidence Scale using data from a large, population-based sample of U.S. parents. Methods We used weighted data from 9,354 parents who completed the 2011 National Immunization Survey. Parents reported on the immunization history of a 19- to 35-month-old child in their households. Healthcare providers then verified children’s vaccination status for vaccines including measles, mumps, and rubella (MMR), varicella, and seasonal flu. We used separate multivariable logistic regression models to assess associations between parents’ mean scores on the 8-item Vaccination Confidence Scale and vaccine refusal, vaccine delay, and vaccination status. Results A substantial minority of parents reported a history of vaccine refusal (15%) or delay (27%). Vaccination confidence was negatively associated with refusal of any vaccine (odds ratio [OR] = 0.58, 95% confidence interval [CI], 0.54–0.63) as well as refusal of MMR, varicella, and flu vaccines specifically. Negative associations between vaccination confidence and measures of vaccine delay were more moderate, including delay of any vaccine (OR = 0.81, 95% CI, 0.76–0.86). Vaccination confidence was positively associated with having received vaccines, including MMR (OR = 1.53, 95% CI, 1.40–1.68), varicella (OR = 1.54, 95% CI, 1.42–1.66), and flu vaccines (OR = 1.32, 95% CI, 1.23–1.42). Conclusions Vaccination confidence was consistently associated with early childhood vaccination behavior across multiple vaccine types. Our findings support expanding the application of the Vaccination Confidence Scale to measure vaccination beliefs among parents of young children. PMID:27391098

  16. Vaccination Confidence and Parental Refusal/Delay of Early Childhood Vaccines.

    Directory of Open Access Journals (Sweden)

    Melissa B Gilkey

    Full Text Available To support efforts to address parental hesitancy towards early childhood vaccination, we sought to validate the Vaccination Confidence Scale using data from a large, population-based sample of U.S. parents.We used weighted data from 9,354 parents who completed the 2011 National Immunization Survey. Parents reported on the immunization history of a 19- to 35-month-old child in their households. Healthcare providers then verified children's vaccination status for vaccines including measles, mumps, and rubella (MMR, varicella, and seasonal flu. We used separate multivariable logistic regression models to assess associations between parents' mean scores on the 8-item Vaccination Confidence Scale and vaccine refusal, vaccine delay, and vaccination status.A substantial minority of parents reported a history of vaccine refusal (15% or delay (27%. Vaccination confidence was negatively associated with refusal of any vaccine (odds ratio [OR] = 0.58, 95% confidence interval [CI], 0.54-0.63 as well as refusal of MMR, varicella, and flu vaccines specifically. Negative associations between vaccination confidence and measures of vaccine delay were more moderate, including delay of any vaccine (OR = 0.81, 95% CI, 0.76-0.86. Vaccination confidence was positively associated with having received vaccines, including MMR (OR = 1.53, 95% CI, 1.40-1.68, varicella (OR = 1.54, 95% CI, 1.42-1.66, and flu vaccines (OR = 1.32, 95% CI, 1.23-1.42.Vaccination confidence was consistently associated with early childhood vaccination behavior across multiple vaccine types. Our findings support expanding the application of the Vaccination Confidence Scale to measure vaccination beliefs among parents of young children.

  17. Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.

    Science.gov (United States)

    Suarez-Castaneda, Eduardo; Burnett, Eleanor; Elas, Miguel; Baltrons, Rafael; Pezzoli, Lorenzo; Flannery, Brendan; Kleinbaum, David; de Oliveira, Lucia Helena; Danovaro-Holliday, M Carolina

    2015-11-27

    Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP-HepB-Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag behind that of pentavalent vaccine, even in years when national rotavirus vaccine stock-outs have not occurred. We analyzed factors associated with receipt of oral rotavirus vaccine among children who received at least 2 doses of pentavalent vaccine in a stratified cluster survey of children aged 24-59 months conducted in El Salvador in 2011. Vaccine doses included were documented on vaccination cards (94.4%) or in health facility records (5.6%). Logistic regression and survival analysis were used to assess factors associated with vaccination status and age at vaccination. Receipt of pentavalent vaccine by age 15 weeks was associated with rotavirus vaccination (OR: 5.1; 95% CI 2.7, 9.4), and receipt of the second pentavalent dose by age 32 weeks was associated with receipt of two rotavirus vaccine doses (OR: 5.0; 95% CI 2.1-12.3). Timely coverage with the first pentavalent vaccine dose was 88.2% in the 2007 cohort and 91.1% in the 2008 cohort (p=0.04). Children born in 2009, when a four-month national rotavirus vaccine stock-out occurred, had an older median age of receipt of rotavirus vaccine and were less likely to receive rotavirus on the same date as the same dose of pentavalent vaccine than children born in 2007 and 2008. Upper age limit recommendations for rotavirus vaccine administration contributed to suboptimal vaccination coverage. Survey data suggest that late rotavirus vaccination and co-administration with later doses of pentavalent vaccine among children born in 2009 helped increase rotavirus vaccine coverage following shortages. PMID:26263200

  18. Therapeutic Vaccines for Chronic Infections

    Science.gov (United States)

    Autran, Brigitte; Carcelain, Guislaine; Combadiere, Béhazine; Debre, Patrice

    2004-07-01

    Therapeutic vaccines aim to prevent severe complications of a chronic infection by reinforcing host defenses when some immune control, albeit insufficient, can already be demonstrated and when a conventional antimicrobial therapy either is not available or has limited efficacy. We focus on the rationale and challenges behind this still controversial strategy and provide examples from three major chronic infectious diseases-human immunodeficiency virus, hepatitis B virus, and human papillomavirus-for which the efficacy of therapeutic vaccines is currently being evaluated.

  19. Social networks and vaccination decisions

    OpenAIRE

    Rao, Neel; Möbius, Markus M.; Rosenblat, Tanya

    2007-01-01

    We combine information on social networks with medical records and survey data in order to examine how friends affect one’s decision to get vaccinated against the flu. The random assignment of undergraduates to residential halls at a large private university allows us to estimate how peer effects influence health beliefs and vaccination choices. Our results indicate that social exposure to medical information raises people’s perceptions of the benefits of immunization. The average student’s b...

  20. Priorities for CMV vaccine development.

    Science.gov (United States)

    Krause, Philip R; Bialek, Stephanie R; Boppana, Suresh B; Griffiths, Paul D; Laughlin, Catherine A; Ljungman, Per; Mocarski, Edward S; Pass, Robert F; Read, Jennifer S; Schleiss, Mark R; Plotkin, Stanley A

    2013-12-17

    A multidisciplinary meeting addressed priorities related to development of vaccines against cytomegalovirus (CMV), the cause of congenital CMV (cCMV) disease and of serious disease in the immunocompromised. Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the value of additional research. A universal childhood CMV vaccine could potentially rapidly reduce cCMV disease, as infected children are sources of viral transmission to seronegative and seropositive mothers. A vaccine administered to adolescents or adult women could also reduce cCMV disease by making them immune prior to pregnancy. Clinical trials of CMV vaccines in women should evaluate protection against cCMV infection, an essential precursor of cCMV disease, which is a more practical and acceptable endpoint for assessing vaccine effects on maternal-fetal transmission. Clinical trials of vaccines to evaluate prevention of CMV disease in stem cell transplant recipients could use CMV viremia at a level triggering pre-emptive antiviral therapy as an endpoint, because widespread use of pre-emptive and prophylactic antivirals has rendered CMV-induced disease too rare to be a practical endpoint for clinical trials. In solid organ transplant patients, CMV-associated disease is sufficiently common for use as a primary endpoint. Additional research to advance CMV vaccine development should include identifying factors that predict fetal loss due to CMV, determining age-specific incidence and transmission rates, defining the mechanism and relative contributions of maternal reactivation and re-infection to cCMV disease, developing assays that can distinguish between reactivation and re-infection in seropositive vaccinees, further defining predictors of sequelae from cCMV infection, and identifying clinically relevant immune response parameters to CMV (including developing validated assays that could assess CMV antibody avidity) that could lead to the establishment of immune

  1. Is an HIV vaccine possible?

    Directory of Open Access Journals (Sweden)

    Nancy A. Wilson

    2009-08-01

    Full Text Available The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult over the ensuing twenty years. Most vaccines are developed by inducing neutralizing antibodies against the target pathogen or by using attenuated strains of the particular pathogen to engender a variety of protective immune responses. Unfortunately, simple methods of generating anti-HIV antibodies have already failed in a phase III clinical trial. While attenuated SIV variants work well against homologous challenges in non-human primates, the potential for reversion to a more pathogenic virus and recombination with challenge viruses will preclude the use of attenuated HIV in the field. It has been exceedingly frustrating to vaccinate for HIV-specific neutralizing antibodies given the enormous diversity of the Envelope (Env glycoprotein and its well-developed glycan shield. However, there are several antibodies that will neutralize many different strains of HIV and inducing these types of antibodies in vaccinees remains the goal of a vigorous effort to develop a vaccine for HIV based on neutralizing antibodies. Given the difficulty in generating broadly reactive neutralizing antibodies, the HIV vaccine field has turned its attention to inducing T cell responses against the virus using a variety of vectors. Unfortunately, the results from Merck's phase IIb STEP trial proved to be disappointing. Vaccinees received Adenovirus type 5 (Ad5 expressing Gag, Pol, and Nef of HIV. This vaccine regimen failed to either prevent infection or reduce the level of HIV replication after challenge. These results mirrored those in non-human primate testing of Ad5 using rigorous SIV challenge models. This review will focus on recent developments in HIV vaccine development. We will deal largely with attempts to develop a T cell-based vaccine using the non-human primate SIV challenge model.

  2. Hepatitis virus vaccines: present status.

    OpenAIRE

    Krugman, S.

    1982-01-01

    During the past decade there has been extraordinary progress toward the development of vaccines for the prevention of type A and type B hepatitis. The successful propagation of hepatitis A virus in cell culture in 1979 was followed by the preparation of experimental live attenuated hepatitis A vaccines that have been shown to induce antibody in marmosets and chimpanzees and protect immunized marmosets against challenge with hepatitis A virus. The first human immunization trials will begin in ...

  3. VACCINATION IN RHEUMATOLOGY: CURRENT ASPECTS

    OpenAIRE

    B S Belov; M. S. Naumtseva; G M Tarasova; M V Polyanskaya

    2014-01-01

    Infectious diseases still remain a serious social and medical problem. The importance of comorbid infections in rheumatology has increased substantially in recent years, particularly due to the clinical introduction of biologicals. The investigation and active use of different vaccines are one of the ways to solve the above problem. This review considers the issues concerning the use of vaccines against influenza, infections caused by pneumococci, herpesviruses, human papillomavirus, and hepa...

  4. Immune Response After Measles Vaccination

    Directory of Open Access Journals (Sweden)

    Bhardwaj A.K

    1991-01-01

    Full Text Available Measles immunization of 192 under 5 years of age children was undertaken and the overall seroconversion was 76.0%. Seroconversion rate in the age group of 9-12 months was 70.9% and it was 100% after one year. Immune response in malnourished children was more as compared to normal children. There were negligible side reactions after measles vaccination, and this vaccine passed normal potency tests under field conditions.

  5. [Towards a new vaccine economy?].

    Science.gov (United States)

    Poirot, P; Martin, J F

    1994-01-01

    When Jonas Salk announced in the mid-50s the availability of a new vaccine against poliomyelitis, the world had the impression that it was now controlling infectious diseases. In fact, the success of this vaccine has been considerable and although some innovations lead to the launch of vaccines against flu, measles, rubella or mumps, the world vaccine market remained remarkably stable till the mid-80s. However, since 1984 (launch of the hepatitis B vaccine) there have been very substantial changes and further change is expected in the next ten years in the world market. Today, big companies are making a concentrated supply: Pasteur Mérieux with its subsidiary Connaught, SmithKline Beecham who acquired the Belgian company RIT, and Merck & Co. who is joining its forces with Pasteur Mérieux. Medium sized and small companies remain and reflect the situation of the past, but must work hard to secure their long term existence eventhough the world demand is going to double before the year 2000. Very substantial technological innovations explain to a large extent the development of the supply: progress in molecular biology, and particularly genetic engineering, lead to recombinant vaccines of which hepatitis B is the best example with worldwide sales in the range of $600 million a year. Similarly, conjugation technologies have allowed the development of new vaccines against meningitis, particularly Haemophilus influenzae type b. More recently, an efficacious vaccine against hepatitis A has been launched and many new products will be marketed in the next years against herpes, Lyme disease, and agents of other meningitis, etc.(ABSTRACT TRUNCATED AT 250 WORDS) PMID:7921683

  6. Assembly and Assessment of DNA Scaffolded Vaccines.

    Science.gov (United States)

    Liu, Xiaowei; Wang, Lili; Yan, Hao; Chang, Yung

    2016-01-01

    Vaccines play an important role in preventing many life-threatening infectious diseases. To meet the demand of vaccination for treating a wide range of diseases, rational vaccine design has been recognized as a desirable and necessary strategy for development of safe and effective vaccines. DNA nanostructures are advantageous in the design and construction of synthetic vaccines, owing to their robust self-assembly, programmability, and precision control in complex organization, as well as their intrinsic adjuvant activity. Here, we describe a modular assembly of DNA scaffolded vaccine complex, composing of a model antigen, streptavidin, and adjuvant, CpG oligonucleotide. The DNA-assembled vaccines were found to elicit strong antigen-specific antibody responses, but causing little or no adverse reactions. Conceivably, this vaccine platform can be further optimized for improved immunogenicity and extended to the construction of various subunit vaccines. PMID:27076307

  7. Mucosal adjuvants to improve wildlife rabies vaccination.

    Science.gov (United States)

    Fry, Tricia; Van Dalen, Kaci; Hurley, Jerome; Nash, Paul

    2012-10-01

    RABORAL V-RG(®)a is a recombinant vaccine used in oral rabies vaccination (ORV) programs for wildlife in the United States. Vaccination rates for raccoons are substantially lower than vaccination rates for gray foxes and coyotes. Research suggests that the low viscosity of the oral vaccine may preclude animals from receiving an effective dose when biting into the vaccine bait delivery system. We evaluated the possibility of using two benign compounds, chitosan and N,N,N-trimethylated chitosan (TMC), to increase the viscosity of the vaccine and potentially act as adjuvants to improve the immune response in raccoons (Procyon lotor). Forty mildly sedated raccoons were orally vaccinated via needleless syringe with either RABORAL V-RG (n = 12), chitosan+RABORAL V-RG (n = 12), TMC+ RABORAL V-RG (n = 12), or no vaccine (n = 4), on day 0 and again on day 90. We collected sera every 2-4 wk for 4 mo and evaluated rabies virus-neutralizing antibodies (rVNA). Raccoons were considered responders if rVNA titers were ≥ 0.1 IU/mL. Eleven of 12 raccoons vaccinated with TMC+RABORAL V-RG responded after one dose of vaccine, as did eight of 12 vaccinated with RABORAL V-RG, and three of 12 vaccinated with chitosan+ RABORAL V-RG. Our results suggest that the inclusion of an adjuvant, such as TMC, could increase vaccine efficacy to aid in controlling rabies virus spread in wildlife reservoirs. PMID:23060506

  8. Differences in HIV vaccine acceptability between genders.

    Science.gov (United States)

    Kakinami, Lisa; Newman, Peter A; Lee, Sung-Jae; Duan, Naihua

    2008-05-01

    The development of safe and efficacious preventive HIV vaccines offers the best long-term hope of controlling the AIDS pandemic. Nevertheless, suboptimal uptake of safe and efficacious vaccines that already exist suggest that HIV vaccine acceptability cannot be assumed, particularly among communities most vulnerable to HIV. The present study aimed to identify barriers and motivators to future HIV vaccine acceptability among low socioeconomic, ethnically diverse men and women in Los Angeles County. Participants completed a cross-sectional survey assessing their attitudes and beliefs regarding future HIV vaccines. Hypothetical HIV vaccine scenarios were administered to determine HIV vaccine acceptability. Two-sided t-tests were performed, stratified by gender, to examine the association between vaccine acceptability and potential barriers and motivators. Barriers to HIV vaccine acceptability differed between men and women. For women, barriers to HIV vaccine acceptability were related to their intimate relationships (pnegative experiences with health care providers (pGender-specific interventions may increase vaccine acceptability among men and women at elevated risk for HIV infection. Among women, interventions need to focus on addressing barriers due to gendered power dynamics in relationships and discrimination in health care. Among men, education that addresses fears and misconceptions about adverse effects of HIV vaccination on health and the importance of vaccination as one component of integrated HIV prevention may increase vaccine acceptability. PMID:18484322

  9. Tuberculosis: looking beyond BCG vaccines.

    Directory of Open Access Journals (Sweden)

    Mustafa Abu S

    2003-01-01

    Full Text Available Tuberculosis (TB is an infectious disease of international importance and ranks among the top 10 causes of death in the World. About one-third of the world′s population is infected with Mycobacterium tuberculosis. Every year, approximately eight million people develop active disease and two million die of TB. The currently used BCG vaccines have shown variable protective efficacies against TB in different parts of the world. Moreover, being a live vaccine, BCG can be pathogenic in immunocompromised recipients. Therefore, there is an urgent need to develop new vaccines against TB. The comparative genome analysis has revealed the existence of several M. tuberculosis-specific regions that are deleted in BCG. The work carried out to determine the immunological reactivity of proteins encoded by genes located in these regions revealed several major antigens of M. tuberculosis, including the 6 kDa early secreted antigen target (ESAT6. Immunization with ESAT6 and its peptide (aa51-70 protects mice challenged with M. tuberculosis. The protective efficacy of immunization further improves when ESAT6 is recombinantly fused with M. tuberculosis antigen 85B. In addition, ESAT6 delivered as a DNA vaccine is also protective in mice. Whether these vaccines would be safe or not cannot be speculated. The answer regarding the safety and efficacy of these vaccines has to await human trials in different parts of the world.

  10. Adult Vaccinations | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Adult Vaccinations Adults Need Vaccines, Too! Past Issues / Summer 2015 Table ... cough). Are you one of the millions of adults not receiving the vaccines you need? What vaccines ...

  11. HPV vaccine (human papillomavirus) Cervarix - what you need to know

    Science.gov (United States)

    ... changes or ringing in the ears. Like all vaccines, HPV vaccines will continue to be monitored for unusual ... Vaccine information statement: HPV (Human Papillomavirus) Cervarix ® VIS. Centers for Disease Control and Prevention Web site. www.cdc.gov/vaccines/ ...

  12. VIROSOMES: A NOVEL VACCINATION TECHNOLOGY

    Directory of Open Access Journals (Sweden)

    Priyanka Rathore et al

    2012-01-01

    Full Text Available Vaccine development has continuously shifted away from live attenuated or inactivated whole organisms. Although this approach having good efficacy but for improvement on comparison of risk/benefit ratio which needs improvement due to their highly complex compositions which result in safety concerns. As a consequence, a number of indications remained unadressed. The next generation vaccines represented as subunit vaccines, whereby the only pathogens fragments used which are relevant in inducing protective immunity. For the successful subunit vaccination two major key requirements are safe carrier and adjuvant system, since the small, isolated pathogen fragments themselves are generally weak immunogens. Pevion’s virus-like particle (VLP vaccine technology, called virosomes, and their design is specifically for the development of safe and effective subunit vaccines. Virosomes based vaccination has already been approved in more than 40 countries, including for elderly and infants. It is successful in solid regulatory & safety track record as well as the feasibility of production upscaling. The outstanding profile with combined efficacy and safety of virosomes-based vaccines are known for its origin in the unique mode of action of these multifunctional particles. It leads to a comprehensive induction of a complete immune response, in contrast to single-sided triggers. Virosomes are reconstituted viral envelopes that can serve as vaccines and as vehicles for cellular delivery of macromolecules. The prospect of drug delivery and targeting using virosomes is an interesting field of research and development. As virosomes are biocompatible, biodegradable, nontoxic, and non-autoimmunogenic, and various attempts have been made to use them as vaccines or adjuvants as well as delivery system for drugs, nuleic acids, nucleic acids, or genes for therapeutic purposes. The virus of choice is influenza virus. Virosomal drug delivery depends on the methods used

  13. Parental Vaccine Hesitancy in Quebec (Canada)

    Science.gov (United States)

    Dubé, Eve; Gagnon, Dominique; Zhou, Zhou; Deceuninck, Genevieve

    2016-01-01

    Introduction: "Vaccine hesitancy" is a concept frequently used in the discourse around vaccine acceptance. This study aims to contribute to the ongoing reflections on tools and indicators of vaccine hesitancy by providing results of a knowledge, attitudes and beliefs (KAB) survey conducted among parents. Methods: Data were collected in 2014 through a computer-assisted telephone interview survey administered to a sample of parents of children aged between 2 months and 17 years of age. Results: The majority of the 589 parents included in the analyses agreed on the importance of vaccination to protect their children’s health and to prevent the spread of diseases in the community. The majority of the parents (81%) reported that their child had received all doses of recommended vaccines and 40% of parents indicated having hesitated to have their child vaccinated. Fear of adverse events and low perceived vulnerability of the child or severity of the disease were the most frequent reasons mentioned by these vaccine-hesitant parents. In multivariate analyses, KAB items remaining significantly associated both with an incomplete vaccination status of the child and parents’ vaccine hesitancy were: not thinking that it is important to have the child vaccinated to prevent the spreading of diseases in the community; not trusting the received vaccination information and having felt pressure to have the child vaccinated. Discussion: Further researches will be needed to better understand when, how and why these beliefs are formed in order to prevent the onset of vaccine hesitancy. PMID:27019766

  14. Pneumococcal Vaccination Strategies. An Update and Perspective.

    Science.gov (United States)

    Berical, Andrew C; Harris, Drew; Dela Cruz, Charles S; Possick, Jennifer D

    2016-06-01

    Streptococcus pneumoniae is an important global pathogen that causes a wide range of clinical disease in children and adults. Pneumococcal pneumonia is by far the common presentation of noninvasive and invasive pneumococcal disease and affects the young, the elderly, and the immunocompromised disproportionately. Patients with chronic pulmonary diseases are also at higher risk for pneumococcal infections. Substantial progress over the century has been made in the understanding of pneumococcal immunobiology and the prevention of invasive pneumococcal disease through vaccination. Currently, two pneumococcal vaccines are available for individuals at risk of pneumococcal disease: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the 13-valent pneumococcal protein-conjugate vaccine (PCV13). The goal of pneumococcal vaccination is to stimulate effective antipneumococcal antibody and mucosal immunity response and immunological memory. Vaccination of infants and young children with pneumococcal conjugate vaccine has led to significant decrease in nasal carriage rates and pneumococcal disease in all age groups. Recent pneumococcal vaccine indication and schedule recommendations on the basis of age and risk factors are outlined in this Focused Review. As new pneumococcal vaccine recommendations are being followed, continued efforts are needed to address the vaccine efficacy in the waning immunity of the ever-aging population, the implementation of vaccines using two different vaccines under very specific schedules and their real world clinical and cost effectiveness, and the development of next generation pneumococcal vaccines. PMID:27088424

  15. Vaccine hesitancy: understanding better to address better.

    Science.gov (United States)

    Kumar, Dewesh; Chandra, Rahul; Mathur, Medha; Samdariya, Saurabh; Kapoor, Neelesh

    2016-01-01

    Vaccine hesitancy is an emerging term in the socio-medical literature which describes an approach to vaccine decision making. It recognizes that there is a continuum between full acceptance and outright refusal of some or all vaccines and challenges the previous understanding of individuals or groups, as being either anti-vaccine or pro-vaccine. The behaviours responsible for vaccine hesitancy can be related to confidence, convenience and complacency. The causes of vaccine hesitancy can be described by the epidemiological triad i.e. the complex interaction of environmental- (i.e. external), agent- (i.e. vaccine) and host (or parent)- specific factors. Vaccine hesitancy is a complex and dynamic issue; future vaccination programs need to reflect and address these context-specific factors in both their design and evaluation. Many experts are of the view that it is best to counter vaccine hesitancy at the population level. They believe that it can be done by introducing more transparency into policy decision-making before immunization programs, providing up-to-date information to the public and health providers about the rigorous procedures undertaken before introduction of new vaccines, and through diversified post-marketing surveillance of vaccine-related events. PMID:26839681

  16. Vaccines and IP Rights: A Multifaceted Relationship.

    Science.gov (United States)

    Durell, Karen

    2016-01-01

    Just as there are many forms of vaccines and components to vaccines-particular compositions, delivery systems, components, and distribution networks-there are a variety of intellectual property (IP) protections applicable for vaccines. IP rights such as patent, copyright, trademarks, plant breeders' rights, and trade secrets may all be applicable to vaccines. Thus, discussion of IP rights and vaccines should not begin and end with the application of one IP right to a vaccine. The discussion should engage considerations of multiple IP rights applicable to a vaccine and how these can be utilized in an integrated manner in a strategy aimed at supporting the development and distribution of the vaccine. Such an approach to IP rights to vaccines allows for the integrated rights to be considered in light of the justifications for protecting vaccines with IP rights, as well as the issues relating to specific IP rights for vaccines, such as compulsory license regimes, available humanitarian purpose IP credits, etc. To view vaccines as the subject of multiple IP protections involves a refocusing, but the outcome can provide significant benefits for vaccine development and distribution. PMID:27076338

  17. Self-reported vaccination in the elderly

    Science.gov (United States)

    Reyes-Ortiz, Carlos; Borda, Miguel German; Arciniegas, Antonio

    2016-01-01

    Objectives: To determine the frequency of vaccination in older adults within the city of Bogotá and to estimate the association with sociodemographic and health factors. Methods: This is a secondary data analysis from the SABE-Bogotá Study, a cross-sectional population-based study that included a total of 2,000 persons aged 60 years. Weighted percentages for self-reported vaccination [influenza, pneumococcal, tetanus] were determined. The association between vaccination and covariates was evaluate by logistic regression models. Results: A total of 73.0% of respondents received influenza, 57.8% pneumococcal and 47.6% tetanus vaccine. Factors independently associated with vaccination included: 1- age (65-74 years had higher odds of receiving vaccinations, compared to 60-64 years); 2- socioeconomic status (SES) (higher SES had lower odds of having influenza and pneumococcal vaccines, compared to those with lower SES); 3- health insurance (those with contributive or subsidized health insurance had higher odds (between 3 and 5 times higher) of having vaccinations, compared to those with no insurance); 4- older adults with better functional status (greater Lawton scores) had increased odds for all vaccinations; 5- older adults with higher comorbidity had increased odds for influenza and pneumococcal vaccinations. Conclusion: Vaccination campaigns should be strengthened to increase vaccination coverage, especially in the group more reticent to vaccination or vulnerable to reach it such as the disabled elder. PMID:27226661

  18. Effective Vaccine for Lassa Fever

    Science.gov (United States)

    Fisher-Hoch, S. P.; Hutwagner, L.; Brown, B.; McCormick, J. B.

    2000-01-01

    Lassa fever has been estimated to cause 5,000 deaths annually in West Africa. Recently, war in the zone where Lassa fever is hyperendemic has severely impeded control and treatment. Vaccination is the most viable control measure. There is no correlation between antibody levels and outcome in human patients, and inactivated vaccines produce high titers of antibodies to all viral proteins but do not prevent virus replication and death in nonhuman primates. Accordingly, we vaccinated 44 macaques with vaccinia virus-expressed Lassa virus structural proteins separately and in combination, with the object of inducing a predominantly TH1-type immune response. Following Lassa virus challenge, all unvaccinated animals died (0% survival). Nine of 10 animals vaccinated with all proteins survived (90% survival). Although no animals that received full-length glycoprotein alone had a high titer of antibody, 17 of 19 survived challenge (88%). In contrast, all animals vaccinated with nucleoprotein developed high titers of antibody but 12 of 15 died (20% survival). All animals vaccinated with single glycoproteins, G1 or G2, died, but all those that received both single glycoproteins (G1 plus G2) at separate sites survived, showing that both glycoproteins are independently important in protection. Neither group had demonstrable antibody levels prior to challenge. We demonstrate that in primates, immune responses to epitopes on both glycoproteins are required to protect against lethal challenge with Lassa virus without having untoward side effects and that this protection is likely to be primarily cell mediated. We show that an effective, safe vaccine against Lassa virus can and should be made and that its evaluation for human populations is a matter of humanitarian priority. PMID:10888616

  19. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.

    Science.gov (United States)

    2003-01-01

    MedImmune Vaccines (formerly Aviron) has developed a cold-adapted live influenza virus vaccine [FluMist] that can be administered by nasal spray. FluMist is the first live virus influenza vaccine and also the first nasally administered vaccine to be marketed in the US. The vaccine will be formulated to contain live attenuated (att) influenza virus reassortants of the strains recommended by the US Public Health Service for each 'flu season. The vaccine is termed cold-adapted (ca) because the virus has been adapted to replicate efficiently at 25 degrees C in the nasal passages, which are below normal body temperature. The strains used in the seasonal vaccine will also be made temperature sensitive (ts) so that their replication is restricted at 37 degrees C (Type B strains) and 39 degrees C (Type A strains). The combined effect of the antigenic properties and the att, ca and ts phenotypes of the influenza strains contained in the vaccine enables the viruses to replicate in the nasopharynx to produce protective immunity. The original formulation of FluMist requires freezer storage throughout distribution. Because many international markets do not have distribution channels well suited to the sale of frozen vaccines, Wyeth and MedImmune are collaborating to develop a second generation, refrigerator-stable, liquid trivalent cold-adapted influenza vaccine (CAIV-T), which is in phase III trials. Initially, the frozen formulation will only be available in the US. For the 2003-2004 season, FluMist will contain A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) (A/Moscow/10/99-like) and B/Hong Kong/330/2001. Aviron was acquired by MedImmune on 15 January 2002. Aviron is now a wholly-owned subsidiary of MedImmune and is called MedImmune Vaccines. Aviron acquired FluMist in March 1995 through a Co-operative Research and Development Agreement (CRADA) with the US NIAID, and a licensing agreement with the University of Michigan, Ann Arbor, USA. In June 2000, the CRADA was

  20. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial

    OpenAIRE

    Long, Joanna E.; Drayson, Mark T; Taylor, Angela E.; Toellner, Kai M.; Lord, Janet M.; Phillips, Anna C

    2016-01-01

    Highlights • Early small studies provide mixed evidence for effects of time of vaccination on antibody response. • This is the first large scale randomised trial of different times of vaccination. • Morning vaccination enhances the antibody response to the influenza vaccine. • This simple manipulation is cost neutral and may improve protection from influenza in older adults.

  1. 75 FR 55503 - National Vaccine Injury Compensation Program: Revisions to the Vaccine Injury Table

    Science.gov (United States)

    2010-09-13

    ..., meningococcal, and human papillomavirus (HPV) vaccines. The Table includes a list of covered vaccines under the..., meningococcal, and human papillomavirus (HPV) vaccines to the VICP have already occurred. The Secretary... human papillomavirus vaccines were covered under the VICP, with an effective date of February 1,......

  2. A Review of Pneumococcal Vaccines: Current Polysaccharide Vaccine Recommendations and Future Protein Antigens

    OpenAIRE

    Daniels, Calvin C.; Rogers, P. David; Shelton, Chasity M.

    2016-01-01

    This review describes development of currently available pneumococcal vaccines, provides summary tables of current pneumococcal vaccine recommendations in children and adults, and describes new potential vaccine antigens in the pipeline. Streptococcus pneumoniae, the bacteria responsible for pneumonia, otitis media, meningitis and bacteremia, remains a cause of morbidity and mortality in both children and adults. Introductions of unconjugated and conjugated pneumococcal polysaccharide vaccine...

  3. Vaccine strategies against schistosomiasis

    Directory of Open Access Journals (Sweden)

    A. Capron

    1992-01-01

    Full Text Available In this review the authors analyze the effector and regulatory mechanisms in the immune response to schistosomiasis. To study these mechanisms two animal models were used, mouse and rat. The mouse totaly permissive host like human, show prominent-T cell control in the acquisition of resistance. But other mechanisms like antibody mediated cytotoxity (ADCC involving eosinophils and IgG antibodies described in humans, are observed in rats. Also in this animal, it is observed specific IgE antibody high production and blood and tisssue eosinophilia. Using the rat model and schistosomula as target, some ADCC features have emerged: the cellular population involved are bone marrow derived inflammatory cell (mononuclear phagocytes, eosinophils and platelets, interacting with IgE through IgE Fc receptors. Immunization has been attempted using the recombinant protein Sm28/GST. Protection has been observed in rodents with significant decrease of parasite fecundity and egg viability affecting the number, size and volume of liver egg granulomas. The association of praziquantel and immunization with with Sm28/GST increases the resistance to infection and decreases egg viability. The authors suggest the possibility of the stablishment of a future vaccine against Schistosoma mansoni.

  4. SARS Immunity and Vaccination

    Institute of Scientific and Technical Information of China (English)

    Minsheng Zhu

    2004-01-01

    Severe acute respiratory syndrome (SARS) is a serious and fatal infectious disease caused by SARS coronavirus (SARS-Cov), a novel human coronavirus. SARS-Cov infection stimulates cytokines (e.g., IL-10,IFN-γ, IL-1, etc.) expression dramatically, and T lymphocytes and their subsets CD4+ and CD8+ T cells are decreased after onset of the disease. SARS-specific IgG antibody is generated in the second week and persists for a long time, whereas IgM is expressed transiently. The spike protein and neucleocapsid protein are most abundant in SARS-Cov and contribute dominantly to the antibody production during the course of disease. Spike protein, especially the ACE-2 binding region (318-510aa) is capable of producing neutralizing antibody to SARS-Cov. Neucleocapsid protein induces protective specific CTL to SARS-Cov. Therefore, applications with spike subunit, neucleocapsid subunit as well as inactivated SARS-Cov are three prospective vaccination strategies for SARS.

  5. SARS Immunity and Vaccination

    Institute of Scientific and Technical Information of China (English)

    MinshengZhu

    2004-01-01

    Severe acute respiratory syndrome (SARS) is a serious and fatal infectious disease caused by SARS coronavirus (SARS-Cov), a novel human coronavirus. SARS-Cov infection stimulates cytokines (e.g., IL-10,IFN-γ, IL-1, etc.) expression dramatically, and T lymphocytes and their subsets CD4+ and CD8+ T cells are decreased after onset of the disease. SARS-specific IgG antibody is generated in the second week and persists for a long time, whereas IgM is expressed transiently. The spike protein and neucleocapsid protein are most abundant in SARS-Cov and contribute dominantly to the antibody production during the course of disease.Spike protein, especially the ACE-2 binding region (318-510aa) is capable of producing neutralizing antibody to SARS-Cov. Neucleocapsid protein induces protective specific CTL to SARS-Cov. Therefore, applications with spike subunit, neucleocapsid subunit as well as inactivated SARS-Cov are three prospective vaccination strategies for SARS.

  6. Agility in adversity: Vaccines on Demand.

    Science.gov (United States)

    De Groot, Anne S; Moise, Leonard; Olive, David; Einck, Leo; Martin, William

    2016-09-01

    Is the US ready for a biological attack using Ebola virus or Anthrax? Will vaccine developers be able to produce a Zika virus vaccine, before the epidemic spreads around the world? A recent report by The Blue Ribbon Study Panel on Biodefense argues that the US is not ready for these challenges, however, technologies and capabilities that could address these deficiencies are within reach. Vaccine technologies have advanced and readiness has improved in recent years, due to advances in sequencing technology and computational power making the 'vaccines on demand' concept a reality. Building a robust strategy to design effective biodefense vaccines from genome sequences harvested by real-time biosurveillance will benefit from technologies that are being brought to bear on the cancer cure 'moonshot'. When combined with flexible vaccine production platforms, vaccines on demand will relegate expensive and, in some cases, insufficiently effective vaccine stockpiles to the dust heap of history. PMID:27389971

  7. Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine

    Science.gov (United States)

    This page contains brief information about recombinant human papillomavirus (HPV) quadrivalent vaccine and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.

  8. Recombinant Human Papillomavirus (HPV) Bivalent Vaccine

    Science.gov (United States)

    This page contains brief information about recombinant human papillomavirus (HPV) bivalent vaccine and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.

  9. Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine

    Science.gov (United States)

    This page contains brief information about recombinant human papillomavirus (HPV) nonavalent vaccine and a collection of links to more information about the use of this vaccine, research results, and ongoing clinical trials.

  10. Malaria Vaccine Shows Promise in Small Study

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158765.html Malaria Vaccine Shows Promise in Small Study It protected ... TUESDAY, May 10, 2016 (HealthDay News) -- An experimental malaria vaccine protects a majority of adults against the ...

  11. Innovation Paradox in Vaccine Target Selection

    NARCIS (Netherlands)

    E.S. Pronker (Esther)

    2013-01-01

    textabstractPublic health is continually threatened by re- and newly emerging infections, as well as pathogen resistance to available intervention strategies, including vaccines. This persistent threat of the unmet medical need challenges vaccine developers to anticipate future epidemiological outbr

  12. Traditional Smallpox Vaccines and Atopic Dermatitis

    Science.gov (United States)

    ... Grant Request DONATE Traditional Smallpox Vaccines and Atopic Dermatitis Frequently Asked Questions Eczema Living with Eczema Get ... News Research Donate Traditional Smallpox Vaccines and Atopic Dermatitis Frequently Asked Questions What is the traditional smallpox ...

  13. Bath vaccination of rainbow trout against yersiniosis

    DEFF Research Database (Denmark)

    Raida, Martin Kristian; Buchmann, Kurt

    2007-01-01

    Studies have been conducted on the temperature-dependent effect of bath vaccination of rainbow trout against Yersinia ruckeri O1. Protection of rainbow trout fry against challenge, following bath vaccination with a bacterin of Yersinia ruckeri O1, the bacterial pathogen causing enteric red mouth...... disease (ERM), was investigated at 5, 15 and 25° C. Rainbow trout fry were kept at controlled temperatures for two month before they were immersed in a commercial Yersinia ruckeri O1 bacterin for 10 minutes. Control groups were sham vaccinated using pure water. Fish were challenged with Yersinia ruckeri O......1 one and two month post vaccination at the three temperatures. Protection of vaccinated fish was seen one and two month post vaccination in rainbow trout reared at 15° C. There was no effect of vaccination in rainbow trout reared at 5 and 25° C. Spleen tissue was sampled from 5 vaccinated and 5...

  14. Vaccine Reduces HPV Infections in Young Men

    Science.gov (United States)

    An international randomized clinical trial has shown that the vaccine Gardasil can reduce the incidence of anogenital human papillomavirus (HPV) infections in young men 16 to 26 years of age at the time of vaccination.

  15. HPV Vaccine Information for Young Women

    Science.gov (United States)

    ... Twitter STD on Facebook Sexually Transmitted Diseases (STDs) HPV Vaccine Information For Young Women Language: English Español ( ... vaccines are available to prevent the human papillomavirus (HPV) types that cause most cervical cancers as well ...

  16. Meningitis B Vaccine Falls Short of Expectations

    Science.gov (United States)

    ... page: https://medlineplus.gov/news/fullstory_159976.html Meningitis B Vaccine Falls Short of Expectations 1 in ... University students given a vaccine to combat a meningitis B outbreak on campus in 2013 didn't ...

  17. Bacillus Calmette-Guerin (BCG) Vaccine

    Science.gov (United States)

    TheraCys® BCG ... TICE® BCG ... WHY is this medicine prescribed?BCG vaccine provides immunity or protection against tuberculosis (TB). The vaccine may be given to persons at high risk of developing TB. ...

  18. Global challenges of implementing human papillomavirus vaccines

    Directory of Open Access Journals (Sweden)

    Mishra Amrita

    2011-06-01

    Full Text Available Abstract Human Papillomavirus vaccines are widely hailed as a sweeping pharmaceutical innovation for the universal benefit of all women. The implementation of the vaccines, however, is far from universal or equitable. Socio-economically marginalized women in emerging and developing, and many advanced economies alike, suffer a disproportionately large burden of cervical cancer. Despite the marketing of Human Papillomavirus vaccines as the solution to cervical cancer, the market authorization (licensing of the vaccines has not translated into universal equitable access. Vaccine implementation for vulnerable girls and women faces multiple barriers that include high vaccine costs, inadequate delivery infrastructure, and lack of community engagement to generate awareness about cervical cancer and early screening tools. For Human Papillomavirus vaccines to work as a public health solution, the quality-assured delivery of cheaper vaccines must be integrated with strengthened capacity for community-based health education and screening.

  19. New Dengue Virus Vaccine Shows Promise

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_157799.html New Dengue Virus Vaccine Shows Promise Research may also aid ... 16, 2016 (HealthDay News) -- An experimental vaccine against dengue -- the mosquito-borne virus behind a very painful ...

  20. NIH Research Leads to Cervical Cancer Vaccine

    Science.gov (United States)

    ... Transmitted Diseases NIH Research Leads to Cervical Cancer Vaccine Past Issues / Fall 2008 Table of Contents For ... Douglas Lowy (left) and John Schiller developed the vaccine to prevent HPV infection in women, the cause ...

  1. CDC Wonder Vaccine Adverse Event Reporting System

    Data.gov (United States)

    U.S. Department of Health & Human Services — The Vaccine Adverse Event Reporting System (VAERS) online database on CDC WONDER provides counts and percentages of adverse event case reports after vaccination,...

  2. Weakened Immune System and Adult Vaccination

    Science.gov (United States)

    ... click "GO" or visit Healthmap Vaccine Finder . Weakened Immune System and Adult Vaccination Recommend on Facebook Tweet Share ... people with health conditions such as a weakened immune system. If you have cancer or other immunocompromising conditions, ...

  3. Tdap (tetanus, diphtheria, pertussis) Vaccine and Pregnancy

    Science.gov (United States)

    Tetanus, Diphtheria and Pertussis (Tdap) Vaccine In every pregnancy, a woman starts out with a 3-5% chance of ... sheet talks about whether exposure to the tetanus, diphtheria, and pertussis (or Tdap) vaccine may increase the ...

  4. Shingles Vaccination: What You Need to Know

    Science.gov (United States)

    ... Zoster or Zoster VZV=varicella zoster virus Shingles Vaccination: What Everyone Should Know Recommend on Facebook Tweet ... few minutes to a few hours after the vaccination. If you have a severe allergic reaction or ...

  5. Vaccination against salmonid bacterial kidney disease

    Science.gov (United States)

    Bacterial kidney disease (BKD) of salmonid fishes, caused by Renibacterium salmoninarum, has presented challenges for development of effective vaccines, despite several decades of research. The only vaccine against BKD that is commercially licensed is an injectable preparation containing live cells ...

  6. Workplace Vaccination and Other Factors Impacting Influenza Vaccination Decision among Employees in Israel

    Directory of Open Access Journals (Sweden)

    Shosh Shahrabani

    2010-03-01

    Full Text Available The study examined the factors affecting the decision to be vaccinated against influenza among employees in Israel. The research, conducted in 2007/2008, included 616 employees aged 18−65 at various workplaces in Israel, among them companies that offered their employees influenza vaccination. The research questionnaire included socio-demographic characteristics, and the Health Belief Model principles. The results show that the significant factors affecting vaccination compliance include a vaccination program at workplaces, vaccinations in the past, higher levels of vaccine's perceived benefits, and lower levels of barriers to getting the vaccine. We conclude that vaccine compliance is larger at companies with workplace vaccination programs providing easier accessibility to vaccination.

  7. Should Pneumococcal Vaccines Eliminate Nasopharyngeal Colonization?

    Science.gov (United States)

    McDaniel, Larry S; Swiatlo, Edwin

    2016-01-01

    Streptococcus pneumoniae remains an important human pathogen. For more than 100 years, there have been vaccine efforts to prevent pneumococcal infection. The pneumococcal conjugate vaccines have significantly reduced invasive disease. However, these vaccines have changed pneumococcal ecology within the human nasopharynx. We suggest that elimination of the pneumococcus from the human nasopharynx can have consequences that should be considered as the next generation of pneumococcal vaccines is developed. PMID:27222469

  8. Nonclinical Development of BCG Replacement Vaccine Candidates

    OpenAIRE

    Bernd Eisele; Martin Gengenbacher; Reginald Kidd; David McCown; Sheldon Morris; Steven Derrick; David Hokey; Dominick Laddy; Rosemary Chang; Megan Fitzpatrick; Leander Grode; Kamalakannan Velmurugan; Stefan H. E. Kaufmann; John Fulkerson; Brennan, Michael J.

    2013-01-01

    The failure of current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccines, given to neonates to protect against adult tuberculosis and the risk of using these live vaccines in HIV-infected infants, has emphasized the need for generating new, more efficacious and safer replacement vaccines. With the availability of genetic techniques for constructing recombinant BCG (rBCG) strains containing well-defined gene deletions or insertions, new vaccine candidates are under evaluation at both ...

  9. Comparison of Two Recombinant Hepatitis B Vaccines

    OpenAIRE

    Hasan Nikui Nejad; Gholamali Ghorbani; Reza Razaghi; Hossain Akbari

    2009-01-01

    Background and Aims: Hepatitis B virus (HBV) infection is an important public health problem. Hepatitis B vaccine induces protective response in the majority of vaccinated persons. In our country, we do not have any evaluation for the efficacy of each type of vaccines used in adult and our objective was therefore to evaluate the efficacy of vaccines..Methods: In a randomized double-blind clinical trial 347 military personnel and their family in Kashan city, central Iran, were studied during A...

  10. A Research Agenda for Malaria Eradication: Vaccines

    OpenAIRE

    ,

    2011-01-01

    Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. We introduce the concept of “vaccines that interrupt...

  11. A research agenda for malaria eradication: vaccines.

    OpenAIRE

    Abdulla, S.; Agre, P; P.L. Alonso; Arevalo-Herrera, M.; Bassat, Q.; Binka, F.; Chitnis, C.; Corradin, G; Cowman, A. F.; Culpepper, J.; Portillo, H. del; Dinglasan, R. R.; Duffy, P.; Gargallo, D; Greenwood, B.

    2011-01-01

    Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. We introduce the concept of "vaccines that interrupt...

  12. Cross-protection by conventional influenza vaccines

    OpenAIRE

    Roos, A.L.E.

    2016-01-01

    In this thesis, we explore whether the protective efficacy of a trivalent virosomal seasonal influenza vaccine (TVV) can be broadened and thereby increase pandemic preparedness until more broadly protective influenza vaccines may become available. Chapter 2 examines the ability of a vaccination regimen comprising multiple immunizations to improve the cross-protective efficacy of TVV in mice. Chapter 3 explores whether priming a TVV with vaccine homologous HA DNA can improve its efficacy of in...

  13. Sources of HPV vaccine hesitancy in parents

    OpenAIRE

    Patel, Pooja R.; Berenson, Abbey B.

    2013-01-01

    Despite strong national recommendations to vaccinate adolescents against the human papillomavirus (HPV), only 14% of teenage girls completed all 3 doses in 2010. Parental hesitancy may be one of the strongest reasons behind this low uptake rate. This review investigates sources of parental hesitancy including parental concerns associated with vaccinations in general, parental knowledge as a basis of HPV vaccine hesitancy, social qualms parents may have with regards to the HPV vaccine, and par...

  14. Vaccine Immunogenetics: Bedside to Bench to Population

    OpenAIRE

    Gregory A Poland; Ovsyannikova, Inna G.; Jacobson, Robert M.

    2008-01-01

    The immunogenetic basis for variations in immune response to vaccines in humans remains largely unknown. Many factors can contribute to the heterogeneity of vaccine-induced immune responses, including polymorphisms of immune response genes. It is important to identify those genes involved directly or indirectly in the generation of the immune response to vaccines. Our previous work with measles reveals the impact of immune response gene polymorphisms on measles vaccine-induced humoral and cel...

  15. Algae-based oral recombinant vaccines

    OpenAIRE

    Specht, Elizabeth A.; Mayfield, Stephen P

    2014-01-01

    Recombinant subunit vaccines are some of the safest and most effective vaccines available, but their high cost and the requirement of advanced medical infrastructure for administration make them impractical for many developing world diseases. Plant-based vaccines have shifted that paradigm by paving the way for recombinant vaccine production at agricultural scale using an edible host. However, enthusiasm for “molecular pharming” in food crops has waned in the last decade due to difficulty in ...

  16. Missed Opportunities: The Vaccine Act of 1813

    OpenAIRE

    Singla, Rohit K.

    1998-01-01

    This Paper simply exposes discontinuities between the theories and the history of the Vaccine Act, suggesting lines of further study. The focus throughout this Paper is on "getting the facts right," i.e., thoroughly recounting the history of the Vaccine Act. Part II of the paper provides some necessary historical background regarding the horrors of smallpox, the breakthrough of vaccination, and the difficulties encountered in implementing vaccination in early 19th century America. In particul...

  17. An update on vaccines against Shigella

    OpenAIRE

    Ashkenazi, Shai; Cohen, Dani

    2013-01-01

    Despite intensive research efforts for more than 60 years, utilizing diverse vaccine strategies, a safe and efficacious vaccine against shigellosis is not available yet. We are currently witnessing innovative approaches based on elucidation of the virulence mechanisms of Shigella, understanding the immune response to the pathogen and progress in molecular technology for developing Shigella vaccines. It is hoped that these will lead to a licensed effective Shigella vaccine to protect humans ag...

  18. Postexposure Management of Vaccine-Preventable Diseases.

    Science.gov (United States)

    Woo, Teri Moser

    2016-01-01

    Because some parents are choosing to not vaccinate or only partially vaccinate their children, vaccine-preventable diseases that once were rarely seen in pediatric practice must now be considered part of the differential diagnosis when caring for these children. Measles, mumps, varicella, meningococcal disease, pertussis, and influenza are reviewed. Recommendations for prevention and treatment of these vaccine-preventable diseases are discussed. PMID:26896379

  19. HIV Vaccine-Challenges and Opportunities

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    The need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of an efficacious HIV/AIDS vaccine proves an enormous scientific challenge. This article reviews the neutralizing antibody problem, elusive immune protection, immunogen design, pre-existing anti-vector immunity and design of phase 3 vaccine trials and the challenges and opportunities in development of HIV/AIDS vaccine are discussed.

  20. Vaccinating captive chimpanzees to save wild chimpanzees

    OpenAIRE

    Warfield, Kelly L.; Goetzmann, Jason E.; Julia E. Biggins; Kasda, Mary Beth; Unfer, Robert C.; Vu, Hong; Aman, M. Javad; Olinger, Gene Gerrard; Walsh, Peter D.

    2014-01-01

    Although infectious disease is now recognized as a major threat to wild gorillas and chimpanzees, safety fears have stifled the use of a powerful disease control tool, vaccination. To illustrate that safety can be rigorously evaluated before vaccines are used on wild apes, we conducted what is, to our knowledge, the first conservation-oriented vaccine trial on captive chimpanzees. We tested an experimental virus-like particle (VLP) vaccine against Ebola virus, a leading killer of wild apes. O...

  1. Influenza B vaccine lineage selection - An optimized trivalent vaccine

    OpenAIRE

    Moster?n H?pping, Ana; Fonville, Judith M; Russell, Colin A.; James, Sarah; Derek J Smith

    2016-01-01

    Highlights • Although it is not known which one of two influenza B lineages will circulate in any one season, only a representative virus of one of the two lineages is part of the trivalent seasonal influenza vaccine. • We describe three lineage selection strategies to choose which lineage to include in the seasonal vaccine, including the common strategy of using the last lineage that has been observed to dominate, and a new strategy which takes into account population immunity. • We show why...

  2. Ontology-based Brucella vaccine literature indexing and systematic analysis of gene-vaccine association network

    OpenAIRE

    Xiang Zuoshuang; Hur Junguk; Feldman Eva L; He Yongqun

    2011-01-01

    Abstract Background Vaccine literature indexing is poorly performed in PubMed due to limited hierarchy of Medical Subject Headings (MeSH) annotation in the vaccine field. Vaccine Ontology (VO) is a community-based biomedical ontology that represents various vaccines and their relations. SciMiner is an in-house literature mining system that supports literature indexing and gene name tagging. We hypothesize that application of VO in SciMiner will aid vaccine literature indexing and mining of va...

  3. Side-effects of pertussis toxin, pertussis vaccines and haemoinfluenza type B vaccine

    OpenAIRE

    van Amsterdam JGC; te Biesebeek JD; Kuil A van de; Vleeming W; van der Laan JW; Spruyt B; Wemer J; Wildt DJ de; LEO; LGM

    1997-01-01

    Doel van de studie is de bijwerkingen van vaccins nader te bestuderen ter onderbouwing van voor te stellen richtlijnen. Bedoelde richtlijnen stellen eisen aan het verrichten van pre-klinische veiligheids-farmacologie van vaccins. Dit rapport beschrijft de cardiovasculaire en autonome effecten, die in-vivo worden waargenomen in jonge en volwassen ratten behandeld met hoge doseringen pertussis toxine, cellulair (DKTP-vaccin) en acellulair pertussis vaccin en Haemoinfluenza type b vaccin. Deze e...

  4. AEROMONAS SALMONICIDA INFECTION IN VACCINATED RAINBOW TROUT

    DEFF Research Database (Denmark)

    Chettri, Jiwan Kumar; Skov, Jakob; Mohammad, Rezkar Jaafar;

    causing furunculosis. Rainbow trout (Oncorhynchus mykiss) were vaccinated with two trivalent adjuvanted experimental vaccines containing formalin-killed A. salmonicida, Vibrio anguillarum O1 and O2a and a commercial corresponding vaccine (Alpha Ject 3000). Fish were challenged by i.p. injection or...

  5. Human immunodeficiency virus vaccine an update

    Directory of Open Access Journals (Sweden)

    V T Beena

    2013-01-01

    Full Text Available Since the discovery of acquired immuno deficiency syndrome (AIDS in late1980s, the spread of human immunodeficiency virus (HIV has reached pandemic proportions, representing a global developmental and public health threat. Finding of a safe, globally effective and affordable HIV vaccine offers the best hope for the future control of the disease pandemic. Significant progress has been made over the past years in the areas of basic virology, immunology, and pathogenesis of HIV/AIDS and the development of anti-retroviral drugs. However, the search for an HIV vaccine faces formidable scientific challenges related to the high genetic variability of the virus, the lack of immune correlates of protection, limitations with the existing animal models and logistical problems associated with the conduct of multiple clinical trials. Most of the vaccine approaches developed so far aim at inducing cell-mediated immune responses. Multiple vaccine concepts and vaccination strategies have been tested, including DNA vaccines, subunit vaccines, live vectored recombinant vaccines, various prime-boost vaccine combinations and vaccine based on broadly neutralizing human anti-HIV Antibody 2G12. This article reviews the state of the art in HIV vaccine research, summarizes the results obtained so far and discusses the challenges to be met in the development of a successful HIV vaccine.

  6. [Which vaccinations for which travel-destination?].

    Science.gov (United States)

    De Crom, Susan; Veit, Olivia; Hatz, Christoph

    2016-01-01

    Several vaccinations are recommended to protect international travellers, especially to tropical countries, from diseases in other parts of the world. Firstly, the routine schedule of childhood vaccinations and booster shots according to the Swiss immunisation programme should be checked, updated or even completed. Additional vaccinations against hepatitis A and B, typhoid fever, poliomyelitis, rabies or Japanese encephalitis may be recommended. This will depend on a number of factors including the exact destination and route (developing countries, rural areas), planned activities (backpacker, family visit, business trip), duration of travel, season, age of the traveller and current health status including the current medication and previous vaccinations. Some vaccinations, such as yellow fever, may be required for travellers to certain countries and the international certificate of vaccination may even be required when entering a country from another country where yellow fever is endemic. The international certificate of vaccination (or a letter of exemption when appropriate) is considered valid only if it is administered by an approved vaccination centre. Furthermore, the meningococcal vaccination (A, C, W, Y) is required for pilgrims to Saudi Arabia. It is recommended to start the vaccinations four to six weeks before departure to ensure enough time to administer all the necessary doses for an adequate immune response. All commonly used vaccines can be administered on the same day. The basic health insurance does not usually cover travel vaccines. PMID:27268450

  7. Recombinant Swinepox Virus for Veterinary Vaccine Development.

    Science.gov (United States)

    Fan, Hong-Jie; Lin, Hui-Xing

    2016-01-01

    Poxvirus-vectors have been widely used in vaccine development for several important human and animal diseases; some of these vaccines have been licensed and used extensively. Swinepox virus (SPV) is well suited to develop recombinant vaccines because of its large packaging capacity for recombinant DNA, its host range specificity, and its ability to induce appropriate immune responses. PMID:26458836

  8. Cancer Vaccines: Past, Present, and Future.

    Science.gov (United States)

    Mohammed, Shamayel; Bakshi, Nasir; Chaudri, Naeem; Akhter, Javed; Akhtar, Mohammed

    2016-05-01

    Cancer is a common and potentially deadly disease. Some of the cancers may be difficult to treat by conventional means such as surgery, radiation, and chemotherapy, but may be controlled by the stimulation of the immune response of the body with the help of cancer vaccines. The use of vaccines for preventing infections by oncogenic viruses such as hepatitis B virus and human papilloma virus has been extremely successful in reducing the incidence of cancers resulting from these infections. The use of vaccines for treating cancers that are not due to viral infections and that are already established is currently the object of numerous clinical trials. Several types of cancer vaccines are being tried. These include antigen vaccines, tumor cell vaccines, dendritic vaccines, deoxyribonucleic acid vaccines, and viral vector vaccines. The development of these therapeutic vaccines is proving difficult with only 1 recent success. However, there is significant enthusiasm and optimism regarding the development of effective therapeutic vaccines stemming from the fact that our understanding regarding the cancer immunology is considerably enhanced in recent years. This expanded knowledge regarding the mechanisms that cancers use to escape the immune system is likely to open new avenues in modulating the immune response to cancer, thus enhancing the effectiveness of therapeutic cancer vaccines. PMID:27058246

  9. Novel Adjuvants and Immunomodulators for Veterinary Vaccines

    DEFF Research Database (Denmark)

    Heegaard, Peter M. H.; Fang, Yongxiang; Jungersen, Gregers

    2016-01-01

    Adjuvants are crucial for efficacy of vaccines, especially subunit and recombinant vaccines. Rational vaccine design, including knowledge-based and molecularly defined adjuvants tailored for directing and potentiating specific types of host immune responses towards the antigens included in the va...

  10. Directed vaccination against pneumococcal disease.

    Science.gov (United States)

    Li, Yi; Hill, Andrew; Beitelshees, Marie; Shao, Shuai; Lovell, Jonathan F; Davidson, Bruce A; Knight, Paul R; Hakansson, Anders P; Pfeifer, Blaine A; Jones, Charles H

    2016-06-21

    Immunization strategies against commensal bacterial pathogens have long focused on eradicating asymptomatic carriage as well as disease, resulting in changes in the colonizing microflora with unknown future consequences. Additionally, current vaccines are not easily adaptable to sequence diversity and immune evasion. Here, we present a "smart" vaccine that leverages our current understanding of disease transition from bacterial carriage to infection with the pneumococcus serving as a model organism. Using conserved surface proteins highly expressed during virulent transition, the vaccine mounts an immune response specifically against disease-causing bacterial populations without affecting carriage. Aided by a delivery technology capable of multivalent surface display, which can be adapted easily to a changing clinical picture, results include complete protection against the development of pneumonia and sepsis during animal challenge experiments with multiple, highly variable, and clinically relevant pneumococcal isolates. The approach thus offers a unique and dynamic treatment option readily adaptable to other commensal pathogens. PMID:27274071

  11. VACCINATION IN RHEUMATOLOGY: CURRENT ASPECTS

    Directory of Open Access Journals (Sweden)

    B. S. Belov

    2014-01-01

    Full Text Available Infectious diseases still remain a serious social and medical problem. The importance of comorbid infections in rheumatology has increased substantially in recent years, particularly due to the clinical introduction of biologicals. The investigation and active use of different vaccines are one of the ways to solve the above problem. This review considers the issues concerning the use of vaccines against influenza, infections caused by pneumococci, herpesviruses, human papillomavirus, and hepatitis B virus in rheumatology patients. It discusses the safety and immunogenicity of vaccination associated with the prevention of airway infections as the most common cause of a poor outcome in rheumatic diseases. The main areas of future investigations in the problem under consideration are defined.

  12. Nanovaccines: recent developments in vaccination

    Indian Academy of Sciences (India)

    Tarala D Nandedkar

    2009-12-01

    In the past 100 years, vaccination has contributed immensely to public health by preventing a number of infectious diseases. Attenuated, killed or part of the microorganism is employed to stimulate the immune system against it. Progress in biotechnology has provided protective immunity through DNA vaccines. In recent years, nanovaccine is a novel approach to the methodology of vaccination. Nanomaterials are delivered in the form of microspheres, nanobeads or micro-nanoprojections. Painless, effective and safe needle-free routes such as the intranasal or the oral route, or patches of microprojections to the skin are some of the approaches which are in the experimental stage at present but may have a great future ahead in nanovaccination.

  13. Recent advances in vaccine delivery.

    Science.gov (United States)

    Cordeiro, Ana S; Alonso, María J

    2016-01-01

    The field of vaccination is moving from the use of attenuated or inactivated pathogens to safer but less immunogenic protein and peptide antigens, which require stronger adjuvant compositions. Antigen delivery carriers appear to play an important role in vaccine development, providing not only antigen protection and controlled release but also an intrinsic adjuvant potential. Among them, carriers based on polymers and lipids are the most representative ones. Patent applications in this area have disclosed, either the design and preparation methods for new biocompatible antigen delivery systems or the application of the previously developed systems for the delivery of novel antigens. Some of them have also reported the use of these technologies for modern therapeutic vaccination approaches. PMID:26667309

  14. Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 2013(1).

    Science.gov (United States)

    Tohme, Rania A; François, Jeannot; Wannemuehler, Kathleen; Iyengar, Preetha; Dismer, Amber; Adrien, Paul; Hyde, Terri B; Marston, Barbara J; Date, Kashmira; Mintz, Eric; Katz, Mark A

    2015-06-01

    In 2013, the first government-led oral cholera vaccination (OCV) campaign in Haiti was implemented in Petite Anse and Cerca Carvajal. To evaluate vaccination coverage, barriers to vaccination, and adverse events following vaccination, we conducted a cluster survey. We enrolled 1,121 persons from Petite Anse and 809 persons from Cerca Carvajal, categorized by 3 age groups (1-4, 5-14, >15 years). Two-dose OCV coverage was 62.5% in Petite Anse and 76.8% in Cerca Carvajal. Two-dose coverage was lowest among persons >15 years of age. In Cerca Carvajal, coverage was significantly lower for male than female respondents (69% vs. 85%; p<0.001). No major adverse events were reported. The main reason for nonvaccination was absence during the campaign. Vaccination coverage after this campaign was acceptable and comparable to that resulting from campaigns implemented by nongovernmental organizations. Future campaigns should be tailored to reach adults who are not available during daytime hours. PMID:25988350

  15. Cancer vaccine--Antigenics.

    Science.gov (United States)

    2002-01-01

    Antigenics is developing a therapeutic cancer vaccine based on heat-shock proteins (HSPs). The vaccine [HSPPC-96, Oncophage] is in a pivotal phase III clinical trial for renal cancer at 80 clinical sites worldwide. The trial is enrolling at least 500 patients who are randomised to receive surgical removal of the primary tumour followed by out-patient treatment with Oncophage((R)) or surgery only. This study was initiated on the basis of results from a pilot phase I/II study and preliminary results from a phase II study in patients with renal cell cancer. In October 2001, Oncophage was designated as a fast-track product by the Food and Drug Administration in the US for the treatment of renal cell carcinoma. Oncophage is in phase I/II trials in Italy for colorectal cancer (30 patients) and melanoma. The trials in Italy are being conducted at the Istituto dei Tumouri, Milan (in association with Sigma-Tau). Preliminary data from the phase II trial for melanoma was presented at the AACR-NCI-EORTC International Conference in Florida, USA, in October 2001. Oncophage is also in a phase I/II (42 patients) and a phase II trial (84 patients) in the US for renal cell cancer, a phase II trial in the US for non-Hodgkin's lymphoma (35 patients), a phase II trial in the US for sarcoma (20-35 patients), a phase I/II trial in the US for melanoma (36 patients), and phase I/II trials in Germany for gastric (30 patients) and pancreatic cancers. A pilot phase I trial in patients with pancreatic cancer began in the US in 1997 with 5 patients enrolled. In November 2000, Antigenics announced that this trial had been expanded to a phase I/II study which would now include survival as an endpoint and would enroll 5 additional patients. The US trials are being performed at Memorial Sloan-Kettering Cancer Center and the M.D. Anderson Cancer Center. The trials in Germany are being carried out at Johannes Gutenberg-University Hospital, Mainz. Oncophage is an autologous vaccine consisting of

  16. Novel Vaccines to Human Rabies

    OpenAIRE

    Ertl, Hildegund C. J.

    2009-01-01

    Rabies, the most fatal of all infectious diseases, remains a major public health problem in developing countries, claiming the lives of an estimated 55,000 people each year. Most fatal rabies cases, with more than half of them in children, result from dog bites and occur among low-income families in Southeast Asia and Africa. Safe and efficacious vaccines are available to prevent rabies. However, they have to be given repeatedly, three times for pre-exposure vaccination and four to five times...

  17. West Nile virus seroconversion in penguins after vaccination with a killed virus vaccine or a DNA vaccine.

    Science.gov (United States)

    Davis, Michelle R; Langan, Jennifer N; Johnson, Yvette J; Ritchie, Branson W; Van Bonn, William

    2008-12-01

    To investigate the serologic response of penguins to West Nile virus (WNV) vaccines, four species of exclusively indoor-housed penguins, negative for WNV by serology, were evaluated: Humboldt (Spheniscus humboldti), Magellanic (Spheniscus magellanicus), Gentoo (Pygoscelis papua), and Rockhopper (Eudyptes chrysoscome) penguins. Birds were inoculated with either a killed virus vaccine or a plasmid-mediated DNA WNV vaccine, and postinoculation serology was evaluated. Both vaccines induced seroconversion in all four species, and no adverse reactions were noted. Postvaccination serology results varied across species and vaccine types. However, in all four species, the killed virus vaccine resulted in a greater seroconversion rate than the DNA vaccine and in a significantly shorter time period. Additionally, the duration of the seropositive titer was significantly longer in those birds vaccinated with the killed virus vaccine compared with those vaccinated with the DNA vaccine. A subset of unvaccinated penguins serving as negative controls remained negative throughout the duration of the study despite the presence of WNV in the geographic locations of the study, suggesting that indoor housing may minimize exposure to the virus and may be an additional means of preventing WNV infection in penguins. PMID:19110700

  18. Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival

    DEFF Research Database (Denmark)

    Fisker, Ane B; Hornshøj, Linda; Rodrigues, Amabelia;

    2014-01-01

    BACKGROUND: In 2008, the GAVI Alliance funded the introduction of new vaccines (including pentavalent diphtheria-tetanus-pertussis [DTP] plus hepatitis B and Haemophilus influenzae type b antigens) in Guinea-Bissau. The introduction was accompanied by increased vaccination outreach services and a...... more restrictive wastage policy, including only vaccinating children younger than 12 months. We assessed coverage of all vaccines in the Expanded Program on Immunizations before and after the new vaccines' introduction, and the implications on child survival. METHODS: This observational cohort study...... used data from the Bandim Health Project, which has monitored vaccination status and mortality in randomly selected village clusters in Guinea-Bissau since 1990. We assessed the change in vaccination coverage using cohort data from children born in 2007 and 2009; analysed the proportion of children who...

  19. Status of vaccine research and development of vaccines for GBS.

    Science.gov (United States)

    Heath, Paul T

    2016-06-01

    Streptococcus agalactiae (group B streptococcus (GBS)) is the leading cause of neonatal sepsis and meningitis in many countries. Intrapartum antibiotic strategies have reduced the incidence of early-onset neonatal GBS in a number of countries but have had no impact on late onset GBS infection (LOD). In low/middle income settings, the disease burden remains uncertain although in several countries of Southern Africa appears comparable to or higher than that of high-income countries. As disease may be rapidly fulminating cases can be missed before appropriate samples are obtained and this may lead to underestimation of the true burden. Given the rapid onset and progression within hours of birth as well as the deficiencies in IAP strategies and absence of a solution for preventing LOD, it is clear that administration of a suitable vaccine in pregnancy could provide a better solution in all settings; it should also be cost effective. The current leading vaccine candidates are CPS-protein conjugate vaccines but protein-based vaccines are also in development and one has recently commenced clinical trials. PMID:26988258

  20. Recombinant vaccines and the development of new vaccine strategies

    International Nuclear Information System (INIS)

    Vaccines were initially developed on an empirical basis, relying mostly on attenuation or inactivation of pathogens. Advances in immunology, molecular biology, biochemistry, genomics, and proteomics have added new perspectives to the vaccinology field. The use of recombinant proteins allows the targeting of immune responses focused against few protective antigens. There are a variety of expression systems with different advantages, allowing the production of large quantities of proteins depending on the required characteristics. Live recombinant bacteria or viral vectors effectively stimulate the immune system as in natural infections and have intrinsic adjuvant properties. DNA vaccines, which consist of non-replicating plasmids, can induce strong long-term cellular immune responses. Prime-boost strategies combine different antigen delivery systems to broaden the immune response. In general, all of these strategies have shown advantages and disadvantages, and their use will depend on the knowledge of the mechanisms of infection of the target pathogen and of the immune response required for protection. In this review, we discuss some of the major breakthroughs that have been achieved using recombinant vaccine technologies, as well as new approaches and strategies for vaccine development, including potential shortcomings and risks

  1. Influenza B vaccine lineage selection-An optimized trivalent vaccine

    NARCIS (Netherlands)

    A. Mosterín Höpping (Ana); J.M. Fonville (Judith); C.A. Russell (Colin); S.L. James (Sarah ); D.R. Smith (Derek Richard)

    2016-01-01

    textabstractEpidemics of seasonal influenza viruses cause considerable morbidity and mortality each year. Various types and subtypes of influenza circulate in humans and evolve continuously such that individuals at risk of serious complications need to be vaccinated annually to keep protection up to

  2. Recombinant vaccines and the development of new vaccine strategies

    Energy Technology Data Exchange (ETDEWEB)

    Nascimento, I.P.; Leite, L.C.C. [Centro de Biotecnologia, Instituto Butantan, São Paulo, SP (Brazil)

    2012-09-07

    Vaccines were initially developed on an empirical basis, relying mostly on attenuation or inactivation of pathogens. Advances in immunology, molecular biology, biochemistry, genomics, and proteomics have added new perspectives to the vaccinology field. The use of recombinant proteins allows the targeting of immune responses focused against few protective antigens. There are a variety of expression systems with different advantages, allowing the production of large quantities of proteins depending on the required characteristics. Live recombinant bacteria or viral vectors effectively stimulate the immune system as in natural infections and have intrinsic adjuvant properties. DNA vaccines, which consist of non-replicating plasmids, can induce strong long-term cellular immune responses. Prime-boost strategies combine different antigen delivery systems to broaden the immune response. In general, all of these strategies have shown advantages and disadvantages, and their use will depend on the knowledge of the mechanisms of infection of the target pathogen and of the immune response required for protection. In this review, we discuss some of the major breakthroughs that have been achieved using recombinant vaccine technologies, as well as new approaches and strategies for vaccine development, including potential shortcomings and risks.

  3. Forebyggelse af herpes zoster med vaccination

    DEFF Research Database (Denmark)

    Kofoed, Kristian; Rønholt, Finn; Gerstoft, Jan; Sand, Carsten

    2011-01-01

    been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.......Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has...

  4. Postgenomics of Neisseria meningitidis for vaccines development.

    Science.gov (United States)

    Bernardini, Giulia; Braconi, Daniela; Martelli, Paola; Santucci, Annalisa

    2007-10-01

    Meningococcal disease is a global problem. Multivalent (A, C, Y, W135) conjugate vaccines have been developed and licensed; however, an effective vaccine against serogroup B has not yet become available. Outer membrane vesicle (OMV) vaccines have been used to disrupt serogroup B epidemics and outbreaks. Postgenomic technologies have been useful in aiding the discovery of new protein vaccine candidates. Moreover, proteomic technologies enable large-scale identification of membrane and surface-associated proteins, and provide suitable methods to characterize and standardize the antigen composition of OMV-based vaccines. PMID:17941821

  5. Dendrimers for Vaccine and Immunostimulatory Uses

    DEFF Research Database (Denmark)

    Heegaard, Peter M. H.; Boas, Ulrik; Sørensen, Nanna Skall

    2010-01-01

    for efficient immunostimulating compounds (adjuvants) that can increase the efficiency of vaccines, as dendrimers can provide molecularly defined multivalent scaffolds to produce highly defined conjugates with small molecule immunostimulators and/or antigens. The review gives an overview on the use of...... dendrimers as molecularly defined carriers/presenters of small antigens, including constructs that have built-in immunostimulatory (adjuvant) properties, and as stand-alone adjuvants that can be mixed with antigens to provide efficient vaccine formulations. These approaches allow the preparation of...... molecularly defined vaccines with highly predictable and specific properties and enable knowledge-based vaccine design substituting the traditional empirically based approaches for vaccine development and production....

  6. Ny Mycoplasma Hyosynoviae vaccine forebygger ikke halthed

    DEFF Research Database (Denmark)

    Nielsen, Elisabeth Okholm; Lauritsen, Klara Tølbøll; Jungersen, Gregers;

    Vaccination af smågrise mod Mykoplasma-ledbetændelser viste sig ikke at kunne forebyggede halthed hos slagtesvin. Smitte med Mycoplasma hyosynoviae (M. hyosynoviae) er ofte årsag til ledbetændelse hos slagtesvin. Der er ingen kommerciel vaccine til grise, der beskytter mod mykoplasma......-ledbetændelse. I et forskningsprojekt har forskere på Danmarks Tekniske Universitet udviklet en vaccine mod M. hyosynoviae. Vaccinen indeholder et hjælpestof, der er udviklet af Statens Seruminstitut. Den nye vaccine er testet i en slagtesvinebesætning. I alt 399 smågrise blev vaccineret med enten vaccine eller...

  7. Forebyggelse af herpes zoster med vaccination

    DEFF Research Database (Denmark)

    Kofoed, Kristian; Rønholt, Finn; Gerstoft, Jan;

    2011-01-01

    Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has...... been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects....

  8. Vaxjo: A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development

    Directory of Open Access Journals (Sweden)

    Samantha Sayers

    2012-01-01

    Full Text Available Vaccine adjuvants are compounds that enhance host immune responses to co-administered antigens in vaccines. Vaxjo is a web-based central database and analysis system that curates, stores, and analyzes vaccine adjuvants and their usages in vaccine development. Basic information of a vaccine adjuvant stored in Vaxjo includes adjuvant name, components, structure, appearance, storage, preparation, function, safety, and vaccines that use this adjuvant. Reliable references are curated and cited. Bioinformatics scripts are developed and used to link vaccine adjuvants to different adjuvanted vaccines stored in the general VIOLIN vaccine database. Presently, 103 vaccine adjuvants have been curated in Vaxjo. Among these adjuvants, 98 have been used in 384 vaccines stored in VIOLIN against over 81 pathogens, cancers, or allergies. All these vaccine adjuvants are categorized and analyzed based on adjuvant types, pathogens used, and vaccine types. As a use case study of vaccine adjuvants in infectious disease vaccines, the adjuvants used in Brucella vaccines are specifically analyzed. A user-friendly web query and visualization interface is developed for interactive vaccine adjuvant search. To support data exchange, the information of vaccine adjuvants is stored in the Vaccine Ontology (VO in the Web Ontology Language (OWL format.

  9. Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

    Directory of Open Access Journals (Sweden)

    Jacqueline M. Miller

    2011-01-01

    Full Text Available Meningococcal diseases are serious threats to global health, and new vaccines specifically tailored to meet the age-related needs of various geographical areas are required. This paper focuses on the meningococcal conjugate vaccines developed by GSK Biologicals. Two combined conjugate vaccines were developed to help protect infants and young children in countries where the incidence of meningococcal serogroup C or serogroup C and Y disease is important: Hib-MenC-TT vaccine, which offers protection against Haemophilus influenzae type b and Neisseria meningitidis serogroup C diseases, is approved in several countries; and Hib-MenCY-TT vaccine, which adds N. meningitidis serogroup Y antigen, is currently in the final stages of development. Additionally, a tetravalent conjugate vaccine (MenACWY-TT designed to help protect against four meningococcal serogroups is presently being evaluated for global use in all age groups. All of these vaccines were shown to be highly immunogenic and to have clinically acceptable safety profiles.

  10. Uniqueness of Nash equilibrium in vaccination games.

    Science.gov (United States)

    Bai, Fan

    2016-12-01

    One crucial condition for the uniqueness of Nash equilibrium set in vaccination games is that the attack ratio monotonically decreases as the vaccine coverage level increasing. We consider several deterministic vaccination models in homogeneous mixing population and in heterogeneous mixing population. Based on the final size relations obtained from the deterministic epidemic models, we prove that the attack ratios can be expressed in terms of the vaccine coverage levels, and also prove that the attack ratios are decreasing functions of vaccine coverage levels. Some thresholds are presented, which depend on the vaccine efficacy. It is proved that for vaccination games in homogeneous mixing population, there is a unique Nash equilibrium for each game. PMID:27465224

  11. Influenza DNA vaccine:an update

    Institute of Scientific and Technical Information of China (English)

    陈则

    2004-01-01

    @@ A series of global studies on the influenza DNA vaccine have revealed that it is capable of eliciting persistent humoral and cell mediated immune responses to influenza following delivery by various routes. DNA vaccines may not only serve as potentially safer alternatives to immunization with certain live virus vaccines, but may also provide a promising approach to the development of effective vaccines. The suggestions, based on our experiment, that both hemagglutinin (HA)- and neuraminidase (NA)- DNAs (or both HA and NA molecules) are highly protective against the influenza virus and are useful in the development of a more efficient vaccine against the influenza virus. In this article, we reviewed DNA vaccine against the influenza A and B viruses and the characteristics of the immune response induced by the DNA vaccine. Moreover, we discussed the importance of neutralizing antibodies to protect the host against a lethal influenza infection.

  12. Recombinant vaccines: experimental and applied aspects

    DEFF Research Database (Denmark)

    Lorenzen, Niels

    1999-01-01

    Development of vaccines for aquaculture fish represent an important applied functional aspect of fish immunology research. Particularly in the case of recombinant vaccines, where a single antigen is usually expected to induce immunity to a specific pathogen, knowledge of mechanisms involved in...... induction of a protective immune response may become vital. The few recombinant vaccines licensd so far, despite much research during the last decade, illustrate that this is not a straightforward matter. However, as vaccine technology as well as our knowledge of the fish immune system is steadily improved......, these fields will open up a number of interesting research objectives of mutual benefit. Recent aspects of recombinant protein vaccines, live recombinant vaccines and DNA vaccines are discussed....

  13. Vaccinating captive chimpanzees to save wild chimpanzees.

    Science.gov (United States)

    Warfield, Kelly L; Goetzmann, Jason E; Biggins, Julia E; Kasda, Mary Beth; Unfer, Robert C; Vu, Hong; Aman, M Javad; Olinger, Gene Gerrard; Walsh, Peter D

    2014-06-17

    Infectious disease has only recently been recognized as a major threat to the survival of Endangered chimpanzees and Critically Endangered gorillas in the wild. One potentially powerful tool, vaccination, has not been deployed in fighting this disease threat, in good part because of fears about vaccine safety. Here we report on what is, to our knowledge, the first trial in which captive chimpanzees were used to test a vaccine intended for use on wild apes rather than humans. We tested a virus-like particle vaccine against Ebola virus, a leading source of death in wild gorillas and chimpanzees. The vaccine was safe and immunogenic. Captive trials of other vaccines and of methods for vaccine delivery hold great potential as weapons in the fight against wild ape extinction. PMID:24912183

  14. Smallpox: clinical highlights and considerations for vaccination.

    Directory of Open Access Journals (Sweden)

    Mahoney M

    2003-01-01

    Full Text Available Smallpox virus has gained considerable attention as a potential bioterrorism agent. Recommendations for smallpox (vaccinia vaccination presume a low risk for use of smallpox as a terrorist biological agent and vaccination is currently recommended for selected groups of individuals such as health care workers, public health authorities, and emergency/rescue workers, among others. Information about adverse reactions to the smallpox vaccine is based upon studies completed during the 1950s and 1960s. The prevalence of various diseases has changed over the last four decades and new disease entities have been described during this period. The smallpox vaccination may be contra-indicated in many of these conditions. This has made pre-screening of potential vaccines necessary. It is believed that at present, the risks of vaccine-associated complications far outweigh the potential benefits of vaccination in the general population.

  15. Knowledge of Hepatitis B Vaccine among Operating Room Personnel in Nigeria and Their Vaccination Status

    Directory of Open Access Journals (Sweden)

    Emeka B. Kesieme

    2011-01-01

    Full Text Available Background. Hepatitis B virus (HBV infection is a well recognised occupational health hazard preventable by vaccination. Objectives. To determine the knowledge of operating room personnel (ORP in Nigeria about the Hepatitis B vaccine, their perception of Hepatitis B vaccination and vaccination status against HBV. Methods. Four university hospitals were selected by simple random sampling. A structured questionnaire was administered to 228 ORP after obtaining consent. Result. Only 26.8% of ORP were vaccinated against HBV. The primary reason for not being vaccinated or for defaulting from vaccination was lack of time. Differences in age, sex, duration of practice and respondent's institution between vaccinated and unvaccinated ORP were not significant (P>0.05. The majority (86.8% had the awareness of the existence of Hepatitis B vaccine. 83.8% of respondents believed that the vaccine should be given to the ORP as part of work place safety measures. The majority were aware of the modes of transmission of HBV infection. 78.9% of respondents believed that Hepatitis B vaccine is safe and 81.1% would recommend it to another staff. Conclusion. Despite a good knowledge about HBV infection and vaccine, most of ORP are still not vaccinated. Hepatitis B vaccination should be a prerequisite for working in the theatre, hence putting surgical patients at reduced risk.

  16. Vaccine independence, local competences and globalisation: lessons from the history of pertussis vaccines.

    Science.gov (United States)

    Blume, Stuart; Zanders, Mariska

    2006-10-01

    In the context of global vaccine politics 'vaccine independence' has been defined as the assumption of financial responsibility for vaccine procurement. This paper suggests 'the possibility of vaccine choice' as an alternative meaning for the term. How far does local competence in vaccine development and production provide that possibility? Coupled to the national vaccination programme, such competence enabled the Netherlands to make use of a polio vaccine (Inactivated Polio Vaccine, or IPV) that it was felt best met national needs even though the rest of the world had switched to the alternative attenuated vaccine (generally known as Oral Polio Vaccine, or OPV); by the 1970s IPV was no longer commercially available. Over the past 20 years major changes in vaccine politics have occurred. Does the earlier conclusion regarding local competence still hold? The more recent example of pertussis (or whooping cough) vaccines, where again controversy surrounds the relative merits of alternative vaccines, permits the question to be posed anew. Results of our analysis from the Netherlands suggest, first, that the pressure to conform has become greater, and second, that the taken-for-granted globalism of today's vaccine system is in need of critical examination. PMID:16764977

  17. Vaccination against feline retrovirus infections

    OpenAIRE

    Horzinek, M.C.

    1996-01-01

    Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV), both of veterinary importance, their antigenic and genetic variability as well as their pathogenicity are described. Disease following FeLV infection is interpreted as a consequence of genetic recombination, as a result of viral evolution in vivo. The principles and efficacy of vaccines are discussed.

  18. [The plague: disease and vaccine?].

    Science.gov (United States)

    Michel, P; Rasoamanana, B; Rasolofonirina, N; Roux, J

    1992-01-01

    Plague has existed in Madagascar since 1896, with epidemic control achieved by GIRARD with an EV vaccine in 1937. Plague persists in Madagascar, however, due to the large animal reservoir. With a predilection for nodal tissues, Yersinia pestis is a virulent bacteria that is potent inducer of antibody synthesis. Immunity mechanisms stimulated by infection were studied: 1. In human by immunoenzymatic methods 2. In mice by seroprotection and vaccinating tests. Induced immunity for people in endemic and endemic-epidemic areas, is significant, affecting approximately 70% of these populations. In non endemic areas, immunity is found in only 33% of the population, perhaps this explains the persistence of epidemic? In all cases, this immunity is a quick onset (6 days), is persistent (> 2 years), and has demonstrable serious recognition of YOP (Yersinia Outer Proteins) by Western Blot method. Human antibodies were shown to be protective for mice. Animals vaccinated by YOP were protected equally well, when compared to animals infected with Yersinia pestis and subsequently treated with antibiotics. Finally, YOP aerosols were also shown to induce antibodies. In conclusion, plague is a vaccinatable bacterial disease and YOP can be used as an animal vaccine to permit plague control in the rat reservoir. PMID:1345094

  19. MMR Vaccination and Febrile Seizures

    DEFF Research Database (Denmark)

    Vestergaard, Mogens; Hviid, Anders; Madsen, Kreesten Meldgaard;

    2004-01-01

    CONTEXT: The rate of febrile seizures increases following measles, mumps, and rubella (MMR) vaccination but it is unknown whether the rate varies according to personal or family history of seizures, perinatal factors, or socioeconomic status. Furthermore, little is known about the long-term outcome...

  20. Irradiated vaccines against bovine babesiosis

    International Nuclear Information System (INIS)

    Experiments were conducted on non-splenectomized Bos taurus calves to determine the immunogenicity of blood vaccines containing either Babesia bigemina or Babesia bovis parasites irradiated in a 60Co source. Groups of calves between 6 and 10 months of age, found to be free of previous babesial infections by serodiagnosis, were inoculated with B. bigemina ('G' isolate) irradiated at rates ranging from 350 to 500 Gy. These vaccines caused low to moderate reactions on primary inoculation which subsided without treatment. Parasites irradiated at 350 Gy produced a strong immunity against virulent homologous challenge. Vaccinated calves also withstood virulent heterologous B. bigemina ('H' isolate) and B. bovis ('A' isolate) challenges made 85 and 129 days later. It also became evident that the use of babesicides to control reactions should be avoided since early treatment of 'reactor' animals caused breakdown of immunity among vaccinates. B. bovis ('A' isolate) parasites irradiated at dose rates of either 300 Gy or 350 Gy caused mild to moderate reactions in immunized calves, with the reactions in the 300 Gy group being slightly more severe. On challenge with homologous parasites, animals that had previously been inoculated with organisms irradiated at 300 Gy showed better protection than those that had received parasites irradiated at 350 Gy. (author). 28 refs, 5 tabs